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Abstract 
The Inflammatory Idiopathic Myopathies (IIM) are a rare group of myopathic 
autoimmune diseases diagnosed in both adults and children. Patients present with 
proximal muscle weakness and Gottron’s papules. Immunohistochemical analysis of 
muscle tissue from these patients has identified immune cell infiltrate and the 
expression of pro-inflammatory cytokines however, little is known about the 
peripheral immunological profile in juvenile and adult patient groups. 
 
There are three aims: Firstly, to investigate mechanisms driving B cell lymphocytosis 
and define pathological features of B cells in the blood of Juvenile Dermatomyositis 
(JDM) patients. Secondly, to identify specific immune cell signatures and cytokine 
profiles for myositis disease subtypes and correlate this data with measurements of 
disease activity. Finally, to delineate a correlation between the up-regulated type I 
interferon signature and dysfunction of cholesterol homeostasis in immune cells. 
 
Using a combination of cell culture, flow cytometry, RNA-seq, q-PCR and ELISA 
techniques this study has assessed the immune cell signature, B cell biology and IFN 
related mechanisms in patients with IIM. The results identified that JDM patients with 
active disease have a significantly expanded immature B cell population which was 
correlated with a type I IFN signature. Activation through TLR7 and IFN-a may drive 
the expansion of immature B cells in JDM and skew the cells towards a more pro-
inflammatory phenotype. There are unique immune signatures in adult disease sub-
types, one example was an expanded Th17 population seen in adult dermatomyositis 
 5 
(ADM). Lastly, IFN-a stimulation of T and B cells does change the expression of 
some genes that are part of the Hallmark cholesterol homeostasis pathway. 
 
In conclusion, the work undertaken during my thesis provides further evidence that 
anti- IFNa biologics could be efficacious in the treatment of JDM. Also, the need for 
further investigation for the use of IL-17A inhibitors in the treatment of IIM. 
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Impact statement 
This body of work has begun to delineate the peripheral immunological profile found 
in juvenile and adult IIM. The results identified that JDM patients with active disease 
have a significantly expanded immature B cell population which was correlated with 
a type I IFN signature. Activation through TLR7 and IFN-a may drive the expansion 
of immature B cells in JDM and skew cells towards a more pro-inflammatory 
phenotype. Novel immunophenotyping signatures have been identified in adult-
disease subgroups, by disease activity and the presence of different auto-antibodies. 
Lastly, lipid rafts and cholesterol homeostasis may be altered by the up-regulation of 
type I interferon pathway in IIM patient immune cells. These findings paint a broader 
picture of the heterogeneity of IIM but also the importance of the re-occurring 
interferon theme found in many autoimmune diseases. 
 
I have identified notable immune cell signatures that may impact the stratification of 
patients and inform the choice and response to treatment. My work substantiates a 
building body of evidence for the use of anti-IFN-a biologic agents and IL-17A 
inhibitors in the treatment of IIM. 
 
This work has already resulted in the submission of a manuscript for publication in a 
peer-reviewed journal, and another is in preparation. Dissemination at National and 
International conferences have enabled my work to be critiqued an acknowledged by 
the scientific community. 
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Interaction with patients at clinics has fostered a relationship where I have been able 
to inform them about the broad aims of the research, and reciprocally they have been 
able to contribute with issues that concern them about the disease. I have developed a 
pipeline to recruit and process samples from child control volunteers from UCLH 
clinics in collaboration with the ARUK Centre for Adolescent Rheumatology at UCL, 
GOSH and UCLH. This experience also involved explaining my research and the 
impact it would have on patients to a wide public audience. 
 
My PhD studies have introduced me to the area of translational medicine. With rare 
diseases, the concept of ‘bench to bedside’ can be extremely challenging with barriers 
including financial commitment, demand for the drug, suitable cohort size for clinical 
trials and the potential response to the drug within heterogenic disease groups. My 
work has implored to bridge the gap in IIM and highlighted the importance of this 
research to both the public and scientific communities. 
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Introduction 
Idiopathic inflammatory myopathies 
Idiopathic Inflammatory Myopathies (IIM) are rare diseases that are heterogeneous in 
terms of pathology and age of onset, but share a common target, namely skeletal 
muscle. Juvenile dermatomyositis (JDM) is the most common subtype of the juvenile 
idiopathic inflammatory myopathies (JIIM); however, it is still rare with an annual 
incidence of three in every million children (Shah et al., 2013, Pachman et al., 2005). 
Children present with a symmetrical proximal and axial muscle weakness and 
characteristic skin changes including Gottron’s papules and heliotrope rash. In severe 
cases, JDM patients can present with skin ulceration, severe pharyngeal weakness 
necessitating nasogastric feeding and rarely gut vasculitis that may be fatal. Long-
term complications of the disease include lung fibrosis, lipodystrophy and calcinosis 
(McCann et al., 2006, Guseinova et al., 2011, Ravelli et al., 2010, Sato et al., 2009, 
Christen-Zaech et al., 2008). Adults, adolescents and children can all develop 
dermatomyositis, but the clinical pathology can differ depending on the age of onset 
as shown in Table I.1. 
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Table I.1 Similarities and differences between juvenile and adult myositis 
 Similarities Differences 
 Juvenile and Adult Juvenile Myositis Adult Myositis 
Epidemiology Female predilection 7.6 years 30-50 years 
Clinical features Share most. - Calcinosis  
- Lipodystophy 
- Interstitial lung 
disease  
- Myocardial 
involvement 
Autoantibodies 
(most common) 
The same for both, 
including association 
with clinical features. 
- Anti-p155/140 
(TIF-1γ) 
- Anti-MJ (NXP2) 
- Antisynthetases 
Immunogenetic 
risk factors 
- MHC gene regions 
(HLA-DRB1* 0301-
DQA1*0501 and 
TNF-α-308A 
- DQA1*0301 
(Caucasians) 
- Gm phenotypes 
- HLA alleles 
(protective) 
- Other cytokine 
polymorphisms 
have not been 
studied 
Pathogenesis - Humoral attack on 
muscle capillaries 
- Up-regulation of 
MHC I on myofibres 
- Infiltration of pDCs 
- Type I interferon 
response 
Increased in JDM 
compared to adult 
DM: 
-Neovascularization 
of capillaries 
- Up-regulation of 
MHC I on myofibres 
- Type I interferon 
response 
 
- PM is mediated 
by CD8+ T cell 
attack on non-
necrotic 
myofibres 
resulting in 
destruction. 
Treatment 
response 
- Prednisolone and 
immunosuppress-ive 
agents 
- Greater response - Lower response 
Outcome - Long-term 
functional disability 
- Disease damage 
- Predictors of 
mortality 
(antisynthetase 
autoantibodies, ILD, 
older age at diagnosis) 
- Lower mortality 
(≤3%) 
- 28-41% with 
functional disability 
- 37-41% with 
monocyclic course. 
- Higher mortality 
(10-26%) 
- 10-year survival 
(53-89%) 
- 35-60% with 
functional 
disability 
17-20% with 
monocyclic 
course. 
(Rider et al., 2016) 
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Dermatomyositis (DM), polymyositis (PM), and cancer-associated myositis are the 
most common forms of IIM diagnosed in adults. These diseases share a similar 
clinical and pathological phenotype to that of juvenile IIMs (JIIM). The peak age of 
onset in adult IIM is 30-50 years. Adult IIM have a higher incidence than juvenile 
IIM at approximately 9.6 per million adults diagnosed annually (Bendewald et al., 
2010). Adults with DM have a more chronic disease course and a higher mortality 
rate than children with DM (Rider et al., 2016). A set of five criteria was developed 
by Bohan and Peter to aid diagnosis in both childhood and adult disease (Table I.2) 
(Bohan and Peter, 1975a, Bohan et al., 1977). Four of these criteria are required for a 
definite diagnosis of dermatomyositis and three for a probable diagnosis (Rider et al., 
2016). 
 
Table I.2 Bohan and Peter criterion for myositis 
1 Progressive proximal symmetrical weakness 
2 Elevated levels of muscle enzymes 
3 An abnormal finding on electromyography 
4 An abnormal finding on muscle biopsy 
5 Compatible cutaneous disease (only in dermatomyositis) 
 
Environmental risk factors 
Dermatomyositis can be triggered by environmental risk factors in individuals 
genetically susceptible to the disease. This condition is characterised by immune 
dysfunction and specific tissue pathology. Some studies have reported an antecedent 
infection prior to the onset of JDM suggesting that infectious pathogens could trigger 
the disease, such as coxsackievirus B2/B4 (CVB) and enterovirus associated with 
both upper respiratory and gastrointestinal symptoms (Pachman et al., 2005, 
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Christensen et al., 1986). Non-infectious environmental exposures have been linked 
with the development of myositis including medications, immunizations, ultraviolet 
light exposure and stressful life events (Neufeld et al., 2013).  
 
Immunopathology found on muscle biopsy 
According to the Bohan and Peter criteria for myositis, the positive findings on 
muscle biopsy include; necrosis, phagocytosis, regenerative activity reflected by 
basophilia, atrophy and degeneration of both type I and II muscle fibres, internal 
migration of nuclei, vacuolization, fibre size variation, and mononuclear cell infiltrate 
(Bohan and Peter, 1975b). Detailed studies have investigated the immunopathology of 
the diseased tissue from myositis patients. An early event to occur in the muscle fibres 
of dermatomyositis patients is complement activation and formation of 
membranolytic attack complexes (MAC) that cause muscle ischaemia, lysis of 
endothelial cells and destruction of capillaries (Dalakas, 1991, Mastaglia and Phillips, 
2002, De Visser et al., 1989, Kissel et al., 1986, Dalakas, 2006). Complement 
activation triggers immune cell recruitment and pro-inflammatory cytokines, these 
include CD4+ T cells, B cells, macrophages, plasmacytoid dendritic cells, interferon-g 
and interferons-a/b (Dalakas and Hohlfeld, 2003, Greenberg et al., 2005b). 
Polymyositis and inclusion body myositis (IBM) share the T-cell-mediated 
autoimmune process of CD8+ cytotoxic T cells attacking non-necrotic muscle fibres 
that express MHC-I antigen. These T cells can persist over many years due to clonal 
expansion (Benveniste et al., 2004, Amemiya et al., 2000). The T cells are drawn to 
the tissue by a pro-inflammatory environment of cytokines and chemokines. PM and 
inclusion body myositis (IBM) are unique in the IIM group of diseases as they 
ubiquitously over express MHC-I on the surface of muscle fibres as first shown by 
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Isenberg and colleagues (Karpati et al., 1988, Emslie-Smith et al., 1989, Rowe et al., 
1981). Muscle biopsies should clearly differentiate between DM, PM, IBM and non-
immune myopathies due to presence or absence of the CD8+/MHC-I complex. 
Genetics 
Familial autoimmunity has been reported in some patients with JDM, most frequently 
type I diabetes mellitus or SLE (Andreoli et al., 2011). JDM is a complex genetic 
disorder that has been explored by a large cohort Genome-wide association study 
(GWAS). Polymorphisms of the major histocompatibility complex (MHC) class II 
region on chromosome 6 have been linked to a strong risk of developing myositis in a 
Caucasian population (Miller et al., 2013). Three of the haplotypes linked to a higher 
risk factor of developing JDM are HLA-B*08, DRB1*0301 and DQA1*0501. 
Protective haplotypes have also been found these include, DQA1*0201 (OR0.37), 
*0101 (OR0.38) and *0102 (OR0.51) (Mamyrova et al., 2006). Examination of 141 
non-MHC single-nucleotide polymorphisms (SNPs) previously linked with other 
autoimmune diseases found three SNPs to be associated significantly with JDM/DM. 
These genes include phospholipase C-like 1 (PLCL1), B lymphoid tyrosine kinase 
(BLK) and chemokine (C-C motif) ligand 21 (CCL21) (Miller et al., 2013). In a 
separate study of JDM, TNF-α-308A allele was associated with the development of 
calcinosis and ulceration, and prolonged disease (Pachman et al., 2000, Mamyrova et 
al., 2008).  
 
Autoantibodies 
Myopathies in both adults and children can be split into subgroups according to their 
clinical and autoantibody phenotype (Deakin et al., 2016b). There are two classes of 
myositis autoantibodies: myositis specific autoantibodies (MSAs) that are unique to 
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myositis, and myositis associated autoantibodies (MAAs) that are detected in myositis 
and other autoimmune diseases. Approximately 70% of JIIM patients have an 
identifiable autoantibody phenotype. The main myositis specific autoantibodies 
detected in juvenile IIMs are anti-p155/140 (TIF1-γ) and anti-MJ (NXP-2) (Rider et 
al., 2013). In adult myositis, the most frequent group of myositis autoantibodies 
detected are the anti-synthetase enzymes. The anti-synthetases are present in 25-40% 
of adult patients compared to 5% of juvenile patients (Shah et al., 2013).  
 
The autoantibody profiles are associated with patient demographics and clinical 
phenotype (Table I.3 and Figure I.1). The anti-p155/140 (TIF1-γ) and anti-MJ 
(NXP-2) autoantibodies are predominantly associated with JDM in Caucasian 
patients. Anti-p155/140 autoantibodies are present in 23-30% of JDM, in particular 
patients that have extensive photosensitive skin rashes. Anti-p155/140 autoantibodies 
have been associated with lipidystrophy and a chronic disease course (Bingham et al., 
2008). Anti-MJ autoantibodies are present in 12-23% of JDM patients and are 
associated with calcinosis, muscle cramps, muscle atrophy, joint contractures, 
dysphonia and absence of a truncal rash (Tansley et al., 2014b). The MDA5 
autoantibody in juvenile cases is associated with mild muscle disease, but strongly 
associated with interstitial lung disease (ILD). In adult IIM anti-Jo-1 is the most 
common of the anti-synthetase autoantibodies and is associated with ILD, arthritis, 
fevers, Raynaud’s phenomenon and mechanics’ hand. The anti-Jo-1 autoantibody 
subgroup in adult IIM has the highest mortality rate predominantly due to its strong 
association with ILD. The majority of mortality in adult and children IIM patients is 
due to ILD (Rider et al., 2013).  
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Table I.3 Myositis-specific autoantibodies; frequencies and clinical 
associations 
Autoantibody Target Prevalence 
in 
JDM 
Prevalence in 
Adult myositis 
Clinical 
association 
Jo-1 Histidyl-tRNA 
synthase 
2-4% 9-24% ILD, 
mechanics’ 
hand, 
arthritis, 
Raynaud’s 
phenomenon 
TIF1-γ Transcriptional 
intermediary 
factor 1 
22-29% 13-31% Cancer - 
adults 
NXP-2 Nuclear matrix 
protein 
23-25% 1-17% Cancer - 
adults 
Calcinosis - 
JDM 
MDA5 Melanoma 
differentiation-
associated gene 
5 
7-38% 0-13% Caucasian 
10-48% Asian 
Amyopathic, 
Rash, ILD 
Mi-2 Nucleosome-
remodelling 
deactylase 
complex 
4-10% 9-24% Rash 
SRP Signal 
recognition 
particle 
<2% 5% Caucasian 
8-
13%Asian/African 
>CK, 
necrotizing 
myopathy, 
dysphagia, 
cardiac, 
arthritis 
HMGCR 3-hydroxy-
3methylglutaryl-
coenzyme A 
reductase 
<1% 6% >CK, 
necrotizing 
myopathy, 
Statins 
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Figure I.1 Myositis autoantibodies and their key clinical associations . IBM, 
inclusion body myositis; CTD, connective tissue disease; SRP, signal recognition 
particle; HMGCR, 3-hydroxy-3methylglutaryl-conenzyme A reductase; TIF1, 
transcription intermediary factor 1; NXP2, nuclear matrix protein 2; MDA5, 
melanoma differentiation-association gene 5; SAE, small ubiquitin-like modifier 
activating enzyme; 5NT1A, cytosolic 5’nucleotidase 1A; Mi-2, nucleosome-
remodeling deacetylase complex, Jo-1, histidyl tRNA synthetase; PL7, threonyl tRNA 
synthetase; PL12, ananyl tRNA synthetase; OJ, isoleucyl tRNA synthetases; EJ, glycyl 
tRNA synthetase; KS, aspararginyl tRNA synthetase; Zo, phenylalanyl tRNA 
synthetase, Ha; tyrosyl tRNA synthetase; snRNP, small nuclear ribonucleic protein. 
(taken with permsission from Betteridge and McHugh, 2016) 
 
Not only are MSAs associated with particular disease phenotypes, they have also been 
found to aid the prediction of the risk of remaining on treatment. Specifically, anti-
Mi-2 autoantibodies have a protective effect reducing the time to remain on treatment. 
Unlike anti-nuclear matrix protein 2, anti-transcription intermediary factor 1g 
autoantibodies, or no detectable autoantibody that were all associated with more 
severe histopathology and prolonged time remaining on treatment (Deakin et al., 
2016a).  
 
two large juvenile cohort studies only identifying
ASAs in 2–4% of their patients [14] (S Tansley,
personal communication).
Patients with ASAs have been traditionally classed
as having antisynthetase syndrome (ASS), the
clinical manifestations of which are ILD, Raynaud’s
phenomenon, mechanics hands, nonerosive arthri-
tis, fever and, in some cases, cutaneous rash.
Although all the ASAs are associated with ASS,
recent studies have demonstrated that the precise
clinical manifestations associated with each indi-
vidual autoantibody are not identical. A meta-
analysis comparing anti-Jo-1-positive nd non-
Jo-1 ASA-positive patients reported an increased
likelihood of myositis, arthralgia and mechanics
hands in anti-Jo-1-positive patients, with non-Jo-1
ASA-positive patients having an increased fre-
quency of DM skin lesions, fever and ILD [11].
Furthermore, anti-Jo-1-positive patients have been
shown to have a better 5- and 10-year survival
compared to non-Jo-1 ASA-positive patients,
although this may be partially explained by a
greater availability of anti-Jo-1 testing compared
to the other ASAs, and a subsequent reduced time
to diagnosis [22]. Recently, a study of 166 Japa-
nese ASA-positive patients has revealed further
clinical differences between the non-Jo-1 sub-
types. Muscle weakness was found to be more
pronounced at both disease onset and during
follow-up in the anti-EJ- and anti-PL7-positive
patients compared with patients with anti-PL12,
anti-OJ or anti-KS autoantibodies. Raynaud’s phe-
nom non was more frequently observed in patients
with anti-PL12 and anti-PL7, and arthritis was less
common in the anti-OJ-positive patients. DM rash
was found to b more commonly associated with
anti-EJ, anti-PL12 and anti-PL7. Additionally,
although ILD was frequently found in patients with
each of t e non-Jo-1 ASAs, patients with anti-EJ or
Fig. 2 Myositis autoantibodies and their key clinical associations. IBM, inclusion body myositis; CTD, connective tissue
disease; SRP, signal recognition particle; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; TIF1, transcription
intermediary factor 1; NXP2, nuclear matrix protein 2; MDA5, melanoma differentiation-associated gene 5; SAE, small
ubiquitin-like modifier activating enzyme; 5NT1A, cytosolic 5’nucleotidas 1A; Mi-2, nucleosome-remodelling deacetyalse
complex; Jo-1, histidyl tRNA synthetase; PL7, threonyl tRNA synthetase; PL12, alanyl tRNA synthetase; OJ, isoleucyl tRNA
synthetases; EJ, glycyl tRNA synthetase; KS, asparaginyl tRNA sythetase; Zo, phenylalanyl tRNA synthetase, Ha; tyrosyl
tRNA synthetase; snRNP, small nuclear ribonucleic protein.
Z. Betteridge & N. McHugh Review Symposium: Myositis specific autoantibodies
ª 2015 The Association for the Publication of the Journal of Internal Medicine 13
Journal of Internal Medicine, 2016, 280; 8–23
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Calcinosis 
Amongst IIM, JDM have the highest frequency of calcinosis (12-47%). Patients 
typically present with subcutaneous calcinotic lumps 1-2 years after disease onset. 
Calcinosis is defined as the presence of dystrophic calcification in subcutaneous, 
myofascial, or muscle tissue (Sato et al., 2009). It is distinct from bone in its mineral 
composition and matrix as the mineral is deposited in fragments and becomes solid 
over time (Rider et al., 2016). Anti-MJ (NXP-2) autoantibodies are strongly 
associated with the presence of calcinosis (Tansley et al., 2014b).  
 
Cancer and myositis 
Adult patients with DM and PM have an increased risk of cancer compared to a 
control cohort, and can have up to a 10-fold increased risk (Chen et al., 2010). Cancer 
is most commonly detected within the first year of IIM diagnosis with about two-
thirds of comorbid cancers occurring after diagnosis (Huang et al., 2009). Population 
based epidemiological studies of IIM conducted around the world have shown 
different types of cancer are prevalent among defined populations and ethnic groups. 
Studies in Denmark, Sweden and Finland identified that IIM was associated with an 
increased comorbidity of ovarian, lung, pancreatic, stomach, urinary tract and 
haemolytic cancers (Hill et al., 2001, Chow et al., 1995). Asian population studies of 
IIM conducted in Korea, Singapore, Hong Kong, South East China and Taiwan have 
demonstrated an increased comorbidity of cancers of the breast, stomach and 
nasopharynx, the last being the most common (Lee et al., 2006, Peng et al., 1995, 
Chan, 1985, Chen et al., 2001, Wang et al., 1993). 
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 As shown in Figure I.1 the MSA TIF1-g has a strong correlation to cancer-associated 
myositis but only in adult disease (Betteridge and McHugh, 2016). In JDM cohorts 
there is no known association between the presence of anti-TIF1-g autoantibody and 
risk of cancer (Gunawardena et al., 2008). Trallero-Araguas et al demonstrate by 
meta-analysis that the sensitivity of using anti-TIF1-g to detect cancer-associated 
myositis in adults is 78% [95% confidence interval(CI) 45-94%] with a specificity of 
89% (95% CI 82-93%) (Trallero-Araguas et al., 2012). The difference between 
juvenile and adult cancer association is thought to be age related, the older the patient 
the higher the risk of developing cancer (Fiorentino et al., 2015). Anti-NXP2, a MSA 
mainly associated with calcinosis in JDM, has been detected in a small percentage 
(~17%) of the adult IIM population (Gunawardena et al., 2009, Ichimura et al., 2012). 
Additionally, there is a growing body of evidence that anti-NXP2 is associated with 
malignancy in adult disease (Fiorentino et al., 2013). 
 
Interstitial lung disease 
Interstitial lung disease (ILD) is the most common respiratory disease associated with 
IIM (Fathi et al., 2004). In adult disease, the prevalence has been reported between 
17-36%, and in large cohort studies of JDM ILD is thought to occur in 8-13% of 
patients. Patients with IIM-associated ILD have a 50% mortality risk from respiratory 
failure (Connors et al., 2010, Shah et al., 2013). ILD can be diagnosed before or after 
the onset of the myositis and does not differ from idiopathic disease (Cottin et al., 
2003). The signs and symptoms related to IIM-associated ILD include dyspnoea on 
exertion, cough, decreased exercise tolerance, digital clubbing and asthenia (Lega et 
al., 2015). In adult disease, there is a strong association to the anti-synthetase 
syndrome autoantibodies (anti - Jo-1, PL7 and PL-12) with ILD (Lega et al., 2014). 
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These autoantibodies have a high prevalence of HLA-DRB1*03, DQA1*05 and 
DQB1*02 haplotypes and a determining factor of IIM-associated ILD is the presence 
of the HLA-DRB1*03 haplotype (Oddis et al., 1992, Chinoy et al., 2006, Rider et al., 
2013). Anti-MDA5 autoantibodies have also been shown to have a strong association 
with interstitial lung disease especially in juvenile disease (Tansley et al., 2014a). A 
‘gain of function’ mutation in the IFIH1 gene that encodes for the MDA5 protein has 
been reported and leads to enhanced type 1 interferon production. This finding 
suggests that type I interferon production may link anti-MDA5 to ILD (Rice et al., 
2014). The treatment of ILD depends on the severity and progression at diagnosis and 
is similar to that of IIM. Treatment includes high-dose corticosteroids with additional 
immunosuppressive drugs such as azathioprine, mycophenolate mofetil, methotrexate, 
cyclosporine and cyclophosphamide (Lega et al., 2015). A better understanding of the 
pathophysiology underlying ILD will lead to more targeted therapy. 
 
Pathophysiology 
JDM can be defined as an autoimmune angiopathy characterised by chronic 
inflammation in a genetically susceptible individual after exposure to an 
environmental trigger. Both humoral and cell mediated mechanisms cause vascular 
and muscle damage in dermatomyositis. Key events that contribute to the 
pathogenesis of JDM are: the immune attack on muscle capillary endothelium, up 
regulation of MHC class I expression on the surface of myofibres, and infiltration of 
plasmacytoid dendritic cells (pDCs) initiating a type I interferon (IFN) response 
(Rowe et al., 1981). These central events are consistent in both adult and juvenile 
DM, but are more prominent in juvenile disease (Huizinga et al., 2005).  
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The main type I interferons are IFN-α and IFN-β. The IFNs bind to the IFN-α 
receptor and activate the Janus kinase (JAK)-signal transducer and transcription 
(STAT) pathway that in turn leads to the transcription of IFN-stimulated genes (ISGs) 
(Ivashkiv and Donlin, 2014). The over production of IFN in the blood and muscle is 
an abnormality in the pathogenesis of dermatomyositis (Walsh et al., 2007, Greenberg 
et al., 2005b). SLE is another autoimmune disease where overproduction of type I 
interferons has been implicated in disease (Baechler et al., 2003). The release of type I 
IFNs leads to immune cell activation and vasculopathy. The main source of type I 
IFNs is from pDCs after activation by either self-DNA or viral nucleic acid (Mauri 
and Menon, 2015, Menon et al., 2016). pDCs have been identified in JDM muscle, 
but IFN is rarely detected in the serum of JDM patients as it is tightly regulated by the 
immune system (Baechler et al., 2011, Niewold et al., 2009). Due to the difficulties in 
measuring IFN directly, the genes induced by IFN, interferon-induced protein with 
tetratricopeptide repeats 1 (IFIT1), ISG15 ubiquitin-like modifier (G1P2), and 
interferon regulatory factor 7 (IRF7), are measured to ascertain the levels of IFN 
signalling in vivo (Bilgic et al., 2009, Menon et al., 2016). Another indirect measure 
of IFN is the IFN chemokine signature that measures serum levels of interleukin 6 
(IL-6), monocyte chemoattractant protein 1 (MCP-1), monocyte chemoattractant 
protein 2 (MCP-2) and interferon gamma-induced protein 10 (IP-10); the chemokine 
signature has correlated with disease activity in JDM (Nistala et al., 2013).  
 
Blockade of the IFN pathway could be a useful therapy in DM. A phase 1b clinical 
trial of sifalimumab, a fully human immunoglobulin G1 k monoclonal antibody that 
binds to and neutralizes the majority of IFN-a subtypes, has been carried out in 
patients with DM and PM using the outcome measures of IFN gene signature 
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suppression against disease improvement. Sifalimumab suppressed the IFN gene 
signature in blood and muscle tissue of the IIM patient cohort; this suppression 
correlated to clinical improvement. These initial results have identified that targeting 
the IFN pathway with sifalimumab achieves a good level of disease suppression in 
DM and PM, but blockade of the type I IFN receptor (IFNAR) may offer superior 
clinical benefit (Higgs et al., 2014). Other potential biomarkers of DM have been 
identified that include interferon gamma-inducible protein (IP)-10, galectin 9 and 
tumour necrosis factor (TNF) receptor type II (Bellutti Enders et al., 2014). 
 
Mouse model experiments have shown that overexpression of HLA class I on muscle 
cells is sufficient to drive muscle damage, leukocyte recruitment, and muscle 
weakness. Therefore, HLA class I overexpression is not necessarily a response to 
inflammatory processes (Nagaraju et al., 2000). Further studies have shown that 
overexpression is due to misfolding of excessive class I protein in the endoplasmic 
reticulum (ER) that triggers cellular damage responses and leads to immune activation 
(Nagaraju et al., 2005). This misfolding is referred to as the ER stress pathway. 
 
Treatment 
The mainstay treatments for IIM are prednisolone and methotrexate. Other 
immunosuppressive treatments are used including mycophenolate mofetil and 
azathioprine. Advances in the understanding of the immunopathology and genetics 
underlying IIM have led to clinical trials of the biological therapies sifalimumab and 
rituximab (Oddis et al., 2013, Higgs et al., 2014). Investigating the functions of B 
cells in IIMs may provide an insight into the mechanisms of the disease and lead to 
novel therapeutic pathways. 
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Immunopathogenesis of IIM 
 
Figure I.2 Immune cells and cytokines involved in the pathogenesis of IIM. 
There have been many identified factors involved in the pathogenesis of myositis that 
can lead to the recruitment of both arms of the innate and the adaptive immune 
system. It has been proposed that genetic and environmental factors can trigger an 
innate immune response by the recruitment of antigen presenting cells (APC) which 
in turn activate CD4+ and CD8+ T cells. These T cells upregulate the expression of B 
cell activating factor (BAFF) and a proliferation-inducing ligand on B cells through 
the engagement of CD40-CD40 ligand and T cell receptor (TCR) to major 
histocompatibility complex (MHC) II. T-helper (TH) and T follicular helper cells (TFH) 
drive cytokine production and recruitment of macrophages, immune complexes and 
cytotoxic T cells to the muscle tissue. Adapted from (Oddis and Aggarwal, 2018) 
0000
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Pathogenesis of IIM summary  
The IIM group share common features of immune-mediated muscle injury. There are 
clear clinical and histopathological differences between the IIM sub-groups (ADM, 
APM, JDM and IBM), this suggests that there are different underlying pathogenic 
mechanisms. DM appears to be driven by a type I IFN response with myofiber injury 
resulting from specific antibody and complement-mediated microangiopathy. In JDM 
the most common MSAs are anti-TIF1g and anti-NXP-2, whereas in adult disease 
anti-Jo-1 is the most prevalent. PM also has a distinct autoantibody profile with links 
to a type I IFN-inducible transcript, but the cellular infiltrate is confined to the 
fascicle within the muscle with diffuse muscle fibre injury. This injury seems to be 
mediated by CD8+ cytotoxic T cells and increased expression of MHCII from muscle 
fibres. 
 
B cells 
T and B lymphocytes work in unison to generate an adaptive immune response. The 
ability to produce variable T or B cell receptors (TCR/BCR) is key to this response.  
 
B cells originate from haematopoietic stem cells in the bone marrow. At this stage, 
pro-B cells express a unique antibody, the immunoglobulin (Ig) variable domain (Fv). 
Re-arrangement of the heavy and light chains of this immunoglobulin (V-D-J and V-J 
recombination) is supported by stromal-cell derived interleukin-7 (Nutt et al., 1999, 
Brack et al., 1978). Ig recombination leads to the development of the pre-B cell 
receptor (BCR). When a pre-B cell acquires antigen specificity by the expression of a 
unique BCR and surface IgM, it can then migrate from the bone marrow as an 
immature B cell (LeBien and Tedder, 2008, Lam et al., 1997). Although immature, 
these B cells are able to execute a rapid antibody response against type-I antigens. 
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Immature B cells migrate to secondary lymphoid structures, such as the spleen and 
lymph nodes, unless they encounter antigen-presenting cells including macrophages 
and dendritic cells. On reaching a lymphoid structure a B cell can either differentiate 
into a plasma cell or enter the germinal centre (GC). To mature into a plasma cell a 
naïve B cell must form either a follicular (FO) or marginal zone (MZ) B cell in the 
spleen after antigen engagement. Short-lived plasma cells secrete IgM, but also other 
Ig subtypes by class switch recombination (CSR).  
 
A GC is formed of mature B cells and T-helper cells. Within a GC antigen 
presentation promotes expansion of the B cells with antigen-specific BCR. The GC 
produces memory and high affinity antibody-producing plasma B cells as a result of 
somatic hyper mutation, clonal expansion and class switch recombination (CSR) 
(Illera et al., 1993, Jacob et al., 1991). Terminally differentiated plasma cells migrate 
back to the bone marrow where they can reside for up to one year (Shapiro-Shelef and 
Calame, 2005). Memory B cells from a GC will not produce antibody unless they 
encounter a secondary antigen (Klein and Dalla-Favera, 2008). T cells aid the 
adaptive immune response performed by memory B cells. The BCR is used to 
recognise, bind and internalize specific antigens. The immune response to a foreign 
antigen is T-cell independent and performed by MZ B cells by the activation of innate 
receptors such as toll-like receptors (TLRs) (Gray et al., 2007). 
 
B cell subsets 
Human B cell subsets can be defined by the expression of the surface markers CD19, 
CD24 and CD38. CD19 positive PBMC co-express CD24 and CD38 whereas CD19 
negative PBMC do not express CD24. Mature B cells are CD38pos and CD24low. 
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Memory B cells are CD38neg and CD24hi. Immature B cells are CD38hi and CD24hi. 
Studies showed that the frequency of immature B cells was higher in the bone marrow 
compared to peripheral blood confirming the origins of B cell development (Carsetti 
et al., 2004). The expression of CD27 can also be used to separate mature and 
memory B cells. Memory B cells are predominantly CD27 positive, while mature B 
cells are predominantly CD27 negative. Definition of early B cells subsets, pro- and 
pre- B cells, can be measured via CD10 and IgM with these subsets having a CD10hi 
and IgMneg  phenotype. Immature and transitional B cells have increasing amounts of 
IgM and decreasing amounts of CD10. The individual roles in the adaptive immune 
response played by each B cell subset are beginning to be defined. 
 
Figure I.3 B cell development pathway in humans. B cells develop from 
hematopoietic stem cells generated in the bone marrow. They proceed into the 
peripheral blood expressing surface markers, B cell receptor (BCR) and Iga/b. In the 
germinal centre they become activated and develop into memory B cells or 
plasmablasts to re-enter the blood. 
 
B cells in IIM 
The precise cause of inflammatory muscle disease including adult and childhood 
onset polymyositis (PM) and dermatomyositis (DM) remains uncertain. However, B-
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lymphocytes have been strongly associated with the disease pathogenesis especially 
in DM (Miller et al., 2013). B cells are thought to contribute primarily towards 
autoimmune pathology through the production of autoantibodies. In approximately a 
third of Juvenile DM (JDM) cases B-lymphocytes have been detected in inflamed 
muscle, and almost 50% of patients have detectable myositis-specific (MSAs) or 
myositis-associated autoantibodies (MAAs) (Shah et al., 2013, Nistala and 
Wedderburn, 2013). MSAs and MAAs have been identified in the serum of myositis 
patients and closely correlate to specific clinical phenotypes. Therefore, B cells are 
important in the pathogenesis of myositis as producers of autoantibodies. B cells have 
long been detected in the inflamed muscle of myositis patients (Arahata and Engel, 
1984). The B cell muscle infiltration has not been determined as pro-inflammatory or 
regulatory. The anti-CD20 antibody, rituximab, which depletes B cells has been 
trialed in JDM and adult DM (Oddis et al., 2013). Although the primary end point of 
the trial was not met, Oddis et al showed that a higher proportion of JDM (87%) 
patients treated with rituximab met the definition of improvement more quickly 
compared to adult DM (78%). These results might imply that B cells in JDM are 
either more pathogenic than in adult DM, or have a greater regulatory role in adult 
DM compared to JDM.  
 
Other functions of B cells in the immune system 
The most well-defined function of B cells is their ability to produce antibodies as part 
of an adaptive immune response. Other defined roles of B cells in the immune system 
have emerged. These include peptide and lipid antigen presentation and cytokine 
production. Activated B cells require immune cell stimulation to differentiate into 
cytokine producing B effector cells. B effector cells are classified as Be1 or Be2, pro-
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inflammatory or regulatory respectively. Naïve B cells can differentiate into Be1 or 
Be2 cells when co-cultured with polarized T helper 1 (Th1) or T helper 2 (Th2) cells 
(Harris et al., 2000). It has been demonstrated that B cell secretion of cytokines 
depends on the stimulus. B cells stimulated with CD40L and BCR signalling 
produced the pro-inflammatory cytokines TNF-α, lymphotoxin, and IL-6. The 
regulatory cytokine, IL-10, was produced with CD40L stimulation without BCR 
signalling. A study in multiple sclerosis (MS) highlights the dysregulation of 
cytokines in the context of autoimmunity. Duddy et al showed that naïve B cells from 
patients with MS could be polarized in vitro to Be1 cells that produce pro-
inflammatory cytokines, or Be2 cells that produce regulatory cytokines (Duddy et al., 
2004). B cells are an integral component of the adaptive response and it is their ability 
to secrete both pro-inflammatory and regulatory cytokines that make them an 
important target for investigation in autoimmune disease. 
 
T cell development 
T cells develop in the thymus which provides a microenvironment directing 
differentiation, positive and negative selection. Hematopoietic stem cells from the 
bone marrow develop into lymphoid progenitors and migrate to the thymus where 
they complete antigen-independent maturation into functional T cells. It is in the 
thymus that T cells gain expression of specific cell surface markers including TCR, 
CD3, CD4 or CD8 (Zuniga-Pflucker, 2004).  
 
Progenitor cells start by expressing CD3, but are double negative (DN) for CD4 and 
CD8 as their TCR genes have not yet rearranged (Ceredig and Rolink, 2002). Once 
the rearrangement of the b chain of the TCR stops, the cells become double positive 
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(DP) for both CD4 and CD8 losing their CD25 and CD44 (CD117) expression 
(Godfrey et al., 1993). Interactions with the Notch receptor-expressing thymocytes 
and Notch ligand expressing thymic stromal cells induce T cell maturation, resulting 
in the generation of singular positive T cells (Godfrey et al., 1993, Huang et al., 2003, 
Harman et al., 2003). This process generates CD4+ helper T cells and CD8+ cytotoxic 
T cells which migrate to the peripheral blood from the thymic medulla (Figure I.3). 
 
Before a T cell can leave the thymus, it must pass through positive and negative 
selection. Firstly, double positive T cells that have rearranged abTCR must bind to 
self-peptides and cortical epithelial cells expressing Class I or Class II MHC with 
high affinity to produce a survival signal, allowing positive selection. If the double 
positive T cell instead binds to self-peptides and Class I and Class II MHC expressed 
on bone-marrow derived antigen-presenting cells, such as macrophages and dendritic 
cells, negative selection will occur due to apoptotic signals (Alberola-Ila et al., 1996). 
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Figure I.4 Intrathymic T-cell development. T cell differentiation is characterised 
by specific surface markers, including; CD4, CD8, CD44, CD25 and the stability of 
the of the T-cell receptor (TCR). The programme of T-cell maturation in the thymus 
results in the generation of self-tolerant CD4+ helper T cells and CD8+ cytotoxic T 
cells which in turn migrate into the peripheral blood. (Zuniga-Pflucker, 2004) 
 
T cell subsets 
Mature T cells emerging from the thymus are known as naïve T cells as they have not 
yet encountered foreign antigen (Ag). These cells express multiple surface markers 
including CC chemokine receptor 7 (CCR7), L-selectin (CD62L), CD45RO, 
CD45RA, CD127 and CD28. Naïve T cells circulate through the blood and the 
lymphatic system to reside in secondary lymphoid organs where antigen is presented 
to them by dendritic cells (DC). TCR engagement via the APC triggers a cascade of 
intracellular signaling events activating the naïve T cell. Proliferating activated T cells 
© 2004 Nature Publishing Group
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P E R S P E C T I V E S
cells were first shown  support early
haematopoiesis and then B lymphopoiesis
from bone-marrow-derived HSCs35,36.
Nakano et al.37,38 showed that OP9 cells
could also support haematolymphopoiesis
from embryonic stem cells (ESCs). Stromal
cells support haematopoietic differentiation,
in part, by the cytokines they produce, and
MCSF supports myeloid differentiation. So,
the lack of MCSF expression contributed to
the ability of OP9 cells to support B-cell dif-
ferentiation from ESCs by limiting the clonal
favourite in the field. Other stromal cell lines
were described, each with unique features, but
one in particular — the OP9 stromal cell line
— introduced by Kodama and colleagues35,
seemed to have important characteristics,
some of which are discussed below.
OP9 cells
The OP9 stromal cell line was originally
derived from the bone marrow of OP/OP
MICE35, which are deficient in macrophage
colony-stimulating factor (MCSF). The OP9
Myeloeryt roid differentiation events could be
easily examined on culture dishes that con-
tained a mixture of defined cytokines in a
semisolid medium28–31. Moreover, model sys-
tems for B-cell differentiation have been avail-
able for over a decade10. The main components
of these in vitro B-cell systems consisted of a
bone-marrow-derived stromal cell line and the
addition of defined sets of cytokines. Several
stromal cell lines were characterized and some
continue to be widely used, with the S17 cell
line developed by Dorshkind32–34 remaining a
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Figure 1 | Intrathymic T-cell development. The thymic architecture is organized into discrete cortical and medullary areas, each of which is characterized by the
presence of particular stromal cell types, as well as thymocyte precursors at defined maturation stages14 . Thymocyte differentiation is characterized by the
expression of well-defined cell-surface markers, including CD4, CD8, CD44 (or CD117) and CD25, as well as the status of the T-cell receptor (TCR)12,13.
Interactions between Notch receptor-expressing thymocytes78 and thymic stromal cells that express Notch ligands61,62 induce a complex programme of T-cell
maturation in the thymus, which ultimately results in the generation of self-tolerant CD4+ helper T cells and CD8+ cytotoxic T cells, which emigrate from the thymus
to establish the peripheral T-cell pool. Modified from REF. 2.
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mature into cytotoxic CD8+ T cells and CD4+ T helper cells. Cytotoxic CD8+ T cells 
perform direct lysis of infected or malignant cells expressing the antigen, whereas 
CD4+ T helper cells produce cytokines, can be directly toxic, stimulate T cell effector 
functions, B cell antibody production and induce other inflammatory mechanisms. 
Effector T cells (CD45RO+, CD95+, Granzyme B +, CD25+) tend to disappear once 
the antigen has been removed, but can form memory T cells (CCR7+, CD62L+, 
CD45RO+, CD127+, CD28+) which can survive in the lymphoid organs and 
peripheral tissues for many years unlike effector and naïve T cells. Memory T cells 
are rapidly activated to effector function (CD45RO+, CD95+) in response to a 
recognised antigen and quickly eliminate the pathogen at an early stage (Figure I.4). 
 
Figure I.5 Development of T cells upon activation. T cells are activated by 
antigen presenting cells (APC) by the recognition of major histocompatibility 
complex (MHC)-peptide. On activation they proliferate and differentiate into effector 
and memory T cells. Both CD4 T-helper (Th) effector and CD8 cytotoxic T 
lymphocytes (CTL) migrate to the peripheral tissue to exert their function. Memory T 
cells can develop into C-C chemokine receptor type 7 (CCR7) negative effector 
memory cells (EM) that migrate to peripheral tissue or CCR7+ central memory T 
cells (CM) circulating in lymphoid tissue. (Broere, 2011) 
 
Memory T cells respond much faster  th  Ag than 
naïve T cells. Thus, in the case of infection, they help 
to eliminate pathogens at an early stage, thereby 
effectively preventing the disease spreading.
Composition of the T cell network
Lymphoid organs
The primary LYMPHOID ORGANS – the BONE MARROW and 
thymus – are sites of HEMATOPOIESIS and clonal selec-
t on of T cells. The T cell-mediated immune response 
begins in the secondary LYMPHOID ORGANS: spleen, 
lymph nodes, and organized lymphoid tissues associ-
ated with mucosal surfaces including PEYER’S PATCHES, 
tonsils, bronchial, nasal, and gut-associated lymphoid 
tissues. The secondary LYMPHOID ORGANS have spe-
cialized T cell-rich zones where naïve T LYMPHOCYTES 
are concentrated; these include the periarteriolar 
lymphoid sheath of the spleen (PALS) and the para-
cortex of the lymph nodes. Naïve T cells reside in the 
spleen for just a few hours and in the lymph nodes 
for about 1 day before they leave via splenic veins or 
16 T cell subsets and T cell-mediated immunity
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FIGURE 1. DEVELOPMENT OF T CELL-MEDIATED RESPONSES IS A SEQUENTIAL PROCESS
Antigen-presenting cells (APC) can take up antigen (Ag) in peripheral tissues and migrate to secondary lymphoid tis-
sues. Naïve T cells will be activated by recognition of MHC-peptide complexes on the APC, proliferate and differenti-
ate into effector or memory T cells. Both CD8 (CTL) and CD4 (Th) effector T cells will migrate to peripheral tissues to 
exert their function. In addition, memory T cells can develop into CCR7- effector memory cells (TEM) that will migrate 
to p ripheral tissu s or CCD7+ central memory T cells (TCM). These, in turn, can recirculate through lymphoid tissues. 
CCR7 is a chemokine receptor involved in T cell homing into lymphoid tissues.
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Sub-populations of CD4+ T helper cells are defined by cytokine profiles. Th1 produce 
IFN-g but also IL-2, TNF-a and lymphotoxin. Th2 cells secrete IL-4, -5, -6, -10 and -
13. Th1 cells mediate a pro-inflammatory response whereas Th2 promote a more non-
inflammatory immunity. Both instigate B cell production of IgG but Th2 are also 
essential for IgA and IgE. A third type of T helper cell, Th17, secretes the pro-
inflammatory cytokine IL-17 in response to IL-23. In the immunogenesis of 
autoimmune diseases such as rheumatoid arthritis, psoriasis and Crohn’s disease, 
Th17 cells are considered to contribute as a pro-inflammatory effector lineage 
(Miossec and Kolls, 2012, Miossec et al., 2009). Follicular T helper cells (Tfh) have 
been defined by their development in the presence of IL-6 and transcription factor 
Bcl-6.  
 
T regulatory cells (Treg) can express TGF-b, Il-10 and IL-35 which are key 
immunosuppressive cytokines that contribute to the critical role of Tregs in the 
maintenance of peripheral tolerance, down-modulation of the amplitude of an immune 
response, and prevention of autoimmune disease. It is thought that Tregs can fall 
under CD4+ and CD8+ subsets and are characterized by the expression of CD25 and 
the transcription factor forkhead box P3 (Foxp3). It is Foxp3 that is key for Treg 
development and without it severe systemic autoimmune disease can arise in both 
human and mouse (Buckner, 2010, Abdulahad et al., 2011).  
 
T cell pathogenesis in IIM 
The main clinical manifestation of IIM is muscle weakness and fatigue. When 
investigated by muscle biopsy most patients have immune cell infiltrates within the 
muscle fibres. These immune cell infiltrates can consist of both CD4+ and CD8+ T 
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cells. One pathway of T cell migration to inflamed muscle tissue has explored the 
expression of the alpha and beta chemokines acting as chemoattractants. This group 
of chemokines includes CXCL9/10 and CCL2/3/4/19/21 that can be expressed by 
immune cells and muscle fibres alike (Malmstrom et al., 2012). A positive expression 
of CCL2 on muscle biopsies has been demonstrated by immuno-histochemistry 
(Baird and Montine, 2008, De Paepe et al., 2007). CCL2 is a chemoattractant for 
CCR2- and CCR4- expressing cells such as monocytes, memory T cells, and dendritic 
cells. A significant up-regulation of CCL3 has been detected at mRNA level on IBM 
myofibres, and muscle infiltrating mononuclear cells from DM, PM and IBM 
patients. This chemokine can regulate Th1 cells and acts as a chemoattractant for 
macrophages and T cells (Schmidt et al., 2008). Within the affected muscle tissue the 
immune cell infiltrates can have a focal distribution which is thought to reflect a 
chemokine pro-inflammatory feed-back loop. In regard to the type of T cells found in 
muscle tissue the literature suggests that it is dependent on disease type. CD8+ T cells 
were more common in PM and IBM whereas in patients with DM CD4+ T cell 
populations were more prevalent (Salajegheh et al., 2007, Hofbauer et al., 2003).  
 
Skin-infiltrating T cells 
Dermatomyositis is a sub-type of the IIM group and affects both muscle and skin. 
Previous studies have concluded that CD4+ T cells drive DM more than in PM and 
IBM. Granzyme B-expressing T cells and FOXP3+ T cells have been found to be low 
in DM, which contrasts to findings in patients with RA and SLE who have skin 
involvement (Grassi et al., 2009, Solomon and Magro, 2008). In contrast, CXCR3+ 
lymphocytes are enriched in the skin of DM patients, which suggests a strong type I 
interferon involvement. In the peripheral blood of JDM patients a population of 
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CXCR5+ T helper helper cells has been detected. This population was found to 
display Th2 and Th17 functionality and correlated to disease activity. 
 
Interstitial lung disease and Th1 cells  
Myositis-associated ILD is most common in those patients that express autoantibodies 
against Jo-1 (Mammen, 2011). The Jo-1 antigen is highly expressed in the lung 
compared to other organs (Casciola-Rosen et al., 2005). The cleavage of Jo-1 antigen 
by granzyme B in the lung is believed to trigger T cell activation by antigen-
presenting cells (Danoff and Casciola-Rosen, 2011). Jo-1 antigen has been shown to 
trigger chemokine receptors on immature dendritic cells and T cells, in particular the 
expression of CCR5 (Levine et al., 2007, Howard et al., 2002). The main type of T 
cell found to infiltrate lung tissue of ILD patients are pro-inflammatory Th1 cells 
(Kurasawa et al., 2002). The presence of Th1 cells has been associated with elevated 
serum levels of CXCL9 and CXCL10, anti-Jo1 antibodies and ILD (Richards et al., 
2009). Therefore, emphasizing a role for Th1 cells in the pathogenesis of myositis-
associated ILD.  
 
Monocyte development – macrophages and dendritic cells 
Monocytes are derived from hematopoietic stem cells that leave the bone marrow and 
circulate in the blood stream and spleen as mononuclear phagocytes (van Furth and 
Cohn, 1968). Monocytes are immune effector cells that express chemokine and 
adhesion receptors that enable the migration from blood to tissue during infections. 
They can engulf cells and toxic molecules, but also express inflammatory cytokines 
(Auffray et al., 2009, Swirski et al., 2009). When these cells become resident in tissue 
they become macrophages and dendritic cells, these cells are heterogenic in 
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homeostatic turnover, phenotype and function (Geissmann et al., 2010). Macrophages 
are found resident in lymphoid and non-lymphoid tissue acting as phagocytic cells 
during steady-state tissue homeostasis. Their role is to remove apoptotic cells via 
pattern-recognition receptors (PRR) and the induction of inflammatory cytokines. 
Macrophages also excrete growth factors (Gordon, 2002). There are two type of 
dendritic cells; classical (cDCs) and plasmacytoid (pDCs). cDCs present and process 
antigen and as immature cells, they have high phagocytic activity whereas on maturity 
they produce inflammatory cytokines (Banchereau and Steinman, 1998, Mellman and 
Steinman, 2001). cDCs are short-lived, migratory cells that regulate T cell responses 
in homeostasis and infection (Waskow et al., 2008). pDCs have a longer life span than 
cDCs and some have immunoglobulin rearrangements. They are found in the bone 
marrow and peripheral organs (Corcoran et al., 2003). Their main function is to 
respond to viral infection with the production of type I IFNs, they also control T cell 
responses and act as antigen-presenting cells [APC] (Colonna et al., 2004).  
 
Monocyte subsets 
Circulating monocyte sub-populations can be defined by their expression of the 
surface markers CD16 and CD14 (Passlick et al., 1989). The nomenclature for types 
of monocytes was agreed upon in 2010 (Ziegler-Heitbrock et al., 2010). The largest 
population is known as classical monocytes, these are defined by being CD14high. The 
smaller population, known as non-classical monocytes, are CD14low and CD16high. More 
recently an intermediate population has been defined by CD14high CD16high (Ziegler-
Heitbrock, 2015). Studies have shown that the intermediate monocyte population is 
expanded in inflammatory disease (Rogacev et al., 2012). 
 
 56 
Pathogenesis of macrophages and dendritic cells in IIM 
Both dendritic cells and tissue resident macrophages have been found in DM and PM 
biopsies (Rayavarapu et al., 2013). DCs can be divided into immature and mature 
subtypes. Mature DCs express DC-LAMP, this subtype is enriched in perivascular 
inflammatory sites in both adult and juvenile DM (Nagaraju et al., 2006). Both 
myeloid and plasmacytoid DCs have been implicated in the pathogenesis of DM 
through their association with the up-regulated type I IFN signature (Facchetti and 
Vergoni, 2000, Bilgic et al., 2009). Monocytes and macrophages are pathogenic in 
inflammatory myopathies and undergo morphological and functional change during 
inflammation. Studies have indicated that both M1 and M2 macrophages can be found 
in the muscle from myositis patients. It has been found that the detected macrophages 
express both early, MRP14 and 27E10 (M1) and late activation 25F9 (M2) markers in 
addition to the inflammatory markers iNOS and transforming growth factor (TGF)-
beta (Rostasy et al., 2004, Rostasy et al., 2008). The proportion and ratio of M1 and 
M2 macrophages depends on the stage of the disease. The presence of different 
macrophages within the perimysium or endomysium reflects a diagnosis of either PM 
(increased M1) or DM (increased M2) and could contribute as a diagnostic tool 
(Rostasy et al., 2004).  
 
Cytokines 
Cytokines are a group of proteins and glycoproteins involved in signalling between 
lymphocytes, phagocytes and other cells of the body during an immune response. 
There are several sub-categories of cytokines. The interferon family includes type I 
and II IFN including; IFNα, IFNβ and IFNγ. The main role of the type-I IFN family 
is to induce a state of antiviral resistance in uninfected cells. The interleukin family 
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can be produced by many cells types and mainly stimulate cell division and 
differentiation. The colony stimulating factors direct the division and differentiation 
of haematopoietic stem cells in the bone marrow. Chemokines direct leukocyte 
recruitment to different tissues and can activate particular functions in leukocytes. 
Finally, there are the tumour necrosis factors (TNF) and the TGFs that are mainly 
involved in mediating inflammation and cytotoxic reactions.  
 
Cytokines are key communication molecules of the immune system and play a vital 
role in autoimmunity (Schett et al., 2013). Pro-inflammatory cytokines such as IL-6 
and TNF-α have been associated with disease pathology in many conditions, and are 
considered suitable therapeutic targets (Ogata et al., 2012). In rheumatoid arthritis IL-
6 is expressed in excess at sites of inflammation and is considered to have an 
important function in inducing chronic inflammation (Hashizume and Mihara, 2011). 
Monoclonal antibodies against the IL-6 receptor and TNF-α bound receptor complex 
have been developed to block the signaling pathways of these cytokines (Jones et al., 
2011, Tanaka and Martin Mola, 2014). Drugs such as tocilizumab (a humanized 
monoclonal antibody against the IL-6 receptor) and infliximab (a chimeric 
monoclonal antibody against TNF-α) have been very successful in suppressing 
inflammation in autoimmune diseases such as RA. 
 
Type I IFN signature 
Many autoimmune diseases have been found to have an up-regulated type I IFN 
signature, including SLE, RA and DM (Crow, 2014, Baechler et al., 2011, Bilgic et 
al., 2009). The type I IFNs comprise of thirteen types including IFN-α, IFN-b, IFN-k, 
IFN-w and IFN-n, these bind to a common receptor, IFN-α receptor (IFNAR), but the 
 58 
differences in induction of cellular responses is poorly defined (Crow, 2016). There 
are three proposed mechanisms behind this signature. The first mechanism is that 
pDCs are activated by endogenous IFN inducers to produce IFN-α. These inducers 
include autoantibodies and autoantigens that contain immune complexes (IC) that 
activate Toll-like receptor (TLR) 7 or 9 (Ronnblom and Eloranta, 2013). The second 
mechanism is that genes associated with autoimmune disease risk lie within the type I 
IFN signaling pathway that in turn affect the production and response of IFN-α. IFN-
regulatory factor (IRF) 5 was identified as a SLE risk gene as it has increased 
expression and is activated in SLE patients (Sigurdsson et al., 2005, Feng and Barnes, 
2013). Other autoimmune diseases have their own risk genes that associate with the 
IFN signature (Stone et al., 2012). The third identified mechanism proposes that the 
regulation and control of pDCs and the expression interferon regulatory genes (IRG) 
is not functioning correctly. The normal homeostatic negative feedback loop to switch 
off the production of IFNα does not work correctly in the context of SLE. B cells and 
natural killer (NK) cells induce pDC function after IC stimulation, and the NK cells 
are inhibited by monocytes (Berggren et al., 2012, Eloranta et al., 2007). This 
inhibition is deficient in SLE as the monocytes produce less reactive oxygen species 
(ROS). These are just three mechanisms that contribute to the type I IFN signature 
seen in autoimmunity, the relative contribution of each may differ between 
autoimmune disease, severity and patient. 
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Figure I.6 The role of type I IFN and the interaction with other cytokines in the 
immune system.. This is a simplified diagram of the cells involved and cytokines 
produced in an autoimmune disease, highlighting the wide-reaching effects of IFN-a. 
Arrows indicate a major producer or target cell. B-cell activating factor (BAFF), 
interleukin (IL), myeloid dendritic cell (mDC), plasmacytoid dendritic cell (pDC), T-
cell receptor (TCR) and tumour necrosis factor (TNF). Adapted from (Ronnblom and 
Elkon, 2010) 
 
IL-6 
The pleiotropic cytokine IL-6 acts as both a pro-inflammatory cytokine and an anti-
inflammatory myokine. T helper 2 (Th2) cells and macrophages are the predominant 
producers of IL-6 but other sources include monocytes, B-lymphocytes, muscle and 
vascular tissue. The receptor complex mediates the biological activities of IL-6. The 
complex consists of IL-6 binding to the type I trans membrane glycoprotein IL-6 
receptor (CD126) and the type I transmembrane signal transducer protein gp130 
(CD130). IL-6 first binds to the membrane-bound non-signaling IL-6Rα (mbIL-6R). 
The IL-6/ IL-6Rα complex binds to two molecules of gp130. This leads to a signal 
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transduction pathway activating JAK/STAT, ERK and P13K (Scheller et al., 2011). 
Activation of the signal transduction pathway by IL-6 leads to acute phase protein 
synthesis, production of neutrophils in the bone marrow and supports B cell growth 
(Hunter and Jones, 2015). 
 
TNF-α 
TNF-α is an endotoxin-induced glycoprotein that is mainly produced by activated 
macrophages and T-lymphocytes. B-lymphocytes, NK cells, neutrophils, mast cells, 
endothelial cells, osteoclasts, fibroblasts, smooth and cardiac muscle cells are also 
sources of endogenous TNF (Bradley, 2008). There are two main types of TNF-α; 
membrane bound 26kDa protein and the 17kDa soluble form. The two forms are 
active in their trimeric forms and are suggested to have distinct biological activities 
(Black et al., 1997). The signalling pathway acts through the two receptors; TNFR1 
(CD120a) and TNFR2 (CD120b). Both receptors act on the transcription factor NF-
κB. Regulation of NF-κB is a principle component of the TNF signal pathway 
(Bouwmeester et al., 2004). TNFR1 has been shown to mediate pro-inflammatory 
pathways associated with programmed cell death and tissue injury. An opposite affect 
has been shown for TNFR2 that mediates signals that promote tissue repair and 
angiogenesis.  
 
Interleukin-10 
Interleukin-10 (IL-10) is an anti-inflammatory cytokine that plays a vital role in the 
prevention of inflammatory and autoimmune pathologies. Many cells of the innate 
and adaptive immune system are capable of IL-10 production regardless of 
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stimulation (Saraiva and O'Garra, 2010). Recent findings show that a regulatory 
subset of B cells produce IL-10. This B cell production of IL-10 is believed to 
contribute to the differentiation and maintenance of a regulatory T cell population and 
for the inhibition of T helper 17 and Th1 cells (Mauri and Bosma, 2012). IL-10 was 
found to be increased in the sera of patients with PM and DM, and positively 
correlated with an increase of disease activity (Gono et al., 2014).  
Interleukin-17 
The interleukin-17 (IL-17) family of cytokines are pro-inflammatory in nature and are 
produced to protect the body from infection. IL-17 works synergistically with TNF- α 
to induce inflammation (Bartlett and Million, 2015). During chronic inflammation 
and within autoimmune diseases IL-17 contributes to tissue destruction. It was 
discovered that IL-17 producing T cells (Th17) played a central role in autoimmune 
inflammation, making IL-17 an important therapeutic target (Miossec and Kolls, 
2012). IL-17 expressing cells have been detected in the muscle of IIM patients, but 
there is a much higher proportion of IFN-g producing Th1 cells than Th17 cells 
(Tournadre and Miossec, 2012, Tournadre et al., 2009). Again, the mRNA expression 
of IL-23 and IL-17 were detected in muscle tissue from IIM patients, but absent from 
healthy muscle (Kondo et al., 2009). IL-23 promotes the differentiation of the Th17 
population from naïve CD4+ T cells in conjunction (Bettelli et al., 2006). These 
findings support an activation of the IL-23-Th17 pathway in the muscle tissue of IIM 
patients and identify it as a potential therapeutic target. 
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Cytokines in IIM 
Cytokines are important mediators in chronic inflammation and in immune regulation. 
The type I IFN-α and –β are involved in the immunopathology of IIM. Analysis of 
cytokine expression in muscle tissue from patients with IIM showed increased 
expression of IL-1α, IL-1β, TNF-α, macrophage inflammatory proteins (MIP)-1α and 
TGF-β (Lundberg, 2000). As well as elevated expression in muscle tissue, TNF-α is 
increased in the serum of patients that have the TNFα-308A allele (Pachman et al., 
2000). Another cytokine that has been detected in the muscle of patients with IIM is 
IL-6 (Salomonsson and Lundberg, 2006). Studies have shown that IL-6 is elevated in 
JDM serum and closely relates to disease activity (Bilgic et al., 2009, Yang et al., 
2013). Other autoimmune diseases, such as RA, have elevated levels of serum IL-6. 
The therapeutic use of the monoclonal antibodies against the IL-6 receptor, 
tocilizumab is effective in many patients with RA (Okuda, 2008). 
 
Lipid rafts and cell signalling 
Lipid rafts are located within the plasma membrane, they are enriched with 
glycosphingolipid (GSL) and cholesterol (Pike, 2003, Sezgin et al., 2017).They are 
dynamic in nature instigating the formation of larger domains through protein-protein 
and protein-lipid interaction. Lipid rafts range in size from 10-200nm, but are too 
small to identify by optical microscopy (Gupta and DeFranco, 2007). The 
accumulation of lipid rafts within a plasma membrane is quantified by the stain for 
monosialotetrahexosylganglioside (GM1), cholera toxin-B subunit (CTB) (Blank et 
al., 2007). These areas of the plasma membrane accumulate high densities of 
signalling molecules. When the BCR binds to an antigen it associates with a lipid raft 
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which in turn enhances B cell signalling. Lipid rafts have been associated with 
atherogenesis and T–cell hyper-responsiveness (Jury et al., 2007). In SLE, it has been 
shown that CD4+ T cells display an alternative lipid-raft associated glycosphingolipid 
profile when compared to healthy control T cells. The main finding was increased 
levels of GM1 in the lipid rafts (McDonald et al., 2014). Restoration of the lipid rafts 
to normal levels comparative of healthy controls may contribute to restoration of T 
cell function in SLE and other autoimmune diseases (Kidani and Bensinger, 2014). 
 
Cholesterol 
Cholesterol is a vital component of all cell membranes and as such is biosynthesised 
by every cell, providing structural integrity and maintaining fluidity of the membrane. 
There are two transcription families that control cholesterol; sterol regulatory 
element-binding protein (SREBP) and liver X receptor (LXR). SREBP ensures a 
regulatory feedback loop between the biosynthesis and the uptake of cholesterol. LXR 
controls a feedback loop to remove excess cholesterol. Both these transcription factor 
families are additionally involved in regulating cytokine production and phagocytosis 
(Spann and Glass, 2013).  
 
IIM and dyslipidaemia 
A study by Tisseverasinghe et al suggested that patients with DM and PM have a 
significantly increased risk of incurring a cardiovascular event (CV). They also 
showed that CV events were strongly associated with dyslipidaemia (Tisseverasinghe 
et al., 2009). Treatment of dyslipidaemia in patients with IIM is challenging as there 
are no advisory treatment guidelines. The main lipid-lowering agents used are 3-
hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) inhibitors (statins), these 
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drugs have known myopathic side effects. Patients with IIM are considered to be at a 
higher risk of statin-related toxicity, but research is ongoing (Charles-Schoeman et al., 
2012). Patients that are treated for CVD without an IIM can develop self-limited 
myopathies that resolve with discontinuation of the statin (Mohassel and Mammen, 
2013). In rare cases treatment with statins can trigger an immune-mediated 
necrotizing myopathy that can be characterised by the presence of an autoantibody 
against HMGCR, the pharmacological target of statins. Anti-HMGCR myopathies 
require immunosuppressive treatment (Mammen, 2011).  
 65 
Chapter II  
 
 
 
 
 
 
 
 66 
Hypothesis and aims 
Hypothesis 1: 
Immature B cells are pathogenic in JDM  
 Aims: 
1. Investigate the mechanisms driving B cell lymphocytosis 
2. Define pathological features of B cells in JDM patients 
 
Hypothesis 2: 
Subsets of IIM have unique immune signatures 
 Aims: 
1. Immunophenotype adult and adolescent-onset IIM PBMC samples 
2. Define immune signatures by disease subtype and disease activity 
 
Hypothesis 3: 
The up-regulated type I IFN signature dysregulates cholesterol homeostasis in IIM 
 Aims: 
1. Explore the relationship between type I IFN and cholesterol 
homeostasis in JDM 
2. Investigate the effect of IFN-a on plasma membrane-associated lipid 
glycosphingolipids and cholesterol-related genes. 
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Materials and methods 
Ethical approval 
Adult myositis, adult healthy control, adolescent onset juvenile dermatomyositis, 
teenage healthy control and child healthy control samples were donated under the 
North Harrow ethics committee approval REC11/0101. 
 
Juvenile dermatomyositis samples were donated under the London-Bloomsbury and 
Yorkshire research ethics committee approval REC 99RU11. 
 
Sample collection 
JDM peripheral blood mononuclear cells (PBMC), serum, plasma and DNA samples 
were collected through the Juvenile Dermatomyositis Research Group (JDRG) from 
patients recruited to the UK JDM Cohort and Biomarker study and repository 
(JDCBS). The JDCBS consists of 16 centres across the UK and Ireland that collect 
serial blood samples and clinical data from patients with JDM. Adolescent onset 
JDM, adult myositis (AM), teenage healthy control (THC), child healthy control 
(CHC) and adult healthy control (AHC) PBMC, serum and plasma samples were 
collected and stored in the Centre of Adolescent Rheumatology Biobank. JDM 
patients were recruited on the basis that they met the Bohan and Peter criteria for 
probable or definite disease (Bohan and Peter, 1975a). AM patients were recruited on 
the basis that they had a positive diagnosis by a clinician from the University College 
London Hospital (UCLH) with positive myositis findings on Electromyogram 
(EMG), magnetic resonance imaging or muscle biopsy. Child HC and adult HC 
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volunteers were recruited on the criteria that they did not have an immunological 
related condition, were not taking any medications and were healthy on the day that 
the samples were taken. 
 
Recruitment pipeline 
I developed a pipeline to recruit and process samples from adult myositis patients and 
child control volunteers (patients having elective surgery for dental caries or hernia 
repair, but otherwise healthy) from University college London hospital (UCLH) 
clinics in collaboration with the Arthritis Research UK (ARUK) Centre for 
Adolescent Rheumatology at University College London (UCL) Great Ormond Street 
Hospital (GOSH) and UCLH. I identified each patient and child control volunteer 
from clinic lists, recruited them in clinic, collected the blood samples and processed to 
be stored for experimental use. 
 
Measurements of disease activity 
The disease activity score tools described below were used to ascertain disease 
activity for adult and juvenile IIM. 
 
MITAX score 
Clinical assessment of the adult and juvenile myositis patients was undertaken using a 
myositis disease activity assessment tool (MITAX). The MITAX tool was found to be 
reliable and valid in an international study (Sultan et al., 2008).This activity 
assessment tool was developed using the same principles as the British Isles Lupus 
Assessment Tool (BILAG) for lupus. They are both based on the principle of the 
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physician’s intention to treat. In each of the different organs and systems assessed a 
patient deemed sufficiently active to require at least 20mg of steroids +/- an 
immunosuppressive drug is assessed as a grade A; a patient with moderately active 
disease requiring a lesser amount of steroid/immunosuppressive is assessed as a B; a 
patient with mild disease requiring topical treatments only or 
Hydroxychloroquine/non-steroidal anti-inflammatories is assessed as a C; a patient 
whose disease was once active in the individual organ system but is no longer active 
is assessed as a D; and a patient whose organ systems were never previously involved 
is assessed as an E. 
 
In a study involving 369 patients with lupus, the optimal numerical scoring system for 
the BILAG-2004 index was determined to be an A = 12 points; B = 8 points; C = 1 
point; D & E = 0 points (Yee et al., 2010). As the principles on which the MITAX 
index were developed are identical to those for lupus, the same numerical conversion 
has been applied to the patients with myositis that were studied. It should be noted 
however that no formal proof of the validity of this methodology in patients with 
myositis currently exists. 
 
Clinicians decision to treat 
In addition to calculating the MITAX for each individual adult and juvenile myositis 
patient, the clinicians’ decision on treatment was also recorded. At each sample point 
it was determined whether the patient had an increase, decrease or no change (stable) 
in their treatment. This information also informed the categorisation of patient into the 
disease activity groups; active, mildly active, remission on treatment and remission 
off treatment. 
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Manual muscle testing of 8 groups (MMT8)  
The MMT8 scoring tool is a set of 8 designated muscles tested unilaterally. The 
potential maximum score demonstrating full muscle strength is 80 and the minimum 
score is 0 (0-80). The muscle groups tested include; deltoid, biceps, wrist extensors, 
quadriceps, ankle dorsi-flexors, neck flexors, gluteus medius and gluteus maximus. 
This scoring tool was validated in adult and juvenile IIM (Rider et al., 2010). 
 
Childhood myositis assessment scale (CMAS) 
The CMAS is a 14-item observational, performance-based tool that was developed to 
evaluate muscle strength, physical function, and endurance in children with juvenile 
IIM. The scores for the 14 items add up to form a total score ranging from 0 (very 
poor physical function and strength) to 52 (normal physical function and strength). 
This scoring tool was validated in juvenile IIM (Huber et al., 2004). 
 
Physicians global assessment (PGA) 
PGA is an accumulation of scores that represent the ways an illness affects disease 
activity or general health (Rider et al., 1997). The global assessment of disease 
activity is scored by a physician using all the information available to them on the day 
of appointment including the subject’s appearance, history, physical examination, 
diagnostic laboratory testing and the resultant medical therapy. The score range is 0-
10 and is marked as a vertical line on a 10cm scale. The left hand of the scale bar is 
equal to zero and refers to no evidence of disease activity. The midpoint line is equal 
to five and refers to moderate disease activity. The far-right end is equal to 10 and 
refers to extremely active or severe disease activity. 
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PBMC isolation 
JDM samples: 
Whole blood samples (~5ml) were collected into a universal containing ~35µl of 
preservative free sodium heparin (Monoparin, 1000IU/ml) or into a 7.5ml S-
Monovette Na-Heparin vacutainer (Sarstedt). Equal volumes of whole blood to 
medium (RPMI 1640 containing L-Glutamine supplemented with Penicillin (final 
concentration 100 IU/ml), Streptomycin (final concentration 100µg/ml) Gibco) were 
diluted in a universal. Peripheral blood mononuclear cells (PBMC) were isolated by 
density centrifugation using Lymphoprep (Stemcell technologies). Cell count was 
calculated using a haemocytometer with Trypan Blue (Sigma-Aldrich), a dye that 
stains the nuclei of dead cells. To calculate the total number of cells; the number of 
cells counted in the central 5 by 5 square of the haemocytometer was multiplied by 
the dilution factor, 10,000 and the cell suspension volume. The PBMC were frozen in 
cryovials at a cell concentration of 5-10x106 live cells per vial re-suspended in 0.5-
1ml of sterile freezing medium (90% heat inactivated foetal calf serum (FCS) plus 
10% dimethyl sulfoxide (DMSO). Cryovials were labelled with allocated sample 
code, date and number of cells and frozen at -80°C in a Nalgene® Mr.Frosty® freezing 
container (controlled rate of freezing of 1°C/minute with isopropyl alcohol). The 
samples were stored in liquid nitrogen (-196°C) no later than 72 hours after initial 
freezing for future use. 
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AM, THC, CHC and AHC samples: 
Whole blood samples (~15ml) were collected in sodium heparin coated vacutainers. 
PBMC were isolated by density centrifugation using Ficoll-Paque Plus 
(GEHealthcare). The PBMC pellet was re-suspended at 5-10x106 cells/ml of freezing 
media. The samples were aliquoted into labelled cryovials and frozen at -80°C in a 
Nalgene® Mr.Frosty® freezing container. The samples are stored in liquid nitrogen (-
196°C) for future use. 
 
Serum isolation 
JDM samples: 
Whole blood was collected in vacutainers free from coagulant. The blood was 
allowed to clot for 30 minutes at room temperature. The supernatant was transferred 
to sterile Eppendorf’s and sera was isolated by micro-centrifugation (10,000xg for 10 
minutes at room temperature). Supernatant was frozen and stored in labelled aliquots 
at -80°C. 
 
ADM, THC, CHC and AHC samples: 
Serum samples were collected in vacutainers primed with silicon clotting agents (BD 
vacutainer SST II advance). 30 minutes after collection the sera were isolated by 
density macro-centrifugation. The separated serum samples were labelled, aliquoted, 
frozen and stored at -80°C. 
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PBMC thawing and counting 
PBMC samples were thawed in a water bath at 37°C, washed and re-suspended in 
media (RPMI-1640 with L-glutamine and NaHCO3 (Sigma Aldrich) plus 10% FBS 
and 1% penicillin-streptomycin (10,000 units penicillin and 10mg/ml streptomycin in 
0.9% NaCl working solution – Sigma Aldrich)). Cell count was calculated using a 
haemocytometer with Trypan Blue (Sigma-Aldrich). 
 
Cell sorting 
Magnetic bead purification 
CD3+ T cells, CD14+ monocytes and enriched B cells were isolated from PBMC 
suspensions by magnetic bead purification using EasySep positive selection or 
enrichments kits (StemCell technologies), according to manufacturer’s instructions. 
Positive selection is where the cell of interest is bound to a magnetic particle 
recognised by a specific antibody complex and isolated by magnetic selection. 
Negative selection is where all other cells apart from the cell of interest are bound to a 
magnetic particle recognised by a specific antibody cocktail complex and isolated by 
magnetic selection, leaving the negative fraction in the supernatant. 
 
Positive selection of T cells 
PBMC were thawed and then washed twice with ice-cold magnetic-activated cell 
sorting (MACS) buffer (PBS (Sigma-Aldrich) containing 0.5% FCS and 2mM 
ethylenediamine tetra-acetic acid (EDTA; Gibco, Invitrogen)) in a 50ml falcon tube 
and centrifuged at 500xg at 4°C for 8 minutes. The PBMC were re-suspended in 
MACS buffer at an indicated concentration of 1x108 cells/ml in a 5ml polystyrene 
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round-bottom tube. The EasySep Human CD3 positive selection cocktail (tetrameric 
antibody complexes recognizing CD3 and containing an antibody to human Fc 
receptor to minimize nonspecific binding) was added at 100µl/ml of sample, mixed 
and incubated for 15 minutes at room temperature. The dextran-coated magnetic 
particles were mixed and added to sample at 50µl/ml of sample, mixed and incubated 
for 10 minutes at room temperature. The sample was topped up to a volume of 2.5ml 
with MACS buffer, mixed and placed in a cold magnet (chilled to 4°C) without a lid 
for 5 minutes. After the incubation the magnet was picked up and the supernatant 
(containing the negative fraction) was poured off in one continuous movement into a 
new falcon. The round-bottom tube inside the magnet was topped up to 2.5ml of 
MACS buffer and the magnetic incubation step was repeated twice, each time pouring 
off the supernatant (containing the negative fraction). After the final magnetic 
incubation step the isolated CD3+ T cells were re-suspended in MACS buffer and 
counted prior to subsequent use.  
 
Positive selection of Monocytes 
PBMC were thawed and then washed twice with ice-cold MACS buffer (PBS (Sigma-
Aldrich) containing 0.5% FCS and 2mM EDTA and centrifuged at 500xg at 4°C for 8 
minutes. The PBMC were re-suspended in MACS buffer at an indicated concentration 
of 1x108 cells/ml in a 5ml polystyrene round-bottom tube. The EasySep Human CD14 
positive selection cocktail (tetrameric antibody complexes recognizing CD14) was 
added at 100µl/ml of sample, mixed and incubated for 15 minutes at room 
temperature. The dextran-coated magnetic particles were mixed and added to the 
sample at 50µl/ml of sample, mixed and incubated for 10 minutes at room 
temperature. The sample was topped up to a volume of 2.5ml with MACS buffer, 
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mixed and placed in a cold magnet (chilled to 4°C) without a lid for 5 minutes. After 
the incubation the magnet was picked up and the supernatant was poured off in one 
continuous movement into a new falcon. The round-bottom tube inside the magnet 
was topped up to 2.5ml of MACS buffer and the magnetic incubation step was 
repeated twice, each time pouring off the supernatant. After the final magnetic 
incubation step the isolated CD14+ cells were re-suspended in MACS buffer and 
counted prior to subsequent use. Figure II.1B depicts the CD14+ monocyte cell 
purity before and after magnetic purification. 
 
Negative selection of B cells 
PBMC were thawed and then washed twice with ice-cold MACS buffer (PBS (Sigma-
Aldrich) containing 0.5% FCS and 2mM EDTA in a 50ml falcon tube and centrifuged 
at 500xg at 4°C for 8 minutes. The PBMC were re-suspended in MACS buffer at an 
indicated concentration of 5x107 cells/ml cell/ml in a 5ml polystyrene round-bottom 
tube. The EasySep Human B cell enrichment cocktail (tetrameric antibody complexes 
recognizing non-B cells) was added at 50µl/ml of sample, mixed and incubated for 10 
minutes at room temperature. The EasySep D magnetic particles were vortexed and 
added to sample at 75µl/ml of sample, mixed and incubated for 5 minutes at room 
temperature. The sample was topped up to a volume of 2.5ml with MACS buffer, 
mixed and placed in a cold magnet (chilled to 4°C) without a lid for 5 minutes. After 
the incubation the magnet was picked up and the supernatant was poured off in one 
continuous movement into a new falcon tube. Isolated B cells in the supernatant were 
counted prior to subsequent use. Figure II.1C depicts the B cell purity before and 
after magnetic purification. 
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Figure II.1 Monocyte and B cell purification plots before and after isolation. 
Flow cytometry plots demonstrating CD19+CD14-, CD19+CD4+, CD19-CD14+ 
and CD19-CD14- populations. (A) PBMC before purification. (B) PBMC after 
CD14+ monocyte isolation. (C) PBMC after B cell enrichment isolation. 
 
Flow cytometry  
Staining 
PBMC samples were plated in a 96 well plate at 300,000 per well. The PBMC were 
washed with 1xPBS and incubated at room temperature for 20 minutes with 
Live/Dead fixable cell stains (Life Technologies) [1:500 dilution] that were used to 
exclude dead cells from flow cytometric analysis (Table II.1). Flow cytometry was 
performed with directly conjugated antibodies (Table II.2). Surface markers were 
diluted in FACS buffer (500ml 1x PBS (Sigma Aldrich), 1%FBS, 0.01% sodium 
azide). The PBMC were washed with FACS buffer and then incubated at 4°C for 20 
minutes in the presence of surface markers. All samples were fixed with intracellular 
fixation buffer for 20 minutes at 4°C (eBiosciences). For the measurement of ex-vivo 
intra-nuclear Ki-67, cells were fixed with FOXP3 fixation buffer (eBiosciences). 
Intracellular markers were diluted in Perm buffer (10% 10x permeabilisation buffer 
(eBiosciences), 90% FACS buffer). The PBMC were washed with Perm buffer and 
then incubated in the presence of intracellular or intra-nuclear markers for 45 minutes 
at 4°C.  
CD14
C
D
19
A B C
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For samples that were stained for CTB and filipin. All samples were stained with 
50μL of CTB (1:100) (Sigma Life Sciences) in FACS buffer for 20 minutes at 4°C. 
Samples were next washed with 150μL of FACS buffer and spun at 800xg, for 3 
minutes at 4 °C. Samples were fixed with 100μL 2% paraformaldehyde (PFA) 
(Sigma-Aldrich) in foil at room temperature (RT) for 1hour. The samples were 
washed with 100μL of FACS buffer and spun at 800xg, for 3 minutes at 4°C. The 
samples were re-suspended in 200μL of 1xPBS and left overnight in the fridge. The 
samples were washed with 100μL of FACS buffer and spun at 800xg, for 3 minutes at 
4°C. The samples were stained with 100μL of filipin (1:200 in 1 xPBS) for 2hours at 
RT in foil. The samples were washed with 100μL of FACS buffer and spun at 800xg, 
for 3 minutes at 4°C. The samples were re-suspended in 200μL of FACS buffer and 
placed in FACS tubes to be run on LSRII flow cytometer. 
 
Flow cytometry cell sorting 
The PBMC subsets CD4, CD8, CD14 and CD19 were sorted by flow cytometry 
(FACS Aria III), after staining for 30 minutes with CD4 BV711 (1:25), CD8 APC 
(1:200), CD14 FITC (1:100) and CD19 Pe-Cy7 (1:25) in sort buffer (50ml 1x sterile 
PBS, 1ml FBS, 400µl 0.5M EDTA) (Table II.2). Dead cells were excluded by using 
4,6 diamidino-2-phenylindole (DAPI; Sigma) at 1µ/ml. Sorted cells were collected in 
collection media (RPMI+1%penicillin-streptomycin + 20% FBS). A purity check was 
completed on each sorted cell type collecting 500 events for each. 
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Analysis 
Data were collected on an LSRII flow cytometer (BD Pharmingen) using FACS Diva 
software. Application settings were created to begin with and Cytometer Setup and 
Tracking (CS&T) beads were run on the flow cytometer before each session. 
Application settings were applied to panel templates each time prior to compensation 
to ensure that all immunophenotyping data is comparable over time. Data were 
analysed with Flowjo (Tree Star). 
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List of antibodies 
Table II.1 List of live/dead fixable stains 
Live/dead Fluorochrome Manufacturer 
Live/dead fixable blue Live/dead blue Life technologies 
Live/dead fixable yellow QDOT 605 Life technologies 
4,6-diamidino-2phenylindole (DAPI) DAPI Sigma 
 
Table II.2 List of conjugated antibodies used for flow cytometry 
Surface marker Fluorochrome Clone Isotype Manufacturer 
CD3 BUV396 
UCHT1 Mouse BALB/c 
IgG1, k 
BD 
CD185 BV605 J252D4 Mouse IgG1, k Biolegend 
CD4 BUV737 
SK3 Mouse BALB/c 
IgG1, k 
BD 
CD4 BV711 OKT4 Mouse IgG2b, k Biolegend 
CD45RA BV421 HI100 Mouse IgG2b, k Biolegend 
CD27 BV785 O323 Mouse IgG1, k Biolegend 
CD127 BV711 A019D5 Mouse IgG1, k Biolegend 
CD25 PE-Cy7 M-A251 Mouse IgG1, k Biolegend 
TCR V a24-Ja18 APC 6B11 Mouse IgG1, k Biolegend 
CD8 APC-cy7 RPA-T8 Mouse IgG1, k Biolegend 
CD8 APC SK1 Mouse IgG1, k eBioscience 
CD69 BV510 FN50 Mouse IgG1, k Biolegend 
PD-1 PE   NAT105 Mouse IgG1, k Biolegend 
CD278 AF488 
C398.4A Armenian 
Hamster IgG 
Biolegend 
CD19 BV786 HIB19 Mouse IgG1, k Biolegend 
CD19 Pe-Cy7 SJ25C1 Mouse IgG1, k eBioscience 
CD38 BUV737 HB7 Mouse IgG1, k BD 
CD24 BV421 ML5 Mouse IgG2a, k Biolegend 
CD27 BV711 O323 Mouse IgG1, k Biolegend 
CD14 BV605 M5E2 Mouse IgG2a, k Biolegend 
CD14 FITC 61D3 Mouse IgG1, k eBioscience 
CD16 APC-cy7 B73.1 Mouse IgG1, k Biolegend 
IgD FITC IA6-2 Mouse IgG2a, k Biolegend 
CD69 PE-cy7 FN50 Mouse IgG1, k Biolegend 
HLA-DR BV510 L243 Mouse IgG2a, k Biolegend 
CD24 APC SN2 A5-2H10 Mouse IgG1, k eBioscience 
CD27  PECy7 O323 Mouse IgG1, k eBioscience 
CD38 BV605 HIT2 Mouse IgG1, k Biolegend 
IgM Pacific Blue MHM-88 Mouse IgG1, k eBioscience 
Cholera Toxin b 
subunit (CTB) FITC 
  Sigma 
Filipin INDO-1 violet    
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Table II.3 List of conjugated intracellular and intra-nuclear antibodies used for 
flow cytometry 
Intracellular/nuclear Fluorochrome Clone Isotype Manufacturer 
IL-6 PE   MQ2-13A5 Rat IgG1,k eBioscience 
IL-17A AF 488 
N49-653 Mouse 
IgG1, k 
BD 
Ki-67 PE 
B56 Mouse 
IgG1, k 
BD 
IL-10 APC JES3-9D7 Rat IgG1,k BD 
 
 
 
Figure II.2 FACS gating strategy. Representative flow cytometry gating strategy 
plots for sorting CD19+ve B cells, CD14+ve monocytes, CD8+ve and CD4+ve T 
cells from PBMC sample. Gate P1 selects PBMC by size. Gate P2 selects singularly 
stained cells. Gate P3 selects live DAPI negatively stained PBMC.  
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Figure II.3 Purity check for CD19+ve sorted cells. Gate P1 selects PBMC by size. 
Gate P2 selects singularly stained cells. Gate P3 selects live DAPI negatively stained 
PBMC.  
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Figure II.4 Purity check for CD14+ve sorted cells. Gate P1 selects PBMC by size. 
Gate P2 selects singularly stained cells. Gate P3 selects live DAPI negatively stained 
PBMC.  
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Figure II.5 Purity check for CD8+ve sorted cells. Gate P1 selects PBMC by size. 
Gate P2 selects singularly stained cells. Gate P3 selects live DAPI negatively stained 
PBMC.  
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Figure II.6 Purity check for CD4+ve sorted cells. Gate P1 selects PBMC by size. 
Gate P2 selects singularly stained cells. Gate P3 selects live DAPI negatively stained 
PBMC.  
 
Cell culture 
PMA/I/GP 
To detect intracellular cytokines PBMC were stimulated for 4 hours; with 50ng/ml 
PMA and 250ng/ml Ionomycin (both Sigma Aldrich) in the presence of Golgi plug 
(BD Bioscience). 
IFN-a and R848 
For the detection of intracellular IL-6 and IL-10; 300,000 PBMC/B cells were 
cultured for 48/72 hours with R848 at 1µg/ml (Invivogen) +/- recombinant IFN-a at 
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1000 IU/ml (PBL assay Science) in media (RPMI 1640 containing L-Glutamine 
supplemented with 10% FCS and Penicillin (final concentration 100 IU/ml)). To 
detect changes in lipid regulated genes in response to IFN-a, 300,000 sorted 
monocytes, B and T cells were cultured with IFNa for 2/6/24hours. 
 
Chinese hamster ovary (CHO) cells expressing human CD154 (CD40L) 
One million CD154 transfected CHO cells and un-transfected control cells (donated 
by Prof. R. Mageed, Queen May University London) were grown in Dulbecco’s 
Modified Eagle’s Medium (DMEM; Sigma-Aldrich) containing 4500 mg/ml glucose, 
110 mg/ml sodium pyruvate and 2nM L-glutamine, supplemented with 5% FCS and 
100U/ml penicillin and streptomycin in T25 flasks. When the CHO cells were 
adherent and confluent they were washed with ice-cold phosphate-buffered saline 
(PBS), and detached using Trypsin-EDTA (Sigma-Aldrich) and were seeded in new 
culture flasks after each passage. Routinely through the growth period of the CHO 
cells the CD154 expression was checked by flow cytometry. The CHO cells received 
gamma-irradiation via a caesium source for 10 minutes (250kV, 11.6mA, 7 
Gy/minute) in 25cm2 culture flasks with a minimal covering of culture media prior to 
use in an experiment, this was to prevent further proliferation. The irradiated CHO 
cells were then washed with RPMI 1640, detached using Trypsin-EDTA as 
previously and counted using a haemocytometer. A ratio of 1:10 CHO:B cells was 
used in experimental cell cultures. The CHO cells were incubated for 2 hours prior to 
addition of human B cells to allow adherence. 
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Analysis of Kappa-deleting recombination excision circles (KREC) content 
Immature, mature and memory B cells were sorted and DNA was extracted using a 
QIAamp Blood DNA Mini Kit (Qiagen), according to manufacturer’s instructions. 
Quantitative real time PCR (qRT-PCR) was carried out on the DNA samples as 
previously described (Gaspar et al., 2011), with a standard curve method of analysis, 
using serial dilutions of a known quantity (106, 105, 104, 103, 102, 10 copies) of a 
linearised plasmid containing segments of T cell receptor alpha constant (TRAC), 
KREC and T cell receptor excision circles (TREC). The quantity of KREC per 106 
cells were calculated by the following equation, whereby n is the total amount of 
KRECs per 106 cells; k is the mean quantity of KRECs and t is the mean quantity of 
TRAC. 
n= !"/$ 	&10) 
Details of the plasmid and primer/probe sequences used were previously (Sottini et 
al., 2010). 
 
ELISA 
Human serum and PBMC culture supernatants (stimulated with CD40L CHO for 72 
hours) were measured for concentrations of IL-10, IL-6 and soluble IL-6 receptor 
complex. IL-6 and soluble IL-6 receptor complex were measured separately using 
R&D systems human ELISA kits (DY206, DY8139-05) according to manufacturer’s 
instructions. The Ready-set-go human IL-10 ELISA kit (eBioscience) was used 
according to manufacturer’s instructions. Sera from patients were tested for CXCL10, 
CXCL11, MCP-1 and MCP-2 via multiplex cytokine array (Luminex) (Bellutti 
Enders et al., 2014). 
 87 
RNA extraction 
PicoPure 
PBMC and sorted cell sample RNA were extracted following the Arcturus PicoPure 
RNA Isolation protocol, using cell suspension media (0.9ml 1xPBS/10%BSA, 0.1ml 
0.5M EDTA) and extraction buffer (Arcturus PicoPure RNA Isolation Kit). The 
samples were frozen and stored at -80°C.  
 
Within the lab benches, an RNA free zone with RNase was established. RNA was 
isolated following the Arcturus PicoPure RNA manufacturers protocol using reagents 
from the PicoPure RNA Isolation Kit (Thermo Fisher). 250µl of conditioning buffer 
was pipetted onto the purification columns filter membrane and incubated at room 
temperature for 5 minutes. The columns were spun at 16,000xg for 1 minute in a 
micro-centrifuge. The extracted PBMC and sorted cell RNA samples were thawed 
and 100µl of 70% ethanol was added and mixed. The samples were pipetted into the 
pre-conditioned purification columns and spun at 100xg for 2 minutes, followed by 1 
minute at 16,000xg to bind the DNA. 100µl of wash buffer 1 was pipetted into each 
purification column and spun at 8,000xg for 1 minute. A mix of 10ul of DNase I stock 
solution and 30µl of Buffer RDD per sample was made, 40µl was added to each 
purification column and the incubated for 15 minutes. 40µl of wash buffer 1 was 
added to each column and spun at 8,000xg for 1 minutes. 100µl of wash buffer 2 was 
pipetted into each column and spun at 8,000g for 1 minutes. 100µl of wash buffer 2 
was pipetted into the column and spun at 16,000g for 2 minutes. The column was 
transferred into new 0.5ml micro centrifuge tube and 11µl of elution buffer was 
directly pipetted onto each membrane. After being incubated for 1 minute at room 
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temperature each column and tube complex was spun at 1,000xg for a minute 
followed by 16,000xg for another minute to elute the RNA into the micro-centrifuge 
tube. The isolated RNA samples were labelled and stored at -80°C in preparation for 
RNA sequencing or polymerase chain reaction (PCR). 
 
Trizol RNA extraction 
PBMC and sorted cell sample RNA were extracted following the Trizol RNA 
isolation protocol developed within the lab group. The samples were aliquoted into 
RNA free labelled eppendorfs and spun at 400xg for 10 minutes in a micro-
centrifuge. The supernatant was removed and the pellet re-suspended in 200µl of 
Trizol in a fume cupboard. The Trizol samples were stored at -80°C. 
 
Extraction was carried out within the RNA free zone with RNase Zap â and the 
protocol was carried out on ice. The extracted PBMC and sorted cell RNA samples 
were thawed and an identical set of labelled eppendorf’s were placed in the fridge. 
40µl of chloroform was added to thawed samples, vortexed and incubated at room 
temperature for 3 minutes. The samples were spun at 13,500rpm for 20 minutes at 
4°C. Following centrifugation the mixture separates into lower red, phenol-
chloroform phase, an interphase, and a colourless upper aqueous phase. RNA remains 
exclusively in the aqueous phase. The upper aqueous phase was transferred into the 
cold new eppendorf’s, taking care not to disturb the interphase. The RNA was 
precipitated from the aqueous phase by mixing it with 100µl of cold isopropyl alcohol 
and 0.2µl of glycogen (10µg/L) (a carrier to ensure visible RNA pellets) and stored at 
-20°C overnight. 
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The samples were thawed and spun at 13,500rpm for 15 minutes at 4°C. The 
supernatant was removed completely and 500µl of cold 70% ethanol was added to 
each tube. The suspension was mixed and spun at 13,000rpm for 15 minutes at 4°C. 
The wash and spin was repeated. The supernatant was completely removed and the 
pellets were left to dry without lids for 5 minutes at room temperature. The RNA 
pellet was dissolved in 20µl of pre-heated (65°C) molecular water. The quantity and 
quality of the eluted RNA samples were analysed by nanodrop spectrophotometer and 
stored at -80°C. 
 
cDNA synthesis 
cDNA was synthesised using the qScripta cDNA synthesis kit (VWR). 4µl of 5x 
master mix (containing primer blend (oligo dT(20) and random hexamer), dNTPs and 
MgCl2), and 1µl of enzyme (50x concentrated qScript reverse transcriptase) were 
added to 15µl of pre-diluted RNA. The samples were mixed and centrifuged for 30 
seconds to collect the contents. The samples were placed in a thermal cycler 
programmed; one cycle at 22°C for 5 minutes, one cycle at 42°C for 30 minutes, one 
cycle at 85°C for 5 minutes and then stored at 4°C. 
 
PCR 
Primer design 
Primers were designed to be intron spanning or flanking (to avoid amplification of 
genomic DNA) using Primer 3 (Koressaar and Remm, 2007). The specificity was 
checked with NCBI Primer Blast (Ye et al., 2012). The efficiency was validated by 
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amplifying a standard curve of DNA, and the dissociation curves were checked for 
primer dimers.  
 
Table II.4 Primers used to measure gene expression by qPCR 
Gene Forward primer Reverse primer 
Cyclophilin 5’GCATACGGGTC
CTGGCATCTTGT
CC3’ 
5’ATGGTGATCTT
CTTGCTGGTCTT
GC3’ 
3-hydroxy-3methylglutaryl-coenzyme 
A reductase (HMGCR) 
5’CAGCCATTTTG
CCCGAGTTT3’ 
5’AGCGACTGTGA
GCATGAACA3’ 
Fatty acid synthase (FASN) 5’CTGCTGCTGGA
AGTCACCTA3’ 
5’GTGTGTGTTCC
TCGGAGTGA3’ 
Sterol regulatory element-binding 
transcription 1 (SREBP1) 
5’TCAGCGAGGCG
GCTTTGGAG3’ 
5’CATGTCTTCGA
TGTCGGTCAG3’ 
Sterol regulatory element-binding 
transcription 2 (SREBP2) 
5’CTGGAGACCAT
GGAGACCCT3’ 
5’GTCAGGGAACT
CTCCCACTTG3’ 
UDP-glucose ceramide 
glucosyltransferase (UGCG) 
5’CGTCCTCTTCT
TGGTGCTGT3’ 
5’AGAGAGACAC
CTGGGAGCTT3’ 
Stearoyl-CoA desaturase (SCD) 5’GCAAACACCCA
GCTGTCAAA3’ 
5’GCACATCATCA
GCAAGCCAG3’ 
ELOVL fatty acid elongase 5 
(ELOVL5) 
5’CTTGGGCTAAA
AGGTTTTCAAAT
GG3’ 
5’ATCTCGAGGGC
CTAGCAATG3’ 
F-box 06 (FBX06) 5’TGGGGATCCCA
GGCCA3’ 
5’TTCTCGGGCAG
GTCGTTAAT3’ 
Syntaxin 5 (STX5) 5’GACAATCTTGG
CAAAGCGCA3’ 
5’TCCTGGAGCTG
AGCAATTTGT3’ 
Malic enzyme 1 (ME1) 5’TAGTTTGGTGT
TTCGGAAGCC3’ 
5’CCACAATGGCC
TTGATGACA3’ 
 
Quantative PCR (qPCR) 
To measure the expression of the selected genes qPCR was used. SYBR green 
(Quanta Biosciences TM) was the reference dye and cyclophilin was the endogenous 
control (housekeeping) gene. qPCR was carried out using a 2-step protocol (the 
annealing and extension happen in the same step); 30s at 95°C, followed by 40 cycles 
of 5s 95°C (denaturation), 30s 60°C (annealing/extension), finishing with the 
dissociation curve (Figure II.7).  
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Figure II.7 Thermal profile for qPCR 
RNA-sequencing 
Library preparation 
Samples were processed using Illumina’s TruSeq Stranded mRNA LT sample 
preparation kit (p/n RS-122-2101) according to manufacturer’s instructions with 
minor alterations. Products that were used that were not included in this kit have been 
stated. 
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PolyA select mRNA 
250ng total RNA and nuclease free H20 was mixed to a final volume of 50µl. RNA 
purification beads were vortexed and 50µl was added to each RNA sample. The 
sample was mixed by pipetting up and down until beads were in a homogenous 
suspension. Next the sample was incubated in a thermacycler to denature for 5 
minutes at 65°C and hold at 4°C. Once the thermocycler reached 4°C the samples 
were removed and placed on the bench at room temperature for 5 minutes. The 
samples were placed in a magnetic rack for 5 minutes. The supernatant was removed 
and discarded. The samples were removed from the rack. 200µl of Bead Washing 
buffer was added to each sample and pipetted up and down until the beads were in a 
homogenous suspension. The samples were put back into the magnetic rack for 5 
minutes, or until the beads had pelleted. The supernatant was removed and discarded. 
50µl of Elution Buffer was added to each sample and pipetted up and down until 
beads were in a homogenous suspension. The samples were incubated in the 
thermocycler to elute the RNA for 2 minutes at 80°C for 2 minutes and then held at 
25°C. The samples were removed from the thermocycler when they had reached 25°C 
and kept at room temperature. 50µl of Bead Binding Buffer was added to each sample 
and pipetted up and down until beads were in a homogenous suspension. The samples 
were incubated at room temperature for 5 minutes. The samples were placed in the 
magnetic rack for 5 minutes, or until the beads pelleted. The supernatant was removed 
and discarded. The samples were removed from the rack. 200µl of Bead Washing 
Buffer was added to each sample and pipetted up and down until the beads were in a 
homogenous suspension. The samples were placed in a magnetic rack for 5 minutes, 
or until beads pelleted. The supernatant was removed and discarded. 19.5µl of 
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Fragment, Prime, Finish mix was added to each sample and pipetted up and down 
until the beads were in a homogenous suspension. The samples were incubates in the 
thermocycler to prime for 10 minutes at 94°C and then hold at 4°C, then briefly spun  
and placed in a magnetic rack for 5 minutes. Lastly, 17µl of the supernatant was 
transferred to a new 0.2ml PCR tube.  
 
First strand synthesis 
8µl First Strand Synthesis ActD/Superscript II mix (SuperScript II, Life Technologies 
p/n 18064014) was added to each sample. The samples were incubated in the 
thermocycler for the fscDNA stage for 10 minutes at 25°C, then 15minutes at 42°C, 
15 minutes at 70°C and held at 4°C. 
 
Second strand synthesis 
5µl of Resuspension buffer was added to each sample. 20µl of Second Strand 
Marking Master mix was added to each sample. The samples were incubated in the 
thermocycler with the lid open for the sscDNA stage for 60 minutes at 16°C and then 
held at 4°C. The samples were removed and left at room temperature. 
 
Clean up cDNA 
90µl of well vortexed AMPure XP beads (Ampure XP, Beckman Coulter p/n 
A63881) were added to each sample and mixed by pipetting up and down until the 
beads were in a homogenous suspension. The samples were incubated at room 
temperature for 5 minutes, then placed in a magnetic rack for 5 minutes, or until beads 
had pelleted. The supernatant was removed and discarded. The samples were kept in 
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the magnetic rack and 200µl 80% ethanol was added to each. The samples were 
incubated for 30 seconds. All supernatants were removed and discarded. The ethanol 
wash was repeated twice. All the residual ethanol was removed. The samples were 
left to stand at room temperature to dry for 5-15 minutes. 19.5µl Resuspension Buffer 
was added to each sample and pipetted up and down until the beads were in a 
homogenous suspension. The samples were incubated at room temperature for 2 
minutes, and placed in a magnetic rack for 5 minutes, or until beads pelleted. 17.5µl 
of the supernatant was transferred to new 0.2ml PCR tube. 
 
Perform A-tailing 
12.5µl A-Tailing mix was added to each sample. The samples were incubated in the 
thermocycler for the ATAIL step for 30 minutes at 37°C, 5 minutes at 70°C and held 
at 4°C. The samples were removed from the thermocycler when they had reached 
4°C. 
 
Ligate adaptors 
To each sample 2.5µl of Resuspension buffer, 2.5µl ligation mix, and 2.5µl of RNA 
Adaptor index was added. The samples were incubated in a thermocycler for the 
Ligate step for 10 minutes at 30°C. 5µl of Stop ligation mix was added to each. 
 
Clean up Adaptor-ligated cDNA 
42µl of well vortexed AMPure XP beads were added to each sample and mixed by 
pipetting up and down until the beads were in homogenous suspension. The samples 
were incubated at room temperature for 5 minutes. The samples were placed in a 
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magnetic rack for 5 minutes, or until beads had pelleted. The supernatant was 
removed and discarded. The samples were kept in the magnetic rack and 200µl 80% 
ethanol was added. The samples were incubated for 30 seconds. All supernatant was 
removed and discarded. The ethanol wash was repeated twice. All residual ethanol 
was removed. The samples were let to stand at room temperature to dry for 5-15 
minutes. 52.5µl Resuspension buffer was added to each sample and pipetted up and 
down until the beads were in a homogenous suspension. The samples were incubated 
at room temperature for 2 minutes, and placed in a magnetic rack for 5 minutes, or 
until beads had pelleted. 50µl of the supernatant was transferred to a new 0.2ml PCR 
tube. 50µl of well vortex AMPure XP beads was added to each sample and mixed by 
pipetting up and down until the beads were in homogenous suspension. The samples 
were incubated at room temperature for 5 minute, and placed in a magnetic rack for 5 
minutes, or until beads had pelleted. The supernatant was removed and discarded. The 
samples were kept in the magnetic rack and 200µl 80% ethanol was added to each. 
The samples were incubated for 30 seconds. All the supernatant was removed and 
discarded. The ethanol wash was repeated twice. All residual ethanol was removed. 
The samples were let to stand at room temperature to dry for 5-15 minutes. 22.5µl 
Resuspension buffer was added to each sample and pipetted up and down until the 
beads were in a homogenous suspension. The samples were incubated at room 
temperature for 2 minutes. The samples were placed in a magnetic rack for 5 minutes, 
or until beads had pelleted. 20µl of the supernatant was transferred to a new 0.2ml 
PCR tube. 
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Amplify library by PCR 
A mastermix was prepared for each reaction; 5µl of PCR Primer cocktail and 25µl of 
PCR master mix. 30µl of the mastermix was added to 20µl adaptor ligated cDNA and 
mixed by pipetting up and down. The cDNA was amplified by the following PCR 
protocol; 30 seconds at 98°C, then for 14 cycles (10 seconds at 98°C, 30 seconds at 
60°C, 30 seconds at 72°C), 5 minutes at 72°C and then held at 4°C. 
 
Clean up PCR products 
50µl of well vortexed AMPure XP beads was added to each sample and mixed by 
pipetting up and down until the beads were in homogenous suspension. The samples 
were incubated at room temperature for 5 minutes, then placed in a magnetic rack for 
5 minutes, or until beads had pelleted. The supernatant was removed and discarded. 
The samples were kept in the magnetic rack and 200µl 80% ethanol was added. The 
samples were incubated for 30 seconds. All supernatant was removed and discarded. 
The ethanol wash was repeated twice. All residual ethanol was removed. The samples 
were let to stand at room temperature to dry for 5-15 minutes. 32.5µl Resuspension 
buffer was added to each sample and pipetted up and down until the beads were in a 
homogenous suspension. The samples were incubated at room temperature for 2 
minutes, and placed in a magnetic rack for 5 minutes, or until beads had pelleted. 30µl 
of the supernatant was transferred to a new 0.2ml PCR tube. The library distribution 
was assessed on a Bioanalyser DNA 1000 and quantified using the Qubit DNA HS 
assay. The concentration was normalised to 10nM. 
 
 Briefly, mRNA was isolated from 250 ng total RNA using Oligo dT beads to pull 
down Poly-Adenylated transcripts. The purified mRNA was fragmented using 
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chemical fragmentation (heat and divalent metal cation) for 10 minutes and primed 
with random hexamers.  Strand-specific first strand cDNA was generated using 
Reverse Transcriptase and Actinomycin D. This allows for RNA dependent synthesis 
while preventing spurious DNA-dependent synthesis. The second cDNA strand was 
synthesised using dUTP in place of dTTP, to mark the second strand. The resultant 
cDNA is then “A-tailed” at the 3’ end to prevent self-ligation and adapter 
dimerisation. Full length TruSeq adaptors, containing a T overhang are ligated to the 
A-Tailed cDNA. These adaptors contain sequences that allow the libraries to be 
uniquely identified by way of a 6 base pairs Index sequence. Successfully ligated 
fragments were enriched with 14 cycles of PCR. The polymerase is unable to read 
tough uracil, so only the first strand is amplified, thus making the library strand 
specific. 
 
Sequencing 
Libraries to be multiplexed in the same run were pooled in equimolar quantities, 
calculated from Qubit and Bioanalyser fragment analysis. Samples were sequenced on 
the NextSeq 500 instrument (Illumina, San Diego, US) using a 43 bp paired end run 
resulting in >15million reads per sample. 
 
iData Analysis 
Run data were demultiplexed and converted to fastq files using Illumina’s bcl2fastq 
Conversion Software v2.16. Sequencing reads (in fastq format) were aligned to the 
GRCh38 reference sequence using TopHat v2.1.0 (Kim et al., 2013). Alignments 
were processed using samtools version 1.2 and Picard tools version 1.140 
(http://picard.sourceforge.net/)(Li et al., 2009). Aligned reads were filtered for 
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mapq >= 4, i.e. uniquely mapping reads, and putative PCR duplicates were removed. 
Read summarization was performed using featureCounts (Liao et al., 2014). 
Expression analysis was carried out using R version 3.2.2 (Team, 2015), and 
differential gene expression was analysed using edgeR (Robinson et al., 2010). 
 
Gene Set Enrichment Analysis (GSEA) 
GO term and pathway enrichment analysis was carried out using ‘goseq’ which uses a 
test based on the Wallenius’ noncentral hypergometric distribution (Young et al., 
2010). Gene set enrichment analysis was carried out with “Hallmark” gene sets from 
databases (Subramanian et al., 2005). Normalized enrichment scores (NES) and 
multiple adjusted p-values (q values) were calculated. 
 
Statistical analysis 
Data, excluding RNAseq, were analysed using Graphpad Prism 6. Expression analysis 
was carried out using R version 3.2.2, and differential gene expression was analysed 
using edgeR (Team, 2015, Robinson et al., 2010). One way analysis of variance 
(Crow and Casanova) was used to assess significance of differences between group 
means (≥3 groups) and unpaired Student’s t test was used to assess significance 
between 2 groups. Bonferonni, Dunnett’s and Tukey’s corrections were applied for 
multiple comparisons using ANOVA. Pearson’s/ Spearman’s correlation coefficients 
were used to assess correlations. Bar graph data represented as mean ± SEM. For all 
figures, P values are represented as followed: * P <0.05; ** P <0.01; *** P <0.001.  
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Statistical analysis for chapter IV 
Statistical analysis was performed in GraphPad Prism 6 software. Initially unpaired 
student t-tests were used to compare ex-vivo cell populations from patients and 
controls, this calculated p values from testing the significance of the difference. The 
fold change was also calculated to determine the directional change in the mean 
average. Each disease group was also analysed by comparing subsets of the disease; 
dermatomyositis (DM), polymyositis (PM), dermatomyositis with cancer (DM+C), 
dermatomyositis with overlap (DM+O), and polymyositis (PM+O). Also, comparing 
groups of disease activity. These comparisons were made using multiple t tests with 
Holm-Sidak method of correction or one-way ANOVA to calculate an adjusted p 
value by Tukey’s multiple comparison test. SPSS version 24 software was used to 
produce correlation values by calculating Pearson’s correlation between two sets of 
cell types. MultiExperiment Viewer (MeV) was used to produce heat maps and 
perform hierarchical clustering on large data sets. 
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Chapter III  
Immature B cells are expanded in juvenile dermatomyositis and 
are skewed towards a pro-inflammatory phenotype by TLR7 and 
IFNa 
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Results (section 1) 
 
This body of work was completed in collaboration with the following: 
 
Experimental data and interpretation - Christopher JM Piper – Centre for 
Rheumatology, University College London, The Rayne Building, 4th Floor, 5 University 
Street, London WC1E 6JF 
 
RNA-seq data analysis and interpretation – Claire Deakin – Infection, Inflammation 
and Rheumatology, UCL Great Ormond Street Institute of Child Health, University 
College London, London WC1N 1 EH 
 
RNA-seq pipeline and analysis - Georg W Otto – Experimental and Personalised 
Medicine, UCL Great Ormond Street Institute of Child Health,30 Guilford Street, 
London WC1N 1 EH 
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INTRODUCTION 
 
Juvenile Dermatomyositis (JDM) a systemic autoimmune disease, is the most 
common idiopathic inflammatory myopathy (IIM) in childhood. Symptoms include 
proximal muscle weakness and heliotrope rash, which are pathognomonic for JDM 
(Nistala and Wedderburn, 2013). Other organ involvement in JDM is common, with a 
proportion of patients developing complications such as interstitial lung disease 
(ILD), gut involvement and calcinosis (Tansley et al., 2014b). Disease pathology is 
thought to stem from complement mediated vasculopathy and muscular atrophy. The 
inflammatory infiltrate typically seen in affected muscle, is composed of B cells, 
CD4+ and CD8+ T cells, macrophages and dendritic cells (DC). DC are not normally 
present in healthy muscle tissue, however at the onset of myositis, muscle biopsies 
from these patients have an abundance of CD83+ plasmacytoid DCs (pDC) 
(Greenberg et al., 2005b, Lopez de Padilla et al., 2007), which are a major source of 
interferon alpha (IFN-α). 
 
IFN-α-inducible chemokines, CXCL10 and CXCL11 associate strongly with 
mononuclear cell infiltration in JDM muscle (Fall et al., 2005), and disease activity 
(Bellutti Enders et al., 2014). Several reports also document a significant IFNα gene 
signature in peripheral blood samples from DM patients (Baechler et al., 2007, Bilgic 
et al., 2009). As well as increasing MHC class I expression (Rowe et al., 1981), and 
facilitating antigen presentation, IFNα also enhances autoantibody production and 
proliferation of B cells (Braun et al., 2002, Bekeredjian-Ding et al., 2005, Lau et al., 
2005). Importantly, B cells are thought to play a role in JDM pathology tough the 
production of myositis specific autoantibodies (MSA). Although it is currently 
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unknown how autoantibodies contribute to disease pathology, specific MSA are 
associated with distinct clinical phenotypes and the frequency and types of MSA vary 
between adult and juvenile forms of DM (Tansley and McHugh, 2014). The type of 
MSA associates to particular muscle biopsy pathology as assessed by the standardized 
score tool (Wedderburn et al., 2007, Varsani et al., 2015), which is predictive of disease 
progression and outcome (Deakin et al., 2016b). To date, there is no information 
regarding whether IFN-α affects abnormal B cell responses in JDM. 
 
As well as having pathogenic roles in autoimmune disease or protective roles in 
controlling infection, B cells have been shown to have suppressive function, tough the 
production of interleukin-10 (IL-10) (Fillatreau et al., 2002, Mizoguchi et al., 2002, 
Mauri et al., 2003). More recently, these IL-10 producing regulatory B cells been 
identified in the CD19+CD24hiCD38hi (immature B cell) population in humans (Blair et 
al., 2010). Regulatory B cells (Bregs) are known to be diminished and/or functionally 
impaired in a variety of autoimmune diseases, including SLE, systemic sclerosis, 
rheumatoid artitis and ANCA-associated vasculitis (Blair et al., 2010, Matsushita et al., 
2015, Mavropoulos et al., 2015, Flores-Borja et al., 2013, Todd et al., 2014, 
Mavropoulos et al., 2016). Importantly, IFN-α is known to induce both the 
differentiation of Bregs and plasmablasts in a concentration dependent manner (Menon 
et al., 2016). This finding suggests that the type 1 interferonopathy observed in 
paediatric myositis may be influencing both regulatory and pathogenic B cell responses. 
However, previous studies have been limited to investigating changes in total CD19+ 
B cells in JDM (Behan et al., 1987).  
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In this thesis, in-depth phenotyping of B cell compartment in JDM was carried out. The 
results demonstrate that CD19+CD24hiCD24hi immature B cells are expanded in JDM 
patients prior to treatment and correlate with disease severity. The data also confirmed 
that the IFN signature previously observed in JDM extends to include the B cell 
compartment and that this IFN signature positively correlates with this expansion in 
immature B cells. Finally, the TLR7 agonist R848, which is known to be a potent 
inducer of IFN, can no longer induce IL-10 production by JDM B cells.  
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RESULTS 
The JDM pre-treatment patients have more active disease than the on-treatment 
patients 
66 patients who met the Bohan and Peter criteria for probable or definite JDM were 
included, with a median age of 9.9 years at time of sample (Table III.1). Blood was 
collected prior to and serially during treatment as indicated. Patient and CHC 
demographics were summarised in Table III.1. Patients were stratified into pre-
treatment, <6 months, 7-30 months and >30 months on-treatment. This table showed 
that the JDM samples were age matched to the CHC samples, but the female 
predominance seen in the JDM cohort was not proportionally reflected in the CHC 
cohort. The JDM pre-treatment patients had worse disease than patients receiving 
treatment, which was confirmed by significantly higher PGA score and creatine 
kinase (CK) levels, but significantly lower MMT8 and CMAS scores. A broad 
spectrum of autoantibodies were represented in the JDM cohort. A high proportion of 
the ‘on-treatment’ samples were taken from patients on methotrexate and oral 
prednisolone, but other medications were recorded for some patients at longer time 
points including cyclophosphamide and azathioprine. 
Table III.1 Demographic, clinical and serological features. Serial samples were 
used from 37 patients, 15 patients of these patients had pre- and on-treatment 
samples. The median and interquartile range (IQR) was represented for patient 
characteristics and clinical features. Student t-test was used to test the significance 
between JDM pre- and on-treatment groups for PGA, manual muscle testing of 8 
groups (MMT8), and childhood myositis Assessment Scale (CMAS). Mann-Whitney 
test was used to test the significance between JDM pre- and on-treatment groups for 
creatine kinase (CK). The number of patients and percentage of group were shown 
for autoantibody status and medication taken. Autoantibodies included; anti–
transcription intermediary factor 1g (anti–TIF-1g), anti–nuclear matrix protein 2 
(anti–NXP-2), anti-75-and 100kDa polymyositis/systemic sclerosis proteins (anti-
PmScl), Nucleosome-remodelling deactulase complex (anti–Mi2), anti-small ubiquitin 
like modifier activating enzyme (anti-SAE), anti-melanoma differentiation associated 
gene 5 (anti-MDA5), anti-ribonucleoprotein (anti-RNP). Medications were recorded 
at the time of sample.  
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Table 1 Demographic, clinical and serological features of the JDM cohort and child healthy controls *
JDM patients Controls
Patient characteristics Pre-treatment samples (n=20)
On- treatment 
samples           
(n=89)
All JDM samples 
(n=109) 
Child healthy control 
(n=23)
Number of patients 20 46 66
Age at onset (years), median [IQR] 6.81 [4.17-10.06]
Age at diagnosis (years), median [IQR] 5.86[4.86-9.31]
Age at sample (years), median [IQR] 5.0 [4.0-8.9] 9.9[6.4-12.3] 9.9[8.4-12.9] 7.79[5.02-11.63]
Sex, (F/M) [p=0.081] 11/9 31/15 42/24 11/12
Clinical features, median [IQR]
Physician’s Global Assessment (PGA) - (0-10) 
[p<0.0001] 6.70 [5.73-7.68] 0.85 [0.20-1.63]
MMT8 - (0-80) [p<0.0001] 29.00 [28.00-42.00] 80 [76-80]
CMAS - (0-53) [p<0.0001] 11.5 [4.50-22.75] 51 [47-53]
Creatine Kinase (CK) U/L - (>0) (meaured in 
serum at time of PBMC sample) [p<0.0001] 652.5 [265.00-3893.25] 80 [48.5-134]
Myositis-specific autoantibodies, n (%)
Anti-TIF1g 16 (24.24)
Unknown bands 6 (9.09)
Anti-NXP2 15 (22.73)
Anti-Mi2 5 (7.58)
Anti-MDA5 4 (6.06)
Anti-SAE 1 (1.52)
Anti-PmScl 1 (1.52)
Anti-U3RNP 1 (1.52)
Anti-U1RNP 1 (1.52)
No-detectable autoantibodies 12 (18.18)
Unknown 4 (6.06)
Medications (at time of sample) n(%):
Azathioprine 16(17.98)
Cyclophosphamide 17(19.1)
Oral Prednisolone 57(64.0)
Methotrexate 56(62.92)
IV Prednisolone 32(35.96)
Other drugs 11(12.36)
* IQR = interquartile range; anti–TIF-1g = anti–transcription intermediary factor 1g; anti–NXP-2 = anti–nuclear matrix protein 2;
 anti–MDA5 = anti–melanoma differentiation–associated gene 5;  anti-SAE = anti–small ubiquitin-like modifier activating enzyme;
MMT8 = Manual Muscle Testing of 8 groups; CMAS = Childhood Myositis Assessment Scale
§ Serial samples were used from 37 patients, 15 of these patients had pre and on treatment samples
Unknown bands 6 (9.09)
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The Immature B cell compartment is significantly expanded in pre-treatment JDM 
patients 
B cells have been reported to be expanded in the peripheral blood (PB) of JDM 
patients (O'Gorman et al., 1995). However, since the initial observations, further 
characterisation of B cell abnormalities in JDM has not been performed. To address 
this, the frequency and absolute number of total B cells and different B cell sub-
populations were evaluated. Initial analyses showed a significant increase in the 
frequency of CD19+ B cells within PBMC of pre-treatment patients compared to age-
matched CHC (Figure III.1A). However, no lymphocytosis was observed in these 
patients (Figure III.1B).  
 
 
Figure III.1 Expansion of B cells from JDM patients prior to treatment. PBMC 
from patients and age-matched controls were analysed by flow cytometry and B cell 
data compared across disease course and against clinical measures. (A) B cell 
(CD19+ cells within all PBMC) frequencies summarised according to time since 
treatment start in patients, compared to controls. (B) Lymphocyte counts x 109 per 
litre of blood, for pre-treatment and on-treatment JDM patients and age matched 
child controls. *p<0.05, **p<0.01, ***p<0.001 
 
Expression of CD24 and CD38 was used to determine immature 
(CD19+CD24hiCD38hi), mature (CD19+CD24intCD38int) and memory 
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(CD19+CD24hiCD38lo) B cell frequencies (Carsetti et al., 2004) (Figure III.2A). IgD, 
IgM and CD27 were used to confirm immaturity of CD19+CD24hiCD38hi cells (Figure 
III.2B). Pre-treatment, patients had an expansion of immature B cells, which 
significantly reduced in frequency and absolute number within the first 6 months of 
treatment. After 6 months on-treatment equivalent levels of immature B cells were 
seen in CHC and patients. Notably, memory B cells were reduced in pre-treatment 
patients (Figure III.2C-D). To confirm these findings, the same trend was also 
observed over time from patient serial samples (Figure III.2E).  
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Figure III.2 Immature B cells are significantly expanded in JDM patients prior to 
treatment. Immature B cells are significantly expanded in JDM patients prior to 
treatment. PBMC from patients and age-matched controls were analysed by flow 
cytometry and B cell data compared across disease course and against clinical 
measures. (A) Representative flow cytometry plots of B cell subsets, identified using 
expression of CD24 and CD38, shown for child controls (left plot), JDM pre-
treatment (middle plot) and JDM (<6 months) on-treatment (right plot). (B) 
Representative histograms of IgM, IgD and CD27 expression (left to right) on 
immature B cells are shown for pre-treatment JDM patients (black outline) and child 
controls (grey outline). Summary graphs showing (C) frequency and (D) absolute 
numbers of immature, mature, memory B cells and plasmablasts (left-right) from 
JDM pre- treatment (n=20), JDM on-treatment (n=89) and CHC (n=23). (E) 
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Frequencies of immature B cells, mature B cells, memory B cells and plasmablasts 
(left-right respectively) in patients with samples collected pre- (n=10) and on-
treatment (7-30 months) [n=10]. For figures C-D line indicates mean, one-way 
ANOVA was used to measure significance. For figure E student t-test was used to 
measure significance. *p<0.05, **p<0.01, ***p<0.001 
 
Previous publications have shown that immature B cell frequency decreases with age, 
which we confirmed within our cohort of child controls (Morbach et al., 2010). Both 
CHC and pre-treatment patients were age-matched (Figure III.3A). Immature B cells 
did not decrease with age in pre-treatment patients (Figure III.3B). Furthermore, 
frequency and absolute numbers of immature B cells were found to correlate with 
Physicians Global Assessment (PGA) (Figure III.4A-B). This finding was specific to 
immature B cells (Figure III.4C-D). Autoantibody status did not influence the 
frequency of immature B cells in pre-treatment patients (Figure III.4E). 
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Figure III.3 Immature B cell population reduces with age in child healthy 
controls but not JDM. (A) Scatter graph of age at sample of JDM pre-treatment 
(n=20) and child controls (17). (B) Frequencies of immature, mature, memory B cells 
and plasmablasts (left to right) analysed for correlation with age in pre-treatment 
patients (top row) and child controls (bottom row). For figure A student t-test was 
used to measure significance. Pearson correlation was used to measure significance 
and r values for B. *p<0.05, **p<0.01, ***p<0.001 
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Figure III.4 Expanded immature B cell population correlates with increased 
disease activity in JDM. For patients, up to 6 months into treatment (n=22), (A) 
frequency and (B) absolute numbers of immature B cells were correlated to 
Physician’s Global Assessment (PGA). For patients, up to 6 months into treatment 
(including pre-treatment), the (C) frequency and (D) absolute number of cells were 
correlated to PGA for mature, memory and plasmablasts (left to right). (E) 
Frequencies of immature B cells plotted against autoantibody subtype for pre-
treatment patients. Pearson correlation with significance and r values are shown for 
A-D. *p<0.05, **p<0.01, ***p<0.001 
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As immature B cells were significantly expanded pre-treatment compared to CHC, we 
analysed cell proliferation in immature B cells and compared the results to other B 
cell subsets. Ki-67 identifies cells in all stages of cell division, except the resting G0 
phase. Increased proliferation was specifically seen in the immature population in pre-
treatment patients (Figure III.5A-B). KREC were generated following rearrangement 
of the Ig kappa chain locus of the B cell receptor. As KREC DNA is not replicated, 
every cycle of division leads to a halving in the daughter cell’s KREC content (van 
Zelm et al., 2007). Thus, KREC measurement allows the quantification of cell 
division from B cells, providing insight into the replication history of a cell 
population. We sorted B cells subsets from patients and CHC to measure KREC 
content. Patient immature B cells had a significantly lower KREC content compared 
to CHC. No difference was observed in mature B cells (Figure III.5C). KREC 
content was undetectable in memory B cells and plasmablasts (data not shown). 
Taken collectively, these data suggest that immature B cells from pre-treatment JDM 
patients proliferate more than their child healthy control counterparts and that is 
phenomenon is specific to immature B cells. 
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Figure III.5 Immature B cells are highly proliferative in JDM patients prior to 
treatment. PBMC samples were stained ex-vivo for the B cell surface markers CD19, 
CD24 and CD38 and the intra-nuclear marker for proliferation, Ki-67. (A) 
Representative flow cytometry plots of Ki-67 expression in immature (top row) and 
mature B cells (bottom row), in patients and controls. (B) The frequency of Ki-67+ B 
cells were summarised for total B cells, immature B cells and mature B cells (left-
right) for patients (n=8 pre-treatment, 4 £ 6 months, 14 ³6 months) split according to 
time from treatment start, and for child controls. (C) B cell sub-populations were 
sorted from patients on-treatment (n=3) and child controls (n=3) PBMC. DNA 
extracted from immature (CD19+CD24hiCD38hiCD27-) and mature B cells 
(CD19+CD24intCD38intCD27-) were assessed for the levels of kappa-deleting 
recombination excision circles (KRECs). KREC copies per 106 cells were calculated 
for immature and mature B cells. Values represent mean ± SEM for figures B-C. For 
figure B one-way ANOVA was used to measure significance. For figure C the student 
t-test was used to measure significance. *p<0.05, **p<0.01, ***p<0.001 
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Upregulation of the type I interferon signature in JDM B cells 
To understand what drives B cell expansion in patients, we carried out RNA 
sequencing of B cells isolated from 9 pre- and 9 on-treatment patients (median time 
on-treatment 11 months) and 4 CHC (refer to specific demographics in Table V.1). 
Gene set enrichment analysis of Hallmark pathways in the ranked gene lists revealed 
that the IFN-a response was the most upregulated pathway in pre- vs. on-treatment 
isolated B cells (Figure III.6A). The normalized enrichment score was 3.03 with a 
FDR q-value of <0.0001 (Figure III.6B). The 20 most significant differentially 
expressed genes between pre- vs. on-treatment patients and pre-treatment vs CHC are 
summarised (Table III.2-3). 
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Figure III.6 Pre-treatment JDM B cells have up-regulated type I interferon 
signature. JDM B cells have a prominent IFNα and TLR7 pathway signature. (A) 
Heatmap showing the normalized enrichment score (NES) for B cells when JDM pre-
/on-treatment were compared with child healthy control (CHC) from gene set 
enrichment analysis (GSEA) hallmark analysis. Yellow represents significantly up-
regulated pathways and blue represents significantly down-regulated pathways. (B) 
Gene set enrichment analysis (GSEA) plot showing the hallmark IFN-α response 
gene-set in pre- vs on-treatment patient B cells.
BA
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Table III.2  20 most significantly expressed genes in a comparison of B cells from pre- and on-treatment JDM patients.  
 
 
 
 
 
 
Supplementary Table 1: 20 most significantly expressed genes by adjusted p value in a comparison of B cells from pre-and on-treatment JDM patients. 
A positive log fold change signifies up-regulation and n gativ  a down-regulation of gene expression in pre-compared to on-treatment JDM.
hgnc_symbol Description Log fold change p adjusted value
CMPK2 cytidine/uridine monophosphate kinase 2 [Source:HGNC Symbol;Acc:HGNC:27015] 5.015845164 1.17E-24
EIF2AK2 eukaryotic translation initiation factor 2 alpha kinase 2 [Source:HGNC Symbol;Acc:HGNC:9437] 2.204637499 5.82E-19
RSAD2 radical S-adenosyl methionine domain containing 2 [Source:HGNC Symbol;Acc:HGNC:30908] 4.495877258 7.51E-19
HERC6 HECT and RLD domain containing E3 ubiquitin protein ligase family member 6 [Source:HGNC Symbol;Acc:HGNC:26072] 2.999681795 1.94E-18
OASL 2'-5'-oligoadenylate synthetase like [Source:HGNC Symbol;Acc:HGNC:8090] 5.175624818 3.63E-17
IFI44 interferon induced protein 44 [Source:HGNC Symbol;Acc:HGNC:16938] 3.619703923 6.44E-17
OAS3 2'-5'-oligoadenylate synthetase 3 [Source:HGNC Symbol;Acc:HGNC:8088] 3.759215718 6.44E-17
IFIT1 interferon induced protein with tetratricopeptide repeats 1 [Source:HGNC Symbol;Acc:HGNC:5407] 5.661457062 2.58E-16
IFITM1 interferon induced transmembrane protein 1 [Source:HGNC Symbol;Acc:HGNC:5412] 2.65927262 3.71E-16
MX2 MX dynamin like GTPase 2 [Source:HGNC Symbol;Acc:HGNC:7533] 2.075976163 5.91E-16
USP18 ubiquitin specific peptidase 18 [Source:HGNC Symbol;Acc:HGNC:12616] 4.478369432 1.71E-15
DDX60 DExD/H-box helicase 60 [Source:HGNC Symbol;Acc:HGNC:25942] 2.502981805 3.81E-15
IFI44L interferon induced protein 44 like [Source:HGNC Symbol;Acc:HGNC:17817] 4.3932757 4.30E-15
NRIR negative regulator of interferon response (non-protein coding) [Source:HGNC Symbol;Acc:HGNC:51269] 4.367969389 7.08E-15
HERC5 HECT and RLD domain containing E3 ubiquitin protein ligase 5 [Source:HGNC Symbol;Acc:HGNC:24368] 3.122510334 2.81E-14
IFIT3 interferon induced protein with tetratricopeptide repeats 3 [Source:HGNC Symbol;Acc:HGNC:5411] 5.203493029 3.65E-14
PLSCR1 phospholipid scramblase 1 [Source:HGNC Symbol;Acc:HGNC:9092] 2.422234425 4.44E-14
IFI6 interferon alpha inducible protein 6 [Source:HGNC Symbol;Acc:HGNC:4054] 3.059370394 1.51E-13
SLFN5 schlafen family member 5 [Source:HGNC Symbol;Acc:HGNC:28286] 2.935522167 1.81E-13
STAT1 signal transducer and activator of transcription 1 [Source:HGNC Symbol;Acc:HGNC:11362] 2.412777888 1.13E-12
 118 
Table III.31  20 most significantly expressed genes in a comparison of B cells from pre-treatment JDM patients and child healthy 
controls 
 
*A positive log fold change signifies up-regulation and negative a down-regulation of gene expression in pre-compared to on-treatment JDM. 
 
Supplementary Table 2: 20 most significantly expressed genes by adjusted p value in a comparison of B cells from pre-treatment JDM patients and child healthy controls. 
A positive log fold change signifies up-regulation and negative a down-regulation of gene expression in pre-treatment JDM compared to child healthy control.
hgnc_symbol Description Log fold change p adjusted value
CMPK2 cytidine/uridine monophosphate kinase 2 [Source:HGNC Symbol;Acc:HGNC:27015] 4.125949196 2.77E-07
EIF2AK2 eukaryotic translation initiation factor 2 alpha kinase 2 [Source:HGNC Symbol;Acc:HGNC:9437] 2.022581215 2.77E-07
OASL 2'-5'-oligoadenylate synthetase like [Source:HGNC Symbol;Acc:HGNC:8090] 5.097639577 8.76E-07
ADAR adenosine deaminase, RNA specific [Source:HGNC Symbol;Acc:HGNC:225] 1.079673516 1.99E-06
TGFBI transforming growth factor beta induced [Source:HGNC Symbol;Acc:HGNC:11771] -2.889143829 2.50E-06
IFITM1 interferon induced transmembrane protein 1 [Source:HGNC Symbol;Acc:HGNC:5412] 2.429796925 5.49E-06
MX2 MX dynamin like GTPase 2 [Source:HGNC Symbol;Acc:HGNC:7533] 1.875673164 5.49E-06
NRIR negative regulator of interferon response (non-protein coding) [Source:HGNC Symbol;Acc:HGNC:51269] 4.217600512 8.35E-06
CD4 CD4 molecule [Source:HGNC Symbol;Acc:HGNC:1678] -2.522215473 8.35E-06
HERC5 HECT and RLD domain containing E3 ubiquitin protein ligase 5 [Source:HGNC Symbol;Acc:HGNC:24368] 2.967715524 1.16E-05
HERC6 HECT and RLD domain containing E3 ubiquitin protein ligase family member 6 [Source:HGNC Symbol;Acc:HGNC:26072] 2.434812047 1.21E-05
BAHCC1 BAH domain and coiled-coil containing 1 [Source:HGNC Symbol;Acc:HGNC:29279] 3.539876725 1.28E-05
SLFN5 schlafen family member 5 [Source:HGNC Symbol;Acc:HGNC:28286] 2.861670142 1.29E-05
LGALS3BP galectin 3 binding protein [Source:HGNC Symbol;Acc:HGNC:6564] 2.671699546 1.29E-05
IL2RA interleukin 2 receptor subunit alpha [Source:HGNC Symbol;Acc:HGNC:6008] -2.202209619 1.52E-05
OAS3 2'-5'-oligoadenylate synthetase 3 [Source:HGNC Symbol;Acc:HGNC:8088] 3.143704429 1.81E-05
IFI44 interferon induced protein 44 [Source:HGNC Symbol;Acc:HGNC:16938] 3.00981476 1.96E-05
STAT1 signal transducer and activator of transcription 1 [Source:HGNC Symbol;Acc:HGNC:11362] 2.361882153 1.96E-05
DDX60 DExD/H-box helicase 60 [Source:HGNC Symbol;Acc:HGNC:25942] 2.179692129 1.96E-05
MDFIC MyoD family inhibitor domain containing [Source:HGNC Symbol;Acc:HGNC:28870] -1.257982447 3.17E-05
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We validated the IFN-a signature at protein level using Luminex (de Jager et al., 
2007) multiplex array (Trinchieri, 2010). Pre-treatment patients had high serum 
concentrations of CXCL10, CXCL11, MCP-1 and MCP-2, which reduced in patients 
on treatment for >6 months (Figure III.7A). Serum and PBMC were isolated on the 
same day. Serum levels of chemokines were also significantly associated with the 
frequency of immature B cells (Figure III.7B) in all patients. Conversely, no 
significant association was seen with mature or memory B cells (Figure III.7C-D).  
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Figure III.7 IFNα signature validated at a protein level by Luminex multiplex 
array. (A)Patient sera from pre- (n=13) and on-treatment (n=14, =14 £ 6 months, 
=25 ³6 months) JDM patients were analysed for chemokines known to be 
downstream of the IFNα response. Serum concentrations of CXCL10, CXCL11, 
MCP-1 and MCP-2 (left-right) measured by Luminex multiplex array are summarised 
according to time since treatment start. Patient sera and PBMC were collected on the 
same day. (B) Immature B cell frequency and serum levels of CXCL10, CXCL11, 
MCP-1 and MCP-2 (left-right) were correlated in all JDM patients (pre/on treatment, 
n=25). Patient sera and PBMC collected on the same day were used to assess 
correlations between (C) Mature and (D) memory B cell frequency and serum 
concentrations of CXCL10, CXCL11, MCP-1 and MCP-2 (left to right) for all JDM 
patients (pre/on-treatment). For figure A one-way ANOVA was used to measure 
significance. Pearson correlation with significance and r values are shown for B-D. 
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IFNa regulates the expression of TLR7 and enhances the response to endogenous 
TLR7 ligands by B cells and, if overexpressed, can lead to the development of 
autoreactive B cells and autoantibody production (Green et al., 2009, Kiefer et al., 
2012). It was hypothesised that the TLR7 pathway is important to B cell pathology in 
JDM. RNAseq identified upregulation of TLR7 and interferon-regulatory factor 7 
(IRF7) in pre- vs. on-treatment patients (Figure III.8A). Normalised counts (Reads 
Per Kilobase of transcript per Million mapped reads - RPKM) for TLR7 and IRF7 
were significantly higher in pre-treatment patients (Figure III.8B). 
 
Patients with NXP2 autoantibodies often develop a more severe and prolonged 
disease course (Espada et al., 2009) and patients with autoantibodies against TIF1g 
develop severe cutaneous disease (Gunawardena et al., 2008). Interestingly, when 
stratified according to autoantibody status, patients with the TIF1g and NXP2 
autoantibodies trended towards higher TLR7 and IRF7 expression (Figure III.8C-D).  
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Figure III.8 RNA sequencing identified upregulation of TLR7 and IRF7 in pre- 
vs. on-treatment JDM patients. (A) Volcano plot highlighting differentially expressed 
genes downstream of the IFN-α pathway in pre- vs on-treatment patients. (B) 
Normalised counts (RPKM) for pre-treatment, on-treatment patients and child 
controls are shown for TLR7 and IRF7. Figure B, N=10 for pre-treatment, 9 for on-
treatment and 4 for child controls. Normalised counts (RPKM) for (C) TLR7 and (D) 
IRF7, in B cells isolated from pre-treatment patients, stratified according to 
autoantibody status. For figure B-D one-way ANOVA was used to measure 
significance.  *p<0.05, **p<0.01, ***p<0.001 
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TLR7 and IFNa promotes IL-6, but not IL-10 production in B cells from JDM 
patients 
To assess B cell response to TLR7 ligation, I cultured purified B cells for 48 hours 
with or without IFN-a and quantified IL-6 and IL-10 expression. It has been shown 
previously that culturing healthy control B cells with IFN-a increases the 
CD19+CD24hiCD38hi population (Menon et al., 2016). Stimulating B cells with R848 
and IFN-a increased the percentage of CD19+CD24hiCD38hi cells from CHC, but not in 
active on-treatment patients (PGA>3.5). The data did not reach significance (Figure 
III.9A-B).  
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Figure III.9 IFNa may increase the immature B cell population in samples from 
child healthy controls but not JDM patients. B cells were purified from active on-
treatment patients (patients with flares in disease activity (PGA >3.5) and 
were >6months into treatment) and age-matched child control PBMC were 
stimulated with IFN-α (1000 IU/ml), 1µg/ml R848 (a TLR7/8 agonist) or a 
combination of both for 48h. B cells were stained for CD24 and CD38 expression. (A) 
Representative flow cytometry plots showing B cells subset gating for each of the 
conditions are shown (left to right: Isotype control, unstimulated, IFNα, R848, 
R848+IFNα) using child control sample. (B) Percentage of immature, mature and 
memory B cells (left-right) are summarised for each culture condition for child 
controls (top row) and JDM patients on-treatment (bottom row). For figure B, N=3 
for patients and child controls. Two-way ANOVA with Sidak multiple comparisons 
test was used for figure B. Bars represent mean ± SEM. 
 
Concentrations of IL-6 and IL-10 were quantified from cell culture supernatants. 
TLR7 ligation induced IL-10 in CHC, but was significantly diminished in patients on 
treatment (Figure III.10A, C&D). No difference between patients and controls was 
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observed in TLR7-induced IL-6. Furthermore, addition of IFNa increased B cell IL-6 
expression (Figure III.10B, E&F). 
 
 Figure III.10 JDM B cells fail to induce IL-10 after TLR7 stimulation. B cells were 
isolated from on-treatment JDM patients (patients with flares in disease activity 
(PGA >3.5) and were >6months into treatment) and child controls and were 
stimulated for 48h with R848+/- IFN-α. Culture supernatants taken from total B cells 
at 48h were analysed for (A) IL-10 and (B) IL-6 concentrations for patients and 
controls. Representative FACS plots of (C) IL-10 and (E) IL-6 expression in B cells 
after 48h stimulation with R848 (top row) and R848+ IFNα (bottom row). (D) Total 
B cell IL-10 and (F) IL-6 expression are summarised by flow cytometry for child 
controls and on-treatment JDM patients. N=3 per group. Two-way ANOVA with 
Sidak multiple comparisons test was used for figures A, B, D & F. Bars represent 
mean ± SEM. 
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CD40L stimulated JDM B cells have no defect in IL-10 production 
I next assessed if the reduction in B cell IL-10 was an intrinsic defect in JDM patients 
or a signal-specific phenomenon. I used CD40-CD40 ligand (CD40L) interactions to 
assess IL-10 production. Using a well-established co-culture assay, CD40L-
expressing CHO cells were co-cultured with PBMC, and B cell IL-10 expression 
analysed after 72 hours (Blair et al., 2010). I observed no significant difference in IL-
10 expression between pre-treatment patients and CHC. However, IL-10+ cells were 
significantly decreased in patients within the first 6 months of treatment compared to 
pre-treatment patients (Figure III.11A-B). Immature B cells from on-treatment 
patients were the main source of IL-10 and IL-6 upon stimulation with CD40L 
(Figure III.11C-D). No IL-10 was detected in B cells stimulated with PMA and 
Ionomycin alone (Figure III.11E).  
 
In addition, PBMC from patients’ pre-treatment and on-treatment samples were 
stimulated with PMA and Ionomycin for 4hours and the frequency of total B cells 
expressing IL-6 was measured. There was no significant difference in IL-6 expression 
between pre-treatment patients and CHC (Figure III.11F-G). Of note, immature B 
cell IL-6 did not correlate to PGA (Figure III.11H). 
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Figure III.11 B cells from JDM patients can express IL-10 upon CD40 
stimulation. PBMC were stimulated with CD40L-expressing CHO cells for 72h and B 
cell IL-10 expression was analysed by flow cytometry, following the addition of PMA, 
Ionomycin and brefeldin A for the last 4 hours of culture. (A) Representative flow 
cytometry plots of B cell IL-10 expression are shown for JDM pre-treatment, on-
treatment and child controls. (B) Percentage of IL-10 expressing B cells after 72h 
culture with CD40L stimulation are summarised for each of the groups (n=7 pre-
treatment, =33 on-treatment and =8 CHC). Purified B cells subsets from on-
treatment JDM patients were sorted and stimulated with CD40L CHO for 72h and 
concentrations of (C) IL-10 and (D) IL-6 were quantified from the cell culture 
supernatants (N of 1 and 2 respectively). (E) IL-10 expression was assessed by flow 
cytometry. Representative FACS plots of IL-10 expression are shown for patients and 
controls. PBMC were stimulated for 4h with PMA/Ionomycin (F) Representative 
FACS plots of total B cell IL-6 staining are shown (left-right: Isotype control, JDM 
pre-treatment, JDM on-treatment and child control). (G) IL-6 expression by B cells 
are summarised for JDM subgroups (n=15 pre-treatment and =23 on-treatment) and 
child controls (n=6). (H) Analysis of the correlation between IL-6 expression by 
immature B cells and PGA. B, C, D and G were analysed by One-way ANOVA for 
significance. Pearson correlation was used to measure significance and r values for 
H. Values represent mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 
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DISCUSSION 
It is known that B cells are expanded in peripheral blood (PB) of JDM (Strelkauskas 
et al., 1976, Eisenstein et al., 1997) and to have an important role in JDM pathology, 
primarily via the production of MSA. However, to my knowledge, no studies have 
characterised 2B cell phenotype in JDM in detail. I have shown that the immature B 
cells were expanded in the blood of JDM patients pre-treatment and importantly 
correlated with clinical severity. RNAseq analysis revealed that the B cell 
compartment in JDM exhibited a strong IFN gene signature and which was associated 
with an increase of immature B cells. 
 
Studies examining B cell phenotype in patients with autoimmune diseases such as 
systemic sclerosis (Matsushita et al., 2015, Mavropoulos et al., 2015) and 
neuromyelitis optica (Quan et al., 2015), report a reduction in the number of immature 
B cells (CD19+CD24hiCD38hi). Recently Li et al showed that immature B cells are 
decreased in adult DM (Li et al., 2016). However, I now report a significantly 
expanded immature population specifically in pre-treatment JDM. This trend has also 
been documented in SLE patients, which shares some features of aetiopathogenesis 
with DM (Blair et al., 2010). To my knowledge, this is the first report demonstrating 
an expansion of immature B cells in JDM. Immature B cell frequencies in the 
periphery decrease with age, with the frequency highest in infancy (Morbach et al., 
2010). The cohort of CHC further confirms these findings. However, immature B cell 
frequency does not correlate with age in active JDM patients pre-treatment, 
suggesting that normal B cell development is disturbed in patients following the onset 
of autoimmunity. Interestingly, immature B cell frequency directly correlates with 
disease activity, suggesting that these cells are intrinsically linked to the development 
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of disease. The data showed that immature B cells, specifically in patients pre-
treatment, are proliferating and have undergone more cell divisions in-vivo than age 
matched CHC, as determined by their lower KREC content. While these results 
indicate a replication history of a subset of B cells (van Zelm et al., 2007), it would be 
important in future work to distinguish whether there is a higher output of immature B 
cells from the bone marrow, and to determine the site of proliferation.  
 
It has been previously reported that TLR-9 activated pDC, which produce IFNa, 
expand immature B cells in vitro. Interestingly, RNA sequencing analysis comparing 
gene expression between pre-, on-treatment patients and CHC, identified a strong 
IFN-a signature, with molecules downstream of IFN-a receptor signalling being 
highly expressed in pre-treatment patient B cells versus controls (Ng et al., 2016). 
These data suggest that the interferonopathy could be driving the expansion of 
immature B cells in JDM in vivo. Indeed, my analysis found that there was a strong 
positive correlation between interferon-driven chemokines and the frequency of 
immature B cells in JDM patients. Previous studies have also identified a strong IFN-
a signature in muscle (Fall et al., 2005, Baechler et al., 2011), skin (Wenzel et al., 
2006), PBMC and serum of DM and JDM patients (Baechler et al., 2007, Bilgic et al., 
2009); a feature shared with other autoimmune diseases (Higgs et al., 2011). 
Furthermore, pDC, which are the major producers of IFN-a are known to be abundant 
in skin (McNiff and Kaplan, 2008, Wenzel et al., 2006, Lopez De Padilla et al., 2009) 
and muscle (Lopez de Padilla et al., 2007, Lopez De Padilla et al., 2009) in DM and 
JDM patients where they could potentially crosstalk with B cells that have also 
infiltrated inflamed muscle tissue (Lopez De Padilla et al., 2009). More recently, the 
role of IFN-b has been suggested to be pivitol in the pathogenesis of adult DM. 
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Elevated serum levels of IFN-b was associated with an elevated type I interferon gene 
signature and, moreover, correlated with skin disease activity in DM (Huard et al., 
2017). However, the role of IFN-b in JDM disease pathology remains less well 
characterised. It would be important to dissect the relative contributions of IFN-a and 
IFN-b in JDM disease pathogenesis and how this affects B cell function.  
 
Clinical trials testing anti-IFN-a biologics in the treatment of rheumatological 
diseases have started to gain traction (Kalunian et al., 2016). Sifalimumab, a human 
IgG1k monoclonal antibody has been trialled in a phase 1b study in dermatomyositis 
patients (Higgs et al., 2014) and, successfully in phase IIb trial in SLE (Khamashta et 
al., 2016). In addition, Anifrolumab, an anti-interferon-alpha receptor monoclonal 
antibody has been found effective against SLE in a phase IIb trial (Furie et al., 2017). 
My work provides further evidence that anti- IFN-a biologics could be efficacious in 
the treatment of JDM. 
 
Of particular interest, gene expression of TLR7 and its associated downstream 
signalling molecule IRF7 was significantly higher in pre- versus on-treatment B cells. 
It has been previously reported that activation of cells with IFN-a induces IRF7 
expression in multiple cell types (Sato et al., 1998), and can directly induce TLR7 
expression in naïve B cells (Bekeredjian-Ding et al., 2005). Importantly, 
overexpression of TLR7 has been shown to increase susceptibility to autoimmunity 
(Deane et al., 2007) and has a role in disease pathogenesis in mouse models of lupus 
(Celhar et al., 2012). Furthermore, overexpression of TLR7 in murine B cells 
promotes expansion and autoantibody production in the transitional 1 population 
(Giltiay et al., 2013). In this study, whilst TLR7 and IFN-a stimulation increased the 
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CD19+CD24hiCD38hi population in controls, this expansion was not observed in patients 
possibly due to conic activation of this pathway in vivo. Furthermore, TLR7 ligation 
in healthy B cells induces IL-6 and IL-10 production in child controls resembling 
previous studies using B cells isolated from healthy adults (Liu et al., 2014). 
However, in JDM patients stimulation with the TLR7 agonist R848 in JDM patients 
favoured IL-6 production over IL-10. Notably, IL-6 has been linked to disease 
activity in JDM (Bilgic et al., 2009), and is detectable in serum. Given the pre-
disposition of autoantibody production in JDM (Tansley and McHugh, 2014) and that 
IL-6 is an important growth factor for plasmablast generation (Jego et al., 2001), it is 
possible that immature B cells receive the required signals to differentiate to 
plasmablasts in muscle tissue (Menon et al., 2016). 
 
The final investigation was whether there was an intrinsic IL-10 defect in patient B 
cells using the CD40-CD40L interaction which is key for B cell development and 
induce IL-10 in B cells (Elgueta et al., 2009). Contrary to Kalampokis et al, who 
reported a reduction in Breg IL-10 in JDM patients (Kalampokis et al., 2016), I did 
not observe a difference in JDM patients pre-treatment and controls with the CD40L 
stimulus. However, the cohort in Kalampokis et al contained patients already on 
treatment and different stimuli (CD40L+CpG-B) were used which could account for 
the differences seen in both studies. We show that patients on treatment with 
prednisolone and methotrexate have reduced IL-10 production and immature B cell 
frequency; both of which are proportional to each other. We propose that the 
immature B cell population is capable of producing IL-10, given the right signals in-
vivo, but are skewed away from Breg differentiation and towards a pro-inflammatory 
phenotype by over-activation with IFN-a and TLR7 agonists in B cells. 
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In conclusion, the data shows that immature B cells are greatly expanded in JDM pre-
treatment, correlate with disease activity, and decrease upon treatment with 
prednisolone and methotrexate. This is likely to be caused by a reduction in 
inflammation, which drives the expansion of immature B cells. Notably, immature B 
cells from patients re-populate to equivalent levels seen in CHC after >6months on 
treatment. I propose a model whereby TLR7 ligation and stimulation via IFN-a lead 
to the expansion of immature B cells, and prime them towards a pro-inflammatory 
state in JDM. These data support a growing body of evidence that targeting the TLR7 
and IFN-a response in autoimmune disease may be novel therapeutic pathways to 
target in dermatomyositis. 
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Figure III.12 Immature B cells are expanded in juvenile dermatomyositis and are skewed towards a pro-inflammatory phenotype by Toll-
Like Receptor 7 (TLR7) and Interferon-a (IFN-a)
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Chapter IV 
Th17 cells are increased in adult dermatomyositis: a developing 
immune signature for the inflammatory myopathies 
  
 136 
Results (section 2) 
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INTRODUCTION 
The Inflammatory Idiopathic Myopathies (IIM) are a rare group of myopathic 
autoimmune diseases diagnosed in both adults and children. Patients may present with 
a variety of features including proximal muscle weakness and Gottron’s papules. 
Immunohistochemical analysis of muscle tissue from these patients has identified 
immune cell infiltrate and the expression of pro-inflammatory cytokines however, 
little is known about the peripheral immunological profile in juvenile and adult 
patient groups.  
 
There is clear evidence that the adaptive immune system plays an active role in the 
pathogenesis of IIM (Ceribelli et al., 2017). There are immune cellular infiltrates 
found in tissue biopsy and up to 80% of patients have specific clinical features 
correlated to detectable serum autoantibodies (Venalis and Lundberg, 2014). The 
endomysial cellular infiltrates most commonly detected in PM, constitute of CD8+ T 
cells, CD4+ T cells, dendritic cells (DCs) and macrophages. These cells localise 
around the muscle fibres. In DM, the perivascular infiltrates consist of CD4+ T cells, 
DCs, macrophages and B cells. Unlike PM, these cells are found around the inflamed 
blood vessels (Reed and Ernste, 2009).  
 
T cells have been identified as dysfunctional in the context of IIM. 
CD4+CD25+FOXP3+ T cells were shown to have lost their ability to regulate the 
immune system with functional impairment in active JDM (Klein et al., 2010). Th17 
cells have been found in tissue biopsy and an increased dysfunction positively 
correlated to disease activity (Banica et al., 2009). B cells have not been thought to be 
as vital as T cells in the pathogenesis of IIM, but do play an important role. Not only 
 138 
are B cells found in the perivascular infiltrates of muscle tissue in DM patients, there 
is a high detection of myositis associated (MSA) and specific (MSS) autoantibodies 
(Greenberg et al., 2005a). The expression of B cell activating factor (BAFF) has been 
associated with anti-Jo-1 antibodies in DM muscle tissue, specifically in the 
perifascicular area (Baek et al., 2012).  
 
Most studies on IIM have focused on the inflammatory milieu found within the tissue 
biopsy. The biopsy is a key diagnostic tool, but is rarely repeated past initial 
presentation, thus little is known about the histological changes during the disease 
course. This component of my thesis aims to investigate the peripheral blood 
immunological profile from adult and juvenile patients. Comparison will be made 
between adult and juvenile disease, PM and DM subsets, disease activity and 
autoantibody expression.  
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RESULTS 
 
The sample groups included; 44 adult myositis (AM) patients (including DM and 
PM), 15 adolescent-onset juvenile dermatomyositis (JDM) patients, 25 age-matched 
adult healthy controls (AHC), and 15 age-matched teenage healthy controls (THC) 
were recruited with appropriate ethical approval after obtaining written informed 
consent (Chapter II). Demographic and clinical information was gathered for all 
patients and controls including; specific diagnosis, age at diagnosis, age at sample, 
gender, ethnicity, medication, measures of disease activity, autoantibody status and 
medications at time of sample (Table IV.1-2).  
 
Comparing the demographics of all the AM to all the JDM patients, these cohorts had 
a similar sex distribution. The ethnicity distribution was different between the two 
groups primarily the increased representation of south Asian and white other patients 
within the AM cohort, though this did not reach statistical significance. This 
difference may be a reflection of the small sample size or the population 
demographics for that age group. Both cohorts had similar overall clinical findings. 
There were more AM than JDM patients that had had an increase in treatment at time 
of sample and therefore were deemed more active, but again this was not statistically 
significant. There was a difference in medication taken, AM patients were treated 
with a broader spectrum of drugs including tacrolimus, cyclosporine and IVIG. 
Methotrexate and hydroxychloroquine were more common treatments used in the 
JDM compared to AM cohort. The use of biologics was highest in the JDM cohort. 
Rituximab was the only biologic used in the AM cohort, where infliximab and 
adalimumab were used as well as rituximab in the JDM cohort.  
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The AM cohort was split by IIM subgroups including, dermatomyositis (DM), 
polymyositis (PM), DM with cancer, DM/PM with overlap autoimmune rheumatic 
diseases (e.g. SLE, scleroderma and RA)). Detailed analysis of the subgroups of the 
AM cohort identified differences in the demographics. The PM patients were all 
female whereas the DM patient group was constituted of 63.2% female. More DM 
patients were of white British ethnicity than the PM patients. More PM patients were 
of black Caribbean ethnicity than the DM patients. Clinically the DM with cancer 
patients had the highest median ESR (40 mm/hour) and MITAX scores (9.50). The 
higher ESR values were likely to be increased due to the cancer. The PM group had 
the highest percentage of patients with an increase in treatment at time of sample. DM 
patients had the greatest spread of singularly detected auto-antibodies, whereas the 
PM group only possessed anti-Jo-1 and anti-SRP. Hydroxychloroquine and 
mycophenolate mofetil (MMF) were more commonly used in DM compared to the 
other subgroups. Equally cyclosporine and IVIG were only used to treat DM and DM 
with cancer. Though there were differences in clinical data between sub-groups, none 
of the results reached statistical significance and may be not as apparent in a larger 
cohort. 
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Table IV.1 Demographic features of the adult myositis, JDM, adult and teenage healthy control cohorts at time of sample. 44 adult 
myositis (AM) patients, 15 adolescent onset-juvenile dermatomyositis (JDM) patients, 25 adult healthy controls (AHC) and 15 teenage healthy 
controls (THC) were recruited. The AM group was divided into subgroups; dermatomyositis (ADM), polymyositis (APM), dermatomyositis with 
cancer, dermatomyositis with overlap and polymyositis with overlap. For each group, the demographics were recorded including; age at 
diagnosis, age at samples, time since diagnosis, sex ratio and ethnicity. The binary measures were analysed by Chi-square test and the 
continuous variables were analysed by one-way ANOVA. A significant p-value was reached between AM and JDM for age at diagnosis and age 
at sample. p£0.05 for significance. 
 
 
 
 
Table 1 Demographic, clinical and serological features of the adult myositis, JDM, adult and teenage healthy controls chohorts at time of sample
Patients Controls
Patient characteristics Adult Myositis samples (n=44)
Juvenile DM 
(adolescent 
onset) samples 
(n=15)
Adult healthy 
control samples 
(n=25) 
Adolescent healthy 
control samples 
(n=15)
Sub-types of myositis All Dermatomyositis Polymyositis Dermatomyositis with cancer
Dermatomyositis 
with overlap 
syndrome
Polymyositis with 
overlap syndrome All All All
Number of patients 44 19 9 4 7 5 15 25 15
Age at diagnosis (years), median 
[IQR] (p=0.0632) 39.82 [31.65-49.00] 34.02 [30.33-48.96] 41.29 [34.10-44.07] 47.83 [27.65-60.62] 39.87 [31.30-45.80] 39.64 [32.47-43.04]
14.78 [14.02-
16.01]
Age at sample (years), median 
[IQR] (p=0.2194) 55.48 [47.59-60.33] 55.80 [46.21-59.99] 52.37 [48.35-53.10] 63.04 [59.81-67.99] 49.20 [46.82-53.47] 59.72 [55.96-66.73]
21.48[19.07-
23.19] 51.26[43.23-58.31] 20.11[17.40-22.28]
Time since diagnosis (years), 
median [IQR] (p=0.5453) 9.64 [3.39-23.13] 12.39 [4.61-22.29] 6.43 [5.15-10.97] 0.34 [0-6.23] 11.02 [1.02-24.86] 23.48 [7.98-23.69] 6.09 [5.28-7.82]
Sex, (F/M) [p=0.3013] 34/10 12/7 9/0 4/0 5/2 4/1 11/4 14/11 11/4
Ethnicty, n (%) [0.0968]
White British 17 (38.64) 10 (52.63) 1 (11.11) 2 (50.00) 3 (42.86) 1 (20) 9 (60.00) 14 (56.00) 6 (40.00)
Black Carribean 9 (20.45) 1 (5.26) 5 (55.56) 1 (25) 1 (14.29) 1 (20) 2 (13.33) 0 (0.00) 0 (0.00)
Black African 3 (6.81) 1 (5.26) 0 (0.00) 0 (0.00) 1 (14.29) 1 (20) 1 (6.67) 0 (0.00) 1 (6.67)
South Asian 7 (15.91) 2 (10.53) 1 (11.11) 0 (0.00) 2 (28.57) 2 (40.00) 0 (0.00) 2 (8.00) 5 (33.33)
East Asian 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 1 (6.67)
White other 7 (15.91) 4 (21.05) 2 (22.22) 1 (25) 0 (0.00) 0 (0.00) 0 (0.00) 7 (28.00) 0 (0.00)
South American 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Other 1 (2.27) 1 (5.26) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 3 (20.00) 0 (0.00) 1 (6.67)
Unknown 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 2 (8.00) 0 (0.00)
Clinical features, median 
[IQR]
Ethyrocyte sedimentation rate 
(ESR) mm/hour (measured at 
time of sample)[p=0.0394]
18.5 [8.00-28.25] 9.00 [5.75-17.50] 25.00 [22.5-30.00] 40.00 [33.00-43.50] 23.00 [16.50-37.50] 24.5 [16.25-36.25] 16.5 [7.50-22.50]
C-reactive protein (CRP) mg/L 
<3.0mg/L (measured in serum at 
time of sample) [p=0.7019]
2 [0.70-5.80] 1.60 [0.78-2.65] 2.3 [0.70-6.48] 3.00 [1.88-28.45] 4.45 [1.73-17.90] 4.90 [1.65-10.05] 2.75 [2.23-5.00]
Lymphocyte count (1-4x10^9 /L 
of blood) (taken at time of 
sample)
1.35 [0.65-1.67] 1.5 [1.38-1.65] 1.66 [0.81-2.13] 0.46 [0.40-0.57] 0.56 [0.52-0.62] 1.62 [1.44-1.90] 1.72 [1.06-1.85]
Creatinine Kinase (CK) U/L - 
(>0) (meaured in serum at time 
of PBMC sample) [p=0.6966]
147 [93-364] 195 [125-301] 230.5 [142-308] 116 [107.75-696.50] 100 [92.25-949.25] 87 [75.5-192.25] 106  [76.50-464.75]
MITAX score 1.50 [0.00-9.00] 1.00 [0.00-9.00] 3.00 [1.00-9.00] 9.50 [1.75-19.00] 2.00 [0.50-10.50] 0.00 [0.00-2.25] 0.00 [0.00-4.00]
MMT8 (0-80) Not done Not done Not done Not done Not done Not done 80 [77-80]
Clinicians decision on 
treatment, n(%)
Decreased 6 (13.63) 2 (10.53) 1 (11.11) 0 (0.00) 2 (28.57) 1 (20.0) 3 (20.00)
Stable 28 (63.63) 13 (68.42) 5 (55.56) 3 (75.00) 3 (42.86) 4 (80.00) 10 (66.67)
Increased 10 (22.73) 4 (21.05) 3 (33.33) 1 (25.00) 2 (28.57) 0 (0.00) 2 (13.33)
Myositis-specific 
autoantibodies, n (%) [0.3022]
Anti-Jo-1 5 (11.36) 1 (5.26) 3(33.33) 0 (0.00) 1(14.29) 0 (0.00) 0 (0.00)
Anti-Ro 3 (6.81) 2 (10.53) 0 (0.00) 1 (25) 0 (0.00) 0 (0.00) 1 (13.33)
Anti-PL12 1 (2.27) 1 (5.26) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Anti-PM-Scl75 1 (2.27) 1 (5.26) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Anti-Mi2 3 (6.81) 3 (15.78) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 1 (6.67)
Anti-SRP 1 (2.27) 0 (0.00) 1 (11.11) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Anti-NXP2 1 (2.27) 1 (5.26) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
TIF1-y 3 (6.81) 2 (10.53) 0 (0.00) 1 (25) 0 (0.00) 0 (0.00) 0 (0.00)
ANA 2 (4.55) 1 (5.26) 1 (11.11) 0 (0.00) 0 (0.00) 0 (0.00) 5 (33.33)
RF 2 (4.55) 1 (5.26) 1 (11.11) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Multiple 11 (25.00) 2 (10.53) 1 (11.11) 0 (0.00) 4 (57.14) 4 (80) 5 (33.33)
Negative 5 (11.36) 3 (15.78) 1 (11.11) 1 (25) 0 (0.00) 0 (0.00) 0 (0.00)
Not done 6 (13.63) 1 (5.26) 1 (11.11) 1 (25) 2 (28.57) 1 (20) 3 (20.00)
Unknown 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Medications (at time of 
sample) n(%): [p=0.3237]
Prednisolone 28 (63.63) 10 (52.63) 4 (44.44) 3 (75) 7 (100) 4 (80) 8  (53.33)
Methotrexate 5 (11.36) 2 (10.53) 2 (22.22) 0 (0.00) 1 (14.29) 0 (0.00) 10 (66.67)
Azathioprine 9 (20.45) 2 (10.53) 2 (22.22) 1(25.00) 4 (57.14) 0 (0.00) 2 (13.33)
Rituximab past 7 (15.91) 2 (10.53) 2 (22.22) 0 (0.00) 1 (14.29) 2 (40.00) 1 (13.33)
Hydroxychloriquine 5 (11.36) 3 (15.78) 1 (11.11) 0 (0.00) 1 (14.29) 0 (0.00) 6 (40.00)
MMF 8 (18.18) 5 (26.32) 1 (11.11) 0 (0.00) 1 (14.29) 1 (20) 2 (13.33)
Tacrolimus 3 (6.812) 1 (5.26) 1 (11.11) 0 (0.00) 1 (14.29) 0 (0.00) 0 (0.00)
Cyclosporine 2 (4.54) 2 (10.53) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
IVIG 3 (6.82) 2 (10.53) 0 (0.00) 1 (25) 0 (0.00) 0 (0.00) 0 (0.00)
Infliximab 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 2 (13.33)
Adalimumab 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 1 (6.67)
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Table 1 Demographic, clinical and serological features of the adult myositis, JDM, adult and teenage healthy controls chohorts at time of sample
Patients Controls
Patient characteristics Adult Myositis samples (n=44)
Juvenile DM 
(adolescent 
onset) samples 
(n=15)
Adult healthy 
control samples 
(n=25) 
Adolescent healthy 
control samples 
(n=15)
Sub-types of myositis All Dermatomyositis Polymyositis Dermatomyositis with cancer
Dermatomyositis 
with overlap 
syndrome
Polymyositis with 
overlap syndrome All All All
Number of patients 44 19 9 4 7 5 15 25 15
Age at diagnosis (years), median 
[IQR] (p=0.0632) 39.82 [31.65-49.00] 34.02 [30.33-48.96] 41.29 [34.10-44.07] 47.83 [27.65-60.62] 39.87 [31.30-45.80] 39.64 [32.47-43.04]
14.78 [14.02-
16.01]
Age at sample (years), median 
[IQR] (p=0.2194) 55.48 [47.59-60.33] 55.80 [46.21-59.99] 52.37 [48.35-53.10] 63.04 [59.81-67.99] 49.20 [46.82-53.47] 59.72 [55.96-66.73]
21.48[19.07-
23.19] 51.26[43.23-58.31] 20.11[17.40-22.28]
Time since diagnosis (years), 
median [IQR] (p=0.5453) 9.64 [3.39-23.13] 12.39 [4.61-22.29] 6.43 [5.15-10.97] 0.34 [0-6.23] 11.02 [1.02-24.86] 23.48 [7.98-23.69] 6.09 [5.28-7.82]
Sex, (F/M) [p=0.3013] 34/10 12/7 9/0 4/0 5/2 4/1 11/4 14/11 11/4
Ethnicty, n (%) [0.0968]
White British 17 (38.64) 10 (52.63) 1 (11.11) 2 (50.00) 3 (42.86) 1 (20) 9 (60.00) 14 (56.00) 6 (40.00)
Black Carribean 9 (20.45) 1 (5.26) 5 (55.56) 1 (25) 1 (14.29) 1 (20) 2 (13.33) 0 (0.00) 0 (0.00)
Black African 3 (6.81) 1 (5.26) 0 (0.00) 0 (0.00) 1 (14.29) 1 (20) 1 (6.67) 0 (0.00) 1 (6.67)
South Asian 7 (15.91) 2 (10.53) 1 (11.11) 0 (0.00) 2 (28.57) 2 (40.00) 0 (0.00) 2 (8.00) 5 (33.33)
East Asian 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 1 (6.67)
White other 7 (15.91) 4 (21.05) 2 (22.22) 1 (25) 0 (0.00) 0 (0.00) 0 (0.00) 7 (28.00) 0 (0.00)
South American 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Other 1 (2.27) 1 (5.26) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 3 (20.00) 0 (0.00) 1 (6.67)
Unknown 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 2 (8.00) 0 (0.00)
Clinical features, median 
[IQR]
Erythrocyte sedimentation rate 
(ESR) mm/hour (measured at 
time of sample)[p=0.0394]
18.5 [8.00-28.25] 9.00 [5.75-17.50] 25.00 [22.5-30.00] 40.00 [33.00-43.50] 23.00 [16.50-37.50] 24.5 [16.25-36.25] 16.5 [7.50-22.50]
C-reactive protein (CRP) mg/L 
<3.0mg/L (measured in serum at 
time of sample) [p=0.7019]
2 [0.70-5.80] 1.60 [0.78-2.65] 2.3 [0.70-6.48] 3.00 [1.88-28.45] 4.45 [1.73-17.90] 4.90 [1.65-10.05] 2.75 [2.23-5.00]
Lymphocyte count (1-4x10^9 /L 
of blood) (taken at time of 
sample)
1.35 [0.65-1.67] 1.5 [1.38-1.65] 1.66 [0.81-2.13] 0.46 [0.40-0.57] 0.56 [0.52-0.62] 1.62 [1.44-1.90] 1.72 [1.06-1.85]
Creatinine Kinase (CK) U/L - 
(>0) (meaured in serum at time 
of PBMC sample) [p=0.6966]
147 [93-364] 195 [125-301] 230.5 [142-308] 116 [107.75-696.50] 100 [92.25-949.25] 87 [75.5-192.25] 106  [76.50-464.75]
MITAX score 1.50 [0.00-9.00] 1.00 [0.00-9.00] 3.00 [1.00-9.00] 9.50 [1.75-19.00] 2.00 [0.50-10.50] 0.00 [0.00-2.25] 0.00 [0.00-4.00]
MMT8 (0-80) Not done Not done Not done Not done Not done Not done 80 [77-80]
Clinicians decision on 
treatment, n(%)
Decreased 6 (13.63) 2 (10.53) 1 (11.11) 0 (0.00) 2 (28.57) 1 (20.0) 3 (20.00)
Stable 28 (63.63) 13 (68.42) 5 (55.56) 3 (75.00) 3 (42.86) 4 (80.00) 10 (66.67)
Increased 10 (22.73) 4 (21.05) 3 (33.33) 1 (25.00) 2 (28.57) 0 (0.00) 2 (13.33)
Myositis-specific 
autoantibodies, n (%) [0.3022]
Anti-Jo-1 5 (11.36) 1 (5.26) 3(33.33) 0 (0.00) 1(14.29) 0 (0.00) 0 (0.00)
Anti-Ro 3 (6.81) 2 (10.53) 0 (0.00) 1 (25) 0 (0.00) 0 (0.00) 1 (13.33)
Anti-PL12 1 (2.27) 1 (5.26) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Anti-PM-Scl75 1 (2.27) 1 (5.26) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Anti-Mi2 3 (6.81) 3 (15.78) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 1 (6.67)
Anti-SRP 1 (2.27) 0 (0.00) 1 (11.11) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Anti-NXP2 1 (2.27) 1 (5.26) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
TIF1-y 3 (6.81) 2 (10.53) 0 (0.00) 1 (25) 0 (0.00) 0 (0.00) 0 (0.00)
ANA 2 (4.55) 1 (5.26) 1 (11.11) 0 (0.00) 0 (0.00) 0 (0.00) 5 (33.33)
RF 2 (4.55) 1 (5.26) 1 (11.11) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Multiple 11 (25.00) 2 (10.53) 1 (11.11) 0 (0.00) 4 (57.14) 4 (80) 5 (33.33)
Negative 5 (11.36) 3 (15.78) 1 (11.11) 1 (25) 0 (0.00) 0 (0.00) 0 (0.00)
Not done 6 (13.63) 1 (5.26) 1 (11.11) 1 (25) 2 (28.57) 1 (20) 3 (20.00)
Unknown 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Medications (at time of 
sample) n(%): [p=0.3237]
Prednisolone 28 (63.63) 10 (52.63) 4 (44.44) 3 (75) 7 (100) 4 (80) 8  (53.33)
Methotrexate 5 (11.36) 2 (10.53) 2 (22.22) 0 (0.00) 1 (14.29) 0 (0.00) 10 (66.67)
Azathioprine 9 (20.45) 2 (10.53) 2 (22.22) 1(25.00) 4 (57.14) 0 (0.00) 2 (13.33)
Rituximab past 7 (15.91) 2 (10.53) 2 (22.22) 0 (0.00) 1 (14.29) 2 (40.00) 1 (13.33)
Hydroxychloriquine 5 (11.36) 3 (15.78) 1 (11.11) 0 (0.00) 1 (14.29) 0 (0.00) 6 (40.00)
MMF 8 (18.18) 5 (26.32) 1 (11.11) 0 (0.00) 1 (14.29) 1 (20) 2 (13.33)
Tacrolimus 3 (6.812) 1 (5.26) 1 (11.11) 0 (0.00) 1 (14.29) 0 (0.00) 0 (0.00)
Cyclosporine 2 (4.54) 2 (10.53) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
IVIG 3 (6.82) 2 (10.53) 0 (0.00) 1 (25) 0 (0.00) 0 (0.00) 0 (0.00)
Infliximab 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 2 (13.33)
Adalimumab 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 1 (6.67)
Table IV.2 Clinical and 
serological features of the adult 
myositis, JDM, adult and teenage 
healthy control cohorts at time of 
sample. 44 adult myositis (AM) 
patients and 15 adolescent onset-
juvenile dermatomyositis (JDM) 
patients were recruited. The AM 
group was divided into subgroups; 
dermatomyositis (ADM), 
polymyositis (APM), 
dermatomyositis with cancer, 
dermatomyositis with overlap and 
polymyositis with overlap. For each 
group, the clinical and serological 
data were recorded including; 
erythrocyte sedimentation rate (ESR) 
[normal range <20mm/hour], C-
reactive protein (CRP) [normal 
range <5mg/L], lymphocyte count 
[normal range 1.5-2x109/L], creatine 
kinase (CK) [normal range 
<150U/L], MITAX score, MMT8 
score [normal range >78], 
clinician’s decision on treatment, 
auto-antibodies and medication. The 
binary measures were analysed by 
Chi-square test and the continuous 
variables were analysed by one-way 
ANOVA. p£0.05 for significance. 
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PBMC from all sample groups were analysed by flow cytometry to quantify 33 
lymphocyte populations including; T-cell, B-cell and monocyte subsets. Total T cell 
and 16 T cell sub-populations were categorized and measured ex-vivo (Figure IV.1 
and Table IV.3) (McGowan et al., 2015). Total B cell, 8 B cell sub-populations, total 
monocytes, 3 monocyte sub-populations and natural killer (NK) cells were 
categorized and measured ex-vivo (Figure IV.2 and Table IV.4) (Lima et al., 2016, 
Lee et al., 2017). In addition to defining these populations, the expression of CD69 
from each population was measured as a recording of cellular activity (Figure IV.3 
and 5). The expression of IL-6 from monocyte, T and B cell populations and subsets 
were measured from PBMC from all sample groups after a 4hour culture in the 
presence of PMA, ionomycin and golgi plug (Figure IV.4 and 5). The expression of 
IL-17 was measured to identify the Th17 population after the same 4hour culture in 
the presence of PMA, ionomycin and golgi plug (Figure IV.6).  
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Flow cytometry gating 
 
Figure IV.1 Flow cytometry gating strategy for T cells and subsets  
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Table IV.3 T cell panel with defined sub-population by surface cell markers  
Cell type Markers 
T cell CD3+ 
Invariant killer T cells 
(inKT) 
CD3+gdTCR+ 
CD8+ T cell CD3+CD8+ 
C8+ Effector memory 
(EM) 
CD3+CD8+CD45RA-CD27- 
C8+ Central memory 
(CM) 
CD3+CD8+CD45RA-CD27+ 
C8+ CD45RA+ Effector 
memory (EMRA) 
CD3+CD8+CD45RA+CD27- 
C8+ naïve CD3+CD8+CD45RA+CD27+ 
CD4+ T cell CD3+CD8+ 
C4+ Effector memory 
(EM) 
CD3+CD4+CD45RA-CD27- 
C4+ Central memory 
(CM) 
CD3+CD4+CD45RA-CD27+ 
C4+ CD45RA+ Effector 
memory (EMRA) 
CD3+CD4+CD45RA+CD27- 
C4+ naïve CD3+CD4+CD45RA+CD27+ 
Tregs CD3+CD4+CD127lowCD25+ 
CXCR5+ T cell CD3+CD4+CD185+ 
Tfregs CD3+CD4+CD185+CD25+CD127low 
TfH CD3+CD4+CD185+ CD25 lowCD127+ 
Activated T cells CD3+CD4+CD185+ CD25 lowCD127+PD1+ICOS+ 
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Figure IV.2 Flow cytometry gating strategy for B cells and subsets 
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Table IV.4 B cell and monocyte ex-vivo panel with defined sub-population by 
surface cell markers  
Cell type Markers 
B cell CD3-CD19+ 
CD27+ B cells CD3-CD19+CD27+ 
CD27- B cells CD3-CD19+CD27- 
BM1 CD3-CD19+IgD+CD38- 
BM2 CD3-CD19+IgD+CD38+ 
BM2 transitional CD3-CD19+IgDhiCD38hi 
BM3-4 CD3-CD19+IgD-CD38hi 
BM5 early CD3-CD19+IgD-CD38+ 
BM5 late CD3-CD19+IgD+CD38- 
Monocytes CD3-HLA-DR+ 
Natural killer cells (NK) CD3-HLA-DR-CD16+ 
Non-classical monocytes  CD3-HLA-DR+CD14-CD16+ 
Intermediate monocytes CD3-HLA-DR+CD14+CD16+ 
Classical monocytes CD3-HLA-DR+CD14+CD16- 
 
 
Figure IV.3 Flow cytometry gating strategy for CD69 expression 
 
Figure IV.4 Flow cytometry gating strategy for IL-6 expression 
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Figure IV.5 Flow cytometry histograms of CD69 and IL-6 median fluorescence 
intensity (MFI) 
 
 
Figure IV.6 Flow cytometry gating strategy for Th17 cells 
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Distinct changes of the immune cell signature with age and key differences between 
adult and juvenile disease 
All the categorised cell populations were compared between sample groups, AM, 
JDM, AHC and THC, which were demonstrated in a heatmap of p-values (Figure 
IV.7). Clear differences in the immune cell signature between patients and age-
matched healthy donors for both AM and JDM were identified. However, the immune 
signature was altered in adults (AM vs AHC) compared to juveniles (JDM vs THC) 
suggesting an influence of age and/or that the immunopathogensis was different 
between AM and JDM. 
 
Volcano plots (fold changes vs p-value) were used to further visualise the multiple 
differences in the immune cell populations between patients and healthy donors 
(Figure IV.8). When AM was compared to AHC memory B and T cell populations 
(CD27+ve B cells, CD4+ CM, CD8+ CM) and total B cells were significantly 
decreased, whereas CD27-ve B cells and intermediate monocytes were significantly 
increased (Figure IV.8A). However, in JDM patients BM2, CD8+ and CD8+CM 
populations were significantly decreased and CD4+ T cells were increased compared 
to THC (Figure IV.8B). This finding suggested that ADM and JDM patients had 
unique phenotypes compared to age matched controls. This was supported when the 
immune phenotype of AM patients was compared to that of JDM. A significant 
decrease in CD27+ve B cells and CD8+ naïve cell populations was identified in AM 
compared to JDM, however CD27-ve B cells were increased (Figure IV.8C). 
 
Finally, when AHC was compared to THC the CD4+ naïve, CD8+ naïve and classical 
monocyte populations were increased, whilst the BM2 and intermediate monocytes 
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were decreased (Figure IV.8D). These data showed that the immune system changes 
with age which in turn may influence the differences in immunopathogenesis between 
adult and juvenile disease. 
 
Figure IV.7 Heat map identifying significant differences in cell populations, a 
comparison of IIM to healthy samples. The frequency of 33 PBMC populations were 
measured by flow cytometry from 44 adult myositis (AM) patients, 25 adult healthy 
controls (AHC), 15 adolescent-onset juvenile dermatomyositis (JDM) patients and 15 
teenage healthy controls (THC). This heat map demonstrates the statistical difference 
between each cell population by comparing the mean of each group of samples; AM 
vs. AHC, JDM vs. THC, AM, vs. JDM and AHC vs. THC. A student t-test calculated 
the p-values. Black to yellow - p£0.05. Blue to black - p³0.05. 
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Figure IV.8 Volcano plots identifying significant differences and fold change of 
cell populations, a comparison of IIM to healthy samples. Volcano plots represent 
the fold change and p value for each cell population when sample groups were 
compared. A) AM vs. AHC, B) JDM vs. THC, C) ADM vs. JDM, D) AHC, THC. The p 
values were calculated by one-way ANOVA. All p-values represent adjusted p-value 
calculated by Tukey’s multiple comparison. Stringent significance p£0.05 (black 
dotted line). Adjusted significance for small sample size p£0.1 (red dotted line) 
 
A T cell signature in ADM and B cell signature in APM 
Immune signatures in the IIM patient subgroups were also compared to the AHCs. 
Patients with ADM had increased Th17 and Treg T cell populations and decreased 
BM5 early B cells compared to AHC (Figure IV.9A). When the ADM with overlap 
patients were compared to the AHC group an increase in Th17 T cells was also 
identified (Figure IV.9E). However, the APM signature was characterised by a 
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change in the CD27+ve/-ve ratio, with an increase of CD27-ve and there by a 
decrease in CD27+ve B cells. In addition, there was also a decrease in the CD8+ CM 
T cell population (Figure IV.9B). 
 
T follicular regulatory (Tfreg) and CD4+ EMRA T cells were increased in the ADM 
with cancer compared to AHC group (Figure IV.9C). There were no significant 
differences in immune cell populations between the APM with overlap and AHC 
groups (Figure IV.9D). Finally, the ADM group was compared to the JDM group as 
the most comparable disease groups. This comparison identified key differences in 
the immune signature. The ADM group showed an increase of the Th17 and Treg T 
cell populations and a decrease in BM5 early, CD8+ naïve and intermediate monocyte 
cell populations when compared to the JDM group (Figure IV.9F). Thus, confirming 
the association between ADM and increased Th17 and Treg populations. 
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Figure IV.9 Volcano plots identifying significant differences and fold change of 
cell populations, a comparison of AM disease subgroups, JDM and AHC. Volcano 
plots represent the fold change and p value for each cell population when sample 
groups were compared. A) ADM (n=19) vs. AHC (n=25), B) APM (n=9) vs. AHC, C) 
ADM + cancer (n=4) vs. AHC, D) APM + overlap (n=7) vs. AHC, E) ADM + 
overlap (n=5) vs. AHC, F) ADM vs. JDM (n=15). The p values were calculated by 
one-way ANOVA. All p-values represent adjusted p-values calculated by Tukey’s 
multiple comparison. Stringent significance p£0.05 (black dotted line). Adjusted 
significance for small sample size p£0.1 (red dotted line). 
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Autoantibody groups highlight unique immune signatures 
Previous groups have used the autoantibody profile to discriminate between AM 
patient subtypes (Habers et al., 2016). Therefore, the immune phenotype in patients 
with AM was assessed according to autoantibody status. Similar cell types appeared 
in these signatures that had already been observed, but were unique to different 
autoantibody groups. When the anti-synthetase (anti-Jo-1 and anti-Pl-12) group was 
compared to AHC there was a strong B cell signature which suggested a change in the 
CD27-/+ve ratio (Figure IV.10A). The autoimmune rheumatic disease (ARD) overlap 
(anti-Ro, anti-PmSCL and anti-RNP) group demonstrated a T cell signature with 
increased Th17 and decreased CD8+ CM T cell populations (Figure IV.10B). There 
were no significant differences between the individual populations when the severe 
skin (anti-Mi2) group was compared to AHC (Figure IV.10C). The cancer associated 
(anti-NXP2 and anti-TIF1g) group showed increased monocyte, intermediate 
monocyte and BM3-4 B cell populations, but a decreased T cell population (Figure 
IV.10D). Those patients that had multiple auto-antibodies had increased Th17 T cell 
and intermediate monocyte populations (Figure IV.10E). The only significantly 
increased population seen when the negative group were compared to AHC was 
CD8+ naïve T cells (Figure IV.10F). 
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Figure IV.10  Volcano plots demonstrating the significantly different cell 
populations comparing AM autoantibody grouped samples with AHC. Volcano plots 
represent the fold change and p value for each cell population when AM autoantibody 
groups were compared with AHC samples. A) Anti-synthetase group (anti-Jo-1 and 
anti-Pl-12) (n=7) compared to AHC (n=25). B) Autoimmune rheumatic disease 
overlap (ARD) group (anti-Ro, anti-PmScl and anti-RNP) (n=9) compared to AHC. 
C) Severe skin group (anti-Mi2) (n=3) compared to AHC. D) Cancer associated 
group (anti-NXP2 and anti-TIF1g) (n=4) compared to AHC. E) Multiple 
autoantibodies group (n=5) compared to AHC. F) Negative for autoantibodies tested 
group (n=9) compared to AHC. The p values were calculated by one-way ANOVA. 
All p-values represent adjusted p-values calculated by Tukey’s multiple comparison. 
Stringent significance p£0.05 (black dotted line). Adjusted significance for small 
sample size p£0.1 (red dotted line). 
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AM immune signature most distinct from patients in remission 
The AM group was further divided by disease activity status and compared to each 
other and the AHC group to identify changes in the immune signature linked to the 
activity of the disease. I distinguished four groups including, active, mildly active, 
remission on treatment and remission off treatment. The most differences seen were 
between the remission off treatment group when compared to each other group 
(Figure IV.11A). The consistent difference observed was an increase of non-classical 
monocytes, but when compared to AHC an increase of CD27-ve, BM2 and a decrease 
in CD27+ve B cells was also identified. Th17 cells were increased in the remission on 
treatment compared to AHC group (Figure IV.11B), and the CD8+CM T cells were 
decreased from the active compared to AHC group (Figure IV.11D). Table 4 shows 
that there were more differences with less stringent statistical testing which may be 
more applicable for the small sample sizes. These data showed that AM patients in 
remission off treatment have the most striking altered immune signature compared to 
AHC. Therefore, this signature may reflect the true immune changes that occur in AM 
that continue into remission and no longer masked by treatment. 
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Figure IV.11  Volcano plots identifying significant differences and fold change of 
cell populations, a comparison of AM disease activity subgroups and AHC. Volcano 
plots represent the fold change and p value for each cell population when AM disease 
activity groups were compared. Patients’ with cancer, pregnant, treated with 
rituximab or diagnosed in childhood were removed from this analysis. A) Remission 
(n=5) compared to remission on treatment (Tx) (n=12), mildly active (n=9), active 
(n=4) and AHC (n=25). B) remission on Tx compared to mildly active, active and 
AHC. C) Mildly active compared to active and AHC. D) Active compared to AHC. 
The p values were calculated by one-way ANOVA. All p-values represent adjusted p-
values calculated by Tukey’s multiple comparison. Stringent significance p£0.05 
(black dotted line). Adjusted significance for small sample size p£0.1 (red dotted 
line). 
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Table IV.5 A comparison of AM disease activity groups; significantly different 
cell populations by student t-test 
Comparison Increased significantly Decreased significantly 
Remission vs remission 
on Treatment 
 
Non-classical 
monocytes, B cells 
Classical monocytes 
Remission vs mildly 
active 
 
BM2, non-classical 
monocytes, CD27- B 
cells 
BM5 late, Monocytes 
Remission vs active Non-classical monocytes BM5 early 
Remission vs AHC Non-classical 
monocytes, CD27- B 
cells, BM2, Th17 
CD27+ B cells, BM5 
early, BM5 late 
Remission on Treatment 
vs mildly active 
None None 
Remission on Treatment 
vs active 
None None 
Remission on Treatment 
vs AHC 
Th17, Monocytes B cells 
Mildly active vs active None CD4+ EMRA 
Mildly active vs AHC None B cells, CD8+ CM, BM5 
early 
Active vs AHC CD27+ B cells, Tfregs, 
Th17 
CD8+ CM, CD27- B 
cells 
 
CD8+CM T cells were decreased in active disease 
Continued exploration of the correlation between disease activity and an immune cell 
signature revealed that specific markers of disease activity and treatment used were 
correlated to individual cell populations for AM and JDM. This confirmed the 
findings from the previous figures. In particular an increase in CRP showed a positive 
correlation to the Th17 and Tfreg T cell populations, and a decrease of the non-
classical monocyte populations from the AM group. When the MITAX score 
increased so did the BM3-4 B cell population, but the CD8+ CM T cell population 
decreased from the AM group (Figure IV.12A and Table IV.6). For patients with 
JDM an increased CK was linked to a decrease in CD27+ve B cells, the MITAX 
positively correlated to an increase of the BM2 transitional B cell population, and an 
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increase in the MMT8 score was associated with an increased CD8+CM and a 
decreased Tfreg T cell population (Figure IV.12B and Table IV.6). When the 
medications were correlated to the cell populations, this highlighted that some of the 
previous observations may be due to medication. In particular the use of prednisolone 
correlated to a decrease of the B cell and CD8+ CM populations in the AM group 
(Figure IV.12C and Table IV.7).  
 
Figure IV.12 Volcano plots showing correlations between cell populations and 
clinical markers or treatment. Volcano plots show statistical difference by p value 
and r value for directional change of correlation. The correlation between cell 
populations and clinical markers from A) AM (n=44) samples and B) JDM (n=15) 
samples. The correlation between cell populations and medication from C) AM 
samples and D) JDM samples. Pearson’s correlation was conducted. Significance 
reached p£0.05 (dotted red line). 
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Table IV.6 Identified cell populations that correlate with myositis clinical 
markers 
Myositis clinical 
markers 
Positive correlation Negative correlation 
AM:   
CRP iNKT, Tfregs, classical 
monocytes, BM5 early, 
Th17 
Non-classical monocytes 
 
ESR BM5 early, activated T 
cells 
 
TfH, CD4+CXCR5+ 
 
Cholesterol CD4+ naive Tfregs, CD4+ EMRA, 
inKT, T cells 
MITAX BM3-4, CD8+ naive CD8+ CM 
JDM:   
CRP CD8+ EMRA, BM1 None 
ESR None Classical monocytes 
CK None CD27+ B cells 
MITAX BM2 transitional None 
MMT8 CD8+ CM Tfregs 
 
Table IV.7 Identified cell populations that correlate with treatment 
Treatment Positive correlation Negative correlation 
AM:   
Prednisolone iNKT cells B cells, CD8+ CM, 
Tregs 
Prednisolone dose CD4+ EMRA None 
IVIG iNKT cells, classical 
monocytes 
CD8+ T cells 
Rituximab B cells None 
JDM:   
Prednisolone None CD8+ naive 
DMARDs None BM2 transitional 
Biologics BM1 None 
 
Activated immune cells and IL-6 signature in AM 
To assess whether the correlation between disease activity scores were matched by 
immune cell activation the expression of IL-6 and CD69 in immune cell subsets were 
compared between sample groups, AM, JDM, AHC and THC. Figure IV.13 shows 
clear differences in the immune cell signature expression of IL-6 and CD69 between 
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disease and healthy individuals in the adult comparison. IL-6 was measured as it was 
a pro-inflammatory cytokine that has been detected at high levels in the serum and 
muscle of IIM and has been linked to active disease (Bilgic et al., 2009, Yang et al., 
2013, Lundberg et al., 1997). There was an increased expression of IL-6 from 
monocytes, B cells and CD8+ T cells when AM was compared to AHC group, this 
was not observed in the JDM and THC comparisons (Figure IV.14A and B). 
However, there was an increased expression of IL-6 from the BM2 transitional B cell 
population when JDM was compared to THC (Figure IV.14B). Similarly, the AM 
group had a pan increased CD69 expression across all cell types when compared to 
AHC, but there were no observed differences between JDM and THC apart from a 
decreased expression from classical monocytes (Figure IV.14C and D). 
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Figure IV.13  Heat map identifying significant differences in cell populations 
expression of IL-6 and CD69, a comparison of IIM to healthy samples. The 
expression of A) IL-6 and B) CD69 from PBMC populations were measured by flow 
cytometry from 44 adult myositis (AM) patients, 25 adult healthy controls (AHC), 15 
adolescent-onset juvenile dermatomyositis (JDM) patients and 15 teenage healthy 
controls (THC). This heat map demonstrates the statistical difference between each 
cell population by comparing the mean of each group of samples; AM vs. AHC, and 
JDM vs. THC. A student t-test calculated the p-values. Black to yellow - p£0.05. Blue 
to black - p³0.05. 
A B
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Figure IV.14  Volcano plots identifying significant differences and fold change of 
cell population expression of IL-6 and CD69, a comparison of IIM to healthy 
samples. Volcano plots represent the fold change and p value for each cell 
populations expression of IL-6 (A and B) and CD69 (C and D) when sample groups 
were compared. A) AM vs. AHC (IL-6 expression), B) JDM vs. THC (IL-6 
expression), C) AM vs. AHC (CD69 expression), D) JDM vs. THC (CD69 
expression). The p values were calculated by one-way ANOVA. All p-values represent 
adjusted p-value calculated by Tukey’s multiple comparison. Stringent significance 
p£0.05 (black dotted line). Adjusted significance for small sample size p£0.1 (red 
dotted line). 
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sub-group specific. When ADM was compared to the AHC group the B cell and 
monocyte sub-population expression of IL-6 was increased (Figure IV.15A). These 
differences were lost in the comparison between APM and AHC (Figure IV.15B). 
When ADM with cancer was compared to AHC, the positive increase of IL-6 
expression was from T cells (Figure IV.15C). The signature of an increased B cell 
expression of IL-6 reappeared when ADM with overlap was compared to AHC 
(Figure IV.15D). Then disappeared again for APM with overlap compared to AHC 
(Figure IV.15E). The comparison of ADM compared to the JDM group showed that 
there was an increased expression of IL-6 from CD8+ T cell subsets and B cell 
subsets (Figure IV.15F). The final comparison of ADM compared to the APM group 
showed that there was an increased expression of IL-6 from memory B cells (Figure 
IV.15G). 
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Figure IV.15  Volcano plots identifying significant differences and fold change of 
cell population expression of IL-6, a comparison of AM disease subgroups to AHC 
and JDM samples. Volcano plots represent the fold change and p value for each cell 
populations expression of IL-6 when AM sample disease sub-groups were compared 
with AHC and JDM samples. A) ADM (n=19) compared to AHC (n=25) (IL-6 
expression), B) APM (n=9) compared to THC (IL-6 expression), C) ADM + cancer 
(n=4) compared to AHC (IL-6 expression), D) ADM+ overlap (n=7) compared to 
AHC (IL-6 expression), E) PM + overlap (n=5) compared to AHC (IL-6 expression), 
F) ADM compared to JDM (n=15) (IL-6 expression), and G) ADM compared to APM 
(IL-6 expression). The p values were calculated by multiple t-test, significance p£ 
0.05 (bottom dotted black line). Multiple comparison was calculated by the Holm-
Sidak method, therefore adjusted p value significance p£ 0.005116 (top dotted black 
line). Adjusted significance for small sample size p£0.1 (red dotted line). 
 
The expression of IL-6 and CD69 from each cell population was correlated to clinical 
markers. Positive correlations were observed between CRP and IL-6 production by T 
cell sub-populations including; total T cells, CD4+ naïve and EMRA (Figure 
IV.16A). Only Il-6 production in BM2 transitional cells showed a positive correlation 
with CRP and ESR from the B cell IL-6 expression signature. The JDM group had 
only four significant correlations each different clinical markers and cell populations 
(Figure IV.16B). Again, from the AM group the CRP and ESR markers correlated 
with a T cell CD69 expression signature (Figure IV.16C). The JDM group had a 
wider spectrum of cell type CD69 expression correlation to clinical markers 
including; CD27-/+ve to CRP (Figure IV.16D).  
 
Immune cell activation assessed by expression of IL-6 and CD69 also appeared to be 
influenced by treatment (Figure IV.17 and Table IV.8). The analysis of the AM 
group showed that treatment with prednisolone correlated to an increased IL-6 
expression from total CD4+ naïve and total T cell populations. This was similar for 
IVIG with additional populations including; BM2 transitional and CD4+ EMRA T 
cells. In contrast, treatment with cyclosporine and hydroxychloroquine correlated to a 
decreased IL-6 expression from CD8+ cells (Figure IV.17A). There was no 
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significant correlation between treatments and cellular expression of IL-6 from the 
JDM group (Figure IV.17B). The use of prednisolone and an increasing dose 
positively correlated to an increased T cell CD69 expression in the AM group. 
Conversely, the use of hydroxychloroquine and MMF correlated to a decreased 
expression of CD69 from B cells and monocytes (Figure IV.17C). In the JDM group, 
treatment with prednisolone and biologics correlated with an increased expression of 
CD69 from B cells and CXCR5+ T cells (Figure IV.17D). 
 
Figure IV.16  Volcano plots showing correlations between myositis clinical 
markers and cell population expression of IL-6 and CD69. Volcano plots show 
statistical difference by p value and r value for directional change of correlation. The 
correlation between cell population expression of IL-6 and myositis clinical markers 
from A) AM samples and B) JDM samples. The correlation between cell population 
expression of CD69 and myositis clinical markers from C) AM samples and D) JDM 
samples. Pearson’s correlation was conducted. Significance reached p£0.05 (dotted 
red line). 
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Table IV.8 – Summary of positive and negative correlations of myositis clinical 
markers to cell population expression of IL-6 or CD69 
 
Myositis clinical 
markers 
Positively correlated Negatively correlated 
AM (IL-6):   
CRP CD4+ naïve, T cells, 
CXCR5+, BM2 transitional, 
CD4+ EMRA 
None 
ESR BM2 transitional None 
Cholesterol Monocytes None 
AM (CD69):   
CRP CD4+, CD8+, CXCR5+, 
activated T cells, 
CD4+CD8+, Tfregs, CD4+ 
CM, CD4+ naïve, CD4+ 
EM 
None 
ESR TfH, CD4+ naïve, CD4+, 
CD8+, CXCR5+, T cells 
None 
Cholesterol CD4+ T cells None 
MITAX CD4+CD8+ None 
JDM (IL-6):   
CK T cell None 
CRP CD4+CD8+ None 
MITAX None CD8+ CM 
MMT8 None BM3-4 
JDM (CD69):   
CRP CD4+ EM, CD27- B cells, 
CD27+ B cells, classical, 
monocytes 
None 
MITAX CXCR5+, CD4+CD8+, TfH None 
MMT8 None CD4+ EMRA, Tfregs, 
CXCR5+ 
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Figure IV.17 Volcano plots showing correlations between treatments and cell 
population expression of IL-6 and CD69. Volcano plots show statistical difference 
by p value and r value for directional change of correlation. The correlation between 
cell population expression of IL-6 and treatment from A) AM samples and B) JDM 
samples. The correlation between cell population expression of CD69 and treatment 
from C) AM samples and D) JDM samples. Pearson’s correlation was conducted. 
Significance reached p£0.05 (dotted red line). E) Scatter plot showing MITAX scores 
for each IIM sample split into subgroups; ADM, APM, ADM + cancer, ADM + 
overlap, APM + overlap and JDM. Represented mean average with standard 
deviation. 
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Table IV.9 Summary of positive and negative correlations of treatments to cell 
population expression of IL-6 or CD69 
Treatment Positively correlated Negatively correlated 
AM (IL-6):   
Prednisolone dose CD4+ naïve, T cells None 
Azathioprine None BM3-4 
IVIG CXCR5+, CD4+ EMRA, 
CD4+ naive 
None 
Cyclosporin None CD8+naïve, CD8+ CM 
AM (CD69):   
Prednisolone dose CD4+CD8+, T cells, 
CD8+, CD4+ EM 
None 
Prednisolone CD8+  None 
Azathioprine None Tregs,  
Hydroxychloriquine None Non-classical, TfH, 
CD27- B cells 
MMF None Classical, B cells, non-
classical, CD27- B cells 
JDM (CD69):   
Prednisolone dose Tfregs, CXCR5+, B cells, 
CD27- B cells 
None 
Prednisolone CD27+ B cells, CXCR5+ None 
Biologics CD27+ B cells, CD27- B 
cells 
None 
 
Th17 cells; an expanded population in ADM that correlated to an expansion of 
activated T cells 
Increased expression of the Th17 population was identified in the AM group, 
specifically in the ADM sub-group, compared to AHC and JDM. AM patients that 
were in remission on treatment, had the strongest association with an increased Th17 
population. Equally the auto-antibody ARD overlap (anti-Ro, anti-PmSCL and anti-
RNP) group and the group expressing multiple auto-antibodies demonstrated an 
increased Th17 population. Furthermore, a significant positive correlation between 
serum CRP levels and Th17 expression was identified in AM patients (Figure 
IV.18A). The expansion of the Treg, iNKT and CD4+ EMRA T cell populations 
correlated with the increased expression of Th17 cells (Figure IV.18B). Finally, there 
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was a positive correlation between Th17 expansion and the expression of CD69 from 
T cell subsets and IL-6 from BM5 early B cells in Am patients (Figure IV.18C). In 
summary, the expansion of Th17 expression associated with the ADM sub-group and 
aligned with an expansion of activated T cells. 
 
Figure IV.18  The Th17 population correlated to CRP, other PBMC populations, 
and cell populations expressing CD69 and IL-6. The Th17 population was expanded 
in the AM population compared to JDM and AHC samples. A) A scatter graph 
showing that CRP positively correlated to Th17 frequency. B) A volcano plot showing 
all PBMC population frequencies correlation to Th17 frequency. C) A volcano plot 
showing all PBMC population expression of CD69 and IL-6 correlation to Th17 
frequency. Pearson’s correlation was conducted. Significance reached p£0.05 (dotted 
red line).  
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DISCUSSION 
These results represent a novel in-depth immunophenotyping of patients with 
myositis. This was conducted to record differences in PBMC populations present in 
these patients. Previous studies have highlighted changes in total populations of 
monocytes, T and B lymphocytes, but to my knowledge none have correlated changes 
across such a large number of different lymphocyte sub-populations (O'Gorman et al., 
1995, Behan et al., 1987). The analyses were conducted across multiple levels of 
comparison to observe changes between ages, disease and healthy, disease sub-
groups, auto-antibody status, changes in disease activity and with different treatment. 
Activation status and the expression of the pro-inflammatory cytokine IL-6 was also 
measured to characterise the behaviour of these cells within the disease states. 
 
The adult and juvenile patients were recruited from rheumatology out-patient clinics 
and in-patient wards at UCLH. There was no known selection bias for the patients 
with dermatomyositis or polymyositis, therefore the numbers in this cohort were a fair 
representation of the overall cohort seen at UCLH. Dermatomyositis has been 
identified as the most frequently diagnosed IIM in both adult and juvenile groups, 
with polymyositis more commonly diagnosed in adults. These findings were reflected 
in the cohorts used in this study. The results also identified a trend for a difference in 
sex demographics between IIM subgroups; both DM and PM groups had more 
females than males, but PM seemed to have the highest occurrence in females. 
Previous studies have identified that there was a higher incidence of DM and PM in 
females (Mastaglia and Phillips, 2002). The inflammatory idiopathic myopathies have 
been reported to occur in all ethnic groups (Mantegazza R, 2000-2013, Dalakas and 
Hohlfeld, 2003). Immune-response genes have been identified in genetically defined 
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ethnic groups which may predispose certain populations to polymyositis or 
dermatomyositis (Reed, 2001, Shamim et al., 2002). Equally, studies have reported a 
higher incidence of the IIMs in black men and women compared to white Caucasian’s 
(Oddis et al., 1990, Medsger et al., 1970). The JDM and AM cohorts used in this 
study confirmed the spread of ethnicities previously observed. The small sample size 
and the restriction of the cohort recruitment to one hospital, UCLH, impacted the 
ethnic distribution, especially within the JDM cohort.  
 
Generally, all IIM patients are treated with prednisolone on diagnosis (Dalakas, 
2015). If they are responsive then disease modifying anti-rheumatic drugs (DMARDs) 
are introduced including; methotrexate, azathioprine, MMF or cyclosporine (Ernste 
and Reed, 2013). When ILD is also diagnosed cyclophosphamide or tacrolimus can 
be given (Oddis et al., 1999, Dalakas, 2010). Intravenous immunoglobulin (IVIG) is 
often considered in severe and rapidly progressive disease. When the disease is 
irresponsive to the above treatments, biologics approved for use in more commonly 
diagnosed immune conditions, can be introduced as experimental therapies. These 
drugs include; anti-CD20 (rituximab), anti-IL-6 (tocilizumab) and anti-interleukin-1 
receptor (anakinra) (Oddis et al., 2013, Narazaki et al., 2011, Zong et al., 2014). The 
ADM, APM and JDM cohorts in this study demonstrated a difference in their use of 
treatments. Disease activity was highest in the AM compared to JDM, which may 
reflect the broader spectrum of DMARDs used. However, the patients with the most 
severe disease from the JDM cohort had received treatment with the TNF inhibitors, 
infliximab and adalimumab. These therapies were not used in the adult cohort. 
Infliximab was shown to be ineffective and may worsen disease in adults (Dastmalchi 
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et al., 2008). The AM cohort could have a higher rate of ILD which would reflect the 
use of tacrolimus (data not reported).  
 
The MSA are detected in both DM and PM, but there is a wider range found in DM. 
The anti-Jo1 and anti-SRP autoantibodies are more common in PM. However, anti-
Mi2, anti-TIF1g, and anti-NXP2 are rarely detected in PM but more commonly in DM 
and JDM (Ghirardello et al., 2013). The AM cohort for this study displayed 
comparable prevalence of MSA’s to that previously reported. In particular, PM 
patients were only positive for anti-Jo1 and anti-SRP. Unfortunately, accurate data 
was not available for the JDM cohort. 
 
Ageing is a complex process that impacts immunosenescence. T cells have been 
identified to be particular vulnerable to the effects of ageing. This is thought to be 
attributed to age-induced thymic atrophy and the decreased output of naïve T cells 
(Gruver et al., 2007). The comparison of the AHC to THC samples identified 
decreased naïve T cell populations in the older control group. This result implied that 
this was an effect of ageing. B cells have also been shown to decrease with age, the 
BM2 population proportionally makes up the highest sub-population of the B cells 
and therefore would be relatively less the older the population (Morbach et al., 2010). 
The differences seen with the monocyte subset populations do not relate to the 
literature, as previous studies have found that CD16+ monocytes increased with age 
and proportionally the CD16- monocytes decreased (Nyugen et al., 2010). An 
expansion of the B cell population in active PM and DM has been identified, although 
this was not apparent in the cohorts for this study (Ishii et al., 2008, Wang et al., 
2012). However, there was an apparent change in the proportion of CD27ve-/+ B 
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cells. All the patients from this study had received prednisolone and some 
methotrexate, these treatments may impact the B cell expression of CD27. Early 
studies of the use of prednisolone in healthy adults and in SLE patients showed that 
the frequency of B cells reduced in a time and dose dependant manner (Yu et al., 
1974, Chatham and Kimberly, 2001). A recent study showed that both B cells and the 
immature B cell subset were reduced in frequency in JIA patients treated with 
methotrexate alone in comparison to patients who did not receive treatment 
(Glaesener et al., 2014). There have been reports of decreased CD4+ and CD8+ 
populations from active ADM samples when compared to healthy controls, but there 
has been no data on JDM samples that reported similar decreased CD8+ and increased 
CD4+ T cell populations (Wang et al., 2012). CD8+ CM T cells were decreased in 
both adult and juvenile disease in comparison to healthy controls, previous studies 
that have investigated the effects of immunosuppressive agents on this lymphocyte 
population have shown that they remained in a steady state (Meyer et al., 2015).  
 
A particular aim was to report unique immune signatures of the peripheral blood for 
each subtype of AM. The increased population of Th17 cells was specific to ADM 
and ADM with overlap. In addition, this signature was observed in patients with the 
CTD overlap (anti-Ro, anti-PmSCL and anti-RNP) group of autoantibodies and also 
those patients that were in remission on treatment. Th17 cells were recognised as CD4 
expressing T-helper cells that selectively expressed IL-17 over interferon (IFN)- g 
(Tournadre and Miossec, 2012). The differentiation of these cells is dependent on IL-
6, IL-21, IL-23 and transforming-growth factor (TGF)-b (Miossec et al., 2009). The 
IL-23-Th17 pathway has been extensively explored and reported to play a critical role 
in the induction and maintenance of chronic inflammation and autoimmunity, 
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specifically in RA (Miossec, 2017). Th17 cells have been found in the muscle tissue 
from both DM and PM patients (Chevrel et al., 2003, Page et al., 2004, Tournadre et 
al., 2009). IL-17 has a central role in the migration and differentiation of mononuclear 
cells, it does this by inducing IL-6 and b chemokines. Chevrel et al showed that IL-17 
in conjunction with IL-1 and TNF-a increased the expression of MHC class I on 
muscle cells (Chevrel et al., 2003). This is relevant in the context of IIM as the 
overexpression of MHC class I is a common trait (Rowe et al., 1981, Nagaraju et al., 
2005). An inflammatory loop in inflamed muscles exists; this is sustained by 
interactions between IL-17, IL-1, TNF-a and toll-like receptor (TLR) 3 expressed by 
muscle. The induction of IL-6 by IL-17 may also be involved in the dysfunctional 
repair of inflamed muscle (Tournadre and Miossec, 2012).  
 
There are multiple biologic drugs that target the IL-17 pathway. The targets include; 
Il-17, IL-17A, IL-17R, IL17RA and the potential for bispecific in combination with 
TNF-a. Some of these drugs, secukinumab, ixekizumab, and brodalumab, have been 
approved and are in phase 3 trials for the treatment of psoriasis (Langley et al., 2014, 
Gordon et al., 2016, Lebwohl et al., 2015). There were no previous reports of an 
expanded Th17 population in the peripheral blood of IIM patients, or a correlation 
between the periphery and tissue. The identification in muscle and exploration of the 
pathological mechanisms has prompted the potential for using IL-17 targeting agent 
in the treatment of IIM (Tournadre and Miossec, 2012). The preliminary findings 
from this study suggest that ADM was more an IL-17 driven disease than APM or 
JDM. This heterogeneity would imply that not all IIM patients would be responsive to 
an IL-17 targeting drug. Extrapolating from these results, it would be important to 
establish a correlation between the proportion of Th17 cells in the periphery and 
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inflamed tissue at diagnosis and to monitor the change over time on treatment with 
disease progression. 
 
In addition to an expanded Th17 population specifically seen in ADM there was also 
an expansion of T regulatory (Treg) cells. There was a positive correlation identified 
between these T cell populations. FOXP3+ Tregs have been identified as part of the 
infiltrating immune cell mileau detected in muscle biopsies, but the main T cells were 
CD4+/CD8+ memory and Th1 (Malmstrom et al., 2012). The Treg population has 
been noted to reduce with glucocorticoid therapy, where CD4+CD28null T cells are 
persistent on biopsy (Loell, 2011). A recent study identified that Tregs directly 
contributed to muscle damage in infection induced myositis, they were thought to 
promote macrophage homeostatic dysfunction (Jin et al., 2017). The expansion of 
Tregs that was noted reflect a reduction in the prednisolone dose, though there was no 
noted correlation. There was no correlation between the Treg population and disease 
activity either.  
 
Conversely there was a decrease of the CD8+ central memory (CM) T cell population 
in AM and JDM when compared to the age-matched healthy control samples. The 
decrease was most obvious in the APM group. The analysis of muscle biopsies from 
both ADM and APM patients has identified a CD8+ cytotoxic T cell phenotype from 
APM samples, whereas ADM samples portrayed a CD4+ driven inflammation 
(Benveniste et al., 2004, Amemiya et al., 2000). A study that analysed the immune 
infiltrate from two JDM patient biopsies revealed, an oligoclonal expansion of CD8+ 
T cells surrounding inflamed vessels that expressed a characteristic phenotype of 
memory/effector T cells with killer functions (Mizuno et al., 2004). The decrease of 
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the CD8+CM cell population identified from the AM and JDM PBMC samples, could 
be a reflection that these cells were tissue residing in disease and therefore there were 
lower numbers than seen in healthy controls in the periphery. In both AM and JDM, 
the patients with the most active disease had the lowest circulating peripheral 
population of these cells, suggesting that the recruitment to tissue pathway was 
switched off with suppression of disease activity. To investigate this hypothesis 
further, it would be important to correlate the population of tissue residing CD8+CM 
to the PBMC population at time of biopsy. From there, the mechanism of CD8+CM 
migration to tissue, such as complement activation, could be delineated (Dalakas and 
Hohlfeld, 2003).  
 
B cells have also been detected within the inflamed muscle of AM and JDM patients, 
suggesting that B cells exert a pathological function on muscles (Shah et al., 2013, 
Greenberg et al., 2005a). A strong autoantibody profile can be detected in most IIM 
patients implying one function of B cells in this group of diseases is the production of 
autoantibodies (Nistala and Wedderburn, 2013). My results provided an insight into 
the phenotype and function of B cells within the peripheral blood of both AM and 
JDM patients. I found that the B cell compartment was dysregulated in the peripheral 
blood; the AM patients had a lower proportion of CD27- and BM5 early (IgD-
CD38+) B cells than JDM and AHC groups, and the JDM group had an increased 
BM2 transitional (IgDhiCD38hi) population. However, studies in SLE have identified 
that the memory B cell populations, both CD27+ and -, were expanded and 
immunosuppressive resistant (Dorner et al., 2011). The decrease of the CD27+ and 
BM5 B cell populations was most evident in the AM patients expressing anti-
synthetase (anti-Jo-1 and anti-Pl-12) autoantibodies and those that were classified as 
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in remission off treatment. Interestingly, the results from chapter III, which detailed 
an in-depth investigation of B cell populations in JDM from pre- and on-treatment 
patients, showed that the memory B cell population was lowest in pre-treatment 
patients. The low memory B cell population identified in IIM may be a coincidental 
non-pathogenic finding which better reflects changes in related populations. 
Conversely in JDM, the BM2 transitional population positively correlated to an 
increase of disease activity (MITAX score). This result was comparable to those 
reported in chapter III, which suggested a pathological role for immature/BM2 
transitional B cells. 
 
One way to measure the pathogenic potential of immune cells is to examine the 
expression of pro-inflammatory cytokines. Interleukin (IL) 6 is a pro-inflammatory 
cytokine that has been detected at high levels in the serum of IIM and other 
autoimmune diseases and has been linked to active disease (Bilgic et al., 2009). This 
cytokine has also been detected in the muscle (Yang et al., 2013, Salomonsson and 
Lundberg, 2006). Suppression of IL-6 with prednisolone has also been shown to be 
dose dependant (de Kruif et al., 2007). A multi-centre pilot study at the University of 
Pittsburgh has begun recruitment to determine if the monoclonal antibody against the 
IL-6 receptor, tocilizumab, is an effective treatment for adult polymyositis and 
dermatomyositis. This study has been set up from the evidence that tocilizumab is an 
effective treatment in other rheumatological conditions, including RA and systemic 
JIA, and that serum levels of IL-6 significantly correlated with disease activity in both 
adult and juvenile DM (Okuda, 2008, Bilgic et al., 2009). 
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My data showed that the frequency of B cells, monocytes and CD8+ T cells 
expressing IL-6 was higher in AM compared to both JDM and adult healthy control 
samples. This trend was particularly clear in the ADM samples. The differences 
identified could be a reflection of disease activity; there were more active patients in 
the AM group compared to JDM. The use of prednisolone has been shown to suppress 
IL-6. Treatment of childhood primary nephrotic syndrome with prednisolone 
suppressed the levels of serum IL-6 in a steroid-responsive patient group (Yu and 
Zhang, 2005).The only noted IL-6 signature for the JDM group was an increased 
expression from BM2 transitional cells which were identified to be expanded and 
correlate with an increase in disease activity. However, there was no noted difference 
in disease activity between the ADM and APM disease groups, yet there was an IL-6 
signature in uniquely the ADM patients. Equally, the expression of IL-6 did not 
correlate with disease activity or use of different therapeutic agents. These results 
would suggest that the IL-6 signature observed in ADM maybe ancillary to a 
pathological mechanism not yet identified. Without further exploration of this 
signature it is unclear whether IL-6 would be a useful therapeutic target in the context 
of IIM, and specifically ADM. 
 
Not only was an IL-6 signature noted in the AM patients it was also observed that 
there was increased immune cell activation determined by the expression of CD69, a 
type II C-lectin membrane receptor (Gonzalez-Amaro et al., 2013). Previous studies 
have reported that CD69 had an important role in the activation of leukocytes that 
exert a pro-inflammatory effect (Sancho et al., 2005). However, more recently it has 
been identified that CD69 employs a complex immune-regulatory role in humans and 
animal models by the inhibition of Th17 differentiation and function (Martin et al., 
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2010, Cruz-Adalia et al., 2010). In systemic sclerosis (SSc) an association was found 
in the skin between infiltrating Th17 cells, CD69+ leucocytes and enhanced synthesis 
of transforming growth factor (TGF)-b (Kalogerou et al., 2005, Radstake et al., 2009). 
The increased population of Th17 cells reported from the ADM group correlated to an 
increased expression of CD69 from Treg, iNKT and CD4+ EMRA T cells. These 
results support the evidence that CD69+ T cells may exert an immune-regulatory role 
in the context of ADM. 
 
The immune cell signatures identified in this study would need further investigation 
to substantiate their accuracy and relevance in disease pathogenesis. My work was 
restricted by a small sample size for each disease group, and therefore was low-
powered. Preferably each sub-group would have the same number of samples, similar 
time points since diagnosis and a cross-comparison between treatments. The IIMs are 
a very rare group of diseases and are heterogeneous in nature, specifically in their 
clinical presentation and expression of autoantibodies. Each confounder provided a 
new way to cross-compare the disease and identified new signatures. The main 
statistical methods used to analyse the comparisons were multiple t tests with Holm-
Sidak method of correction or one-way ANOVA with a calculated adjusted p value by 
Tukey’s multiple comparison test. Due to low levels of and a discrepancy in the 
sample size, the adjusted p value significance level was likely too stringent, but for 
consistency was applied throughout.  
 
This study provided an insight into the peripheral immune cell signatures of IIM 
patients on treatment. To substantiate these data, it would be useful to observe 
changes in the signature over time, preferably from pre-treatment to remission off 
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treatment. Equally, to correlate the peripheral signature to that found in the muscle 
tissue immune cell milieu. A potential therapeutic target identified from this study is 
Th17 cells and thus IL-17, but this is likely to be confined to ADM patients. IL-6 may 
also be a possible target, but as the data showed no clinical correlation this would 
require further investigation. 
 
 
Figure IV.19  Different immune signatures in adult dermatomyositis, polymyositis 
and juvenile dermatomyositis. ADM was characterised by an increase of CD4+ T 
cells including; Th17, naïve T cells and Tregs, but also plasmablasts and an 
increased cellular expression of IL-6. Common to both ADM and APM there was a 
decrease of memory B cells and central memory CD8+ T cells. This decrease in 
central memory CD8+ T cells was also noted in JDM.  
  
Adult dermatomyositis Adult polymyositis Juvenile dermatomyositis
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Treg
Naive
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Chapter V 
To investigate the effects of type I interferon on immune cell 
lipid membranes 
 
  
 184 
Results (section 3) 
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INTRODUCTION 
 
Type I interferons constitute a large subgroup of interferon proteins involved in 
immune regulation. An up-regulation of the type I interferon signature has been 
described in autoimmune diseases, and in the myopathies correlates with disease 
activity (Bilgic et al., 2009). The type I IFN signature has been shown to be involved 
in the immunopathology of both juvenile and adult IIM, indicated by gene expression 
profiling of muscle tissue and peripheral blood. The signature has been confirmed by 
the detection of IFN producing cells, such as pDCs, in the muscle and skin tissue, and 
the presence of the IFN inducible protein, MxA, in muscle tissue (Lundberg and 
Helmers, 2010). This signature was also identified to be up-regulated in the JDM 
cohort RNA-sequencing data shown in Chapter III.  
 
A study by Tisseverasinghe et al suggested that patients with DM and PM have a 
significantly increased risk of incurring a cardiovascular event (CV). They also 
showed that CV events were strongly associated with dyslipidemia (Tisseverasinghe 
et al., 2009). Changes in cholesterol homeostasis and fatty acid metabolism have been 
related to the IFN pathway. York et al showed with isotype tracer analysis, that type I 
IFN signalling shifts the balance of the biosynthesis and import of cellular lipids by 
decreasing cholesterol and long chain fatty acids. An upregulation of the type I IFN 
signature correlated with a reduction in the pool size of synthesized cholesterol, that 
in turn could be inhibited by replenishing cells with free cholesterol. They showed 
that limiting the flux through the cholesterol biosynthetic pathway engaged the type I 
IFN response in a stimulator of interferon genes (STING)-dependent manner. Overall 
these studies demonstrated a metabolic-inflammatory circuit that links fluctuations in 
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cholesterol biosynthesis with an upregulation of the type I IFN pathway (York et al., 
2015). 
 
The aim of this chapter was to explore the relationship between the type I IFN 
pathway and cholesterol homeostasis. To investigate this relationship, gene mining of 
RNA-seq data was performed to identify specific cholesterol pathway genes with 
altered expression in JDM. Cell culture with IFN-a was performed to identify 
changes in the selected gene, and markers of plasma membrane-associated lipid 
glycosphingolipids (measured by cholera-toxin-B binding, CTB) and cholesterol 
(measured using filipin binding) in healthy control PBMC and isolated T and B cells. 
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RESULTS 
The type I IFN signature was confirmed by analysis of RNA-seq data carried out on 
JDM and CHC samples. Table V.1 highlights the demographics, clinical and 
serological features of both the JDM pre- and on- treatment patient and CHC cohorts. 
This table shows that the JDM samples were age matched to the CHC samples, but 
the female predominance seen in the JDM cohort was not proportionally reflected in 
the CHC cohort. The JDM pre-treatment patients had worse disease than on-treatment 
patients which was confirmed by significantly higher PGA score and CK levels, but 
significantly lower MMT8 and CMAS scores. A broad spectrum of autoantibodies 
was represented in the JDM cohort, however there were no patients with anti-MDA5. 
The majority of the on-treatment samples were taken from patients on methotrexate 
and oral prednisolone, which suggests that this cohort was relatively responsive to 
treatment with DMARDs. 
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Table V.1 Demographic, clinical and serological features of the JDM cohort and 
child healthy controls used in RNA-sequencing data set. The median and interquartile 
range (IQR) was represented for patient characteristics and clinical features. Student 
t-test was used to test the significance between JDM pre- and on-treatment groups for 
PGA, manual muscle testing of 8 groups (MMT8), and childhood myositis Assessment 
Scale (CMAS). Mann-Whitney test was used to test the significance between JDM pre- 
and on-treatment groups for creatine kinase (CK). The number of patients 
(percentage)were shown for autoantibody status and medication taken. 
Autoantibodies included; anti–transcription intermediary factor 1g (anti–TIF-1g), 
anti–nuclear matrix protein 2 (anti–NXP-2), anti-75-and 100kDa 
polymyositis/systemic sclerosis proteins (anti-PmScl), Nucleosome-remodeling 
deactulase complex (anti–Mi2), Signal recognition particle (anti-SRP), and Unknown 
bands (UKB) 
 
 
Up-regulation of the type I interferon alpha signature in JDM 
Gene set enrichment analysis (GSEA) revealed significant differences in the fifty 
Hallmark pathways (Figure V.1). GSEA ranked the pathway associated list of genes, 
JDM patients Controls
Patient characteristics Pre-treatment samples (n=13)
On- treatment 
samples           (n=13)
All JDM samples 
(n=26) 
Child healthy 
control (n=8)
Number of patients 13 13 16
Age at onset (years), median 
[IQR] 7.52 [4.32-12.58]
Age at diagnosis (years), 
median [IQR] 7.81 [4.74-12.74]
Age at sample (years), median 
[IQR] 7.34 [5.00-12.62] 10.4 [5.94-14.32] 8.84 [5.20-13.74] 8.06 [6.00-13.83]
Sex, (F/M) 10/3 8/5 11/5 4/4
Clinical features, median 
[IQR]
Physician’s Global Assessment 
(PGA) - (0-10) [p<0.0001] 7.00 [5.20-7.60] 1.1 [0.90-1.30]
MMT8 - (0-80)  [p<0.0001] 35.00 [25.00-44.50] 80 [79-80]
CMAS - (0-53)  [p<0.0001] 15.5 [6.50-23.00] 49 [45-52]
Creatine Kinase (CK) U/L - 
(>0) (meaured in serum at time 
of PBMC sample)  [p=0.01]
2981 [254.00-
7176.00] 105.50 [86.25-117.00]
Myositis-specific 
autoantibodies, n (%)
Anti-TIF1 gamma 3 (18.75)
Anti-SRP 1 (6.25)
Anti-NXP2 4 (25.00)
Anti-Mi2 3 (18.75)
Anti-PmScl 1 (6.25)
UKB 2 (12.50)
No detectable autoantibodies 2 (12.50)
Medications (at time of 
sample) n(%):
Azathioprine 1 (7.69)
Cyclophosphamide 0 (0.00)
Oral Prednisolone 9 (69.23)
Methotrexate 12 (92.31)
IV Prednisolone 0 (0.00)
Other drugs 6 (46.15)
* IQR = interquartile range; anti–TIF-1g = anti–transcriptio  intermediary factor 1g; 
anti–NXP-2 = anti–nuclear matrix protein 2; anti-PmScl = anti-75-and 100kDa polymyositis/systemic sclerosis proteins
 anti–Mi2 =  Nucleosome-remodelling deactulase complex;  anti-SRP =  Signal recognition particle;
UKB = Unknown bands
MMT8 = Manual Muscle Testing of 8 groups; CMAS = Childhood Myositis Assessment Scale
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comparing between cell types (PBMC, CD19+, CD8+, CD4+, CD14+) and between 
JDM pre/on treatment and child healthy control (CHC) samples. The interferon alpha 
response Hallmark pathway was one of the most up-regulated across all cell types 
when comparing JDM pre- to on-treatment and JDM pre-treatment to CHC. These 
results confirmed previous findings that JDM has a significant IFNa gene signature in 
the peripheral blood (Baechler et al., 2011, Bilgic et al., 2009). These data enhanced 
the results by identifying the signature across multiple cell types including, CD14+ 
monocytes, C19+ B cells, CD8+ and CD4+ T cells. We focused on the gene 
expression from CD19+ B cells, CD8+ and CD4+ T cells (Figure V.2). When JDM 
pre- to on-treatment and JDM pre-treatment to CHC were compared a high proportion 
of the interferon alpha response Hallmark pathway genes were significantly 
upregulated in all three cell types (Table V.2). When JDM on-treatment to CHC were 
compared this up-regulation was lost.  
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Figure V.1 Heatmap of GSEA enriched Hallmark gene sets for JDM and 
control PBMC subsets. Heatmap demonstrating the up-regulation and down-
regulation of GSEA Hallmark pathways from RNA-sequencing data. Total PBMC, 
CD19+ B cells, CD14+ monocytes, CD4+ T cells, and CD8+ T cells were sorted 
from JDM pre-/on-treatment JDM and child healthy controls samples. Gene 
expression was measured by RNA-sequencing. For each cell type every gene was 
ranked comparing pre-treatment JDM to on-treatment JDM, pre-treatment JDM to 
child healthy control and on-treatment JDM to child healthy control. Red represents 
an up-regulated pathway and blue a down-regulated pathway. + = significantly up-
regulated. - = significantly downregulated. 
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Figure 19: heatmap of GSEA enriched hallmark gene sets, JDM
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Figure V.2 IFN Alpha response hallmark gene set pre, on-treatment and CHC. 
Volcano plots representing the log fold change and adjusted p value for the genes 
present in the GSEA Hallmark interferon alpha response pathway. A) CD19+ B cells, 
B) CD4+ T cells, and C) CD8+ T cells were sorted from JDM pre-/on-treatment JDM 
and child healthy controls samples. Gene expression was measured by RNA-
sequencing and adjusted p value (by Bonferroni) and log fold change was calculated 
comparing pre-treatment JDM to on-treatment JDM, pre-treatment JDM to child 
healthy control and on-treatment JDM to child healthy control. For Bonferroni 
multiple comparison the adjusted p value significance level was 0.1. The fold change 
significance was +/-0.5. 
 
Table V.2 A list of upregulated IFN signature genes in all cell types 
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IFN	gene Description
OAS1 2'-5'-oligoadenylate	synthetase	1	[Source:HGNC	Symbol;Acc:HGNC:8086]
IFIT3 interferon	induced	protein	with	tetratricopeptide	repeats	3	[Source:HGNC	Symbol;Acc:HGNC:5411]
RSAD2 radical	S-adenosyl	methionine	domain	containing	2	[Source:HGNC	Symbol;Acc:HGNC:30908]
USP18 ubiquitin	specific	peptidase	18	[Source:HGNC	Symbol;Acc:HGNC:12616]
CMPK2 cytidine/uridine	monophosphate	kinase	2	[Source:HGNC	Symbol;Acc:HGNC:27015]
IFI44L interferon	induced	protein	44	like	[Source:HGNC	Symbol;Acc:HGNC:17817]
ISG15 ISG15	ubiquitin-like	modifier	[Source:HGNC	Symbol;Acc:HGNC:4053]
OASL 2'-5'-oligoadenylate	synthetase	like	[Source:HGNC	Symbol;Acc:HGNC:8090]
SAMD9L sterile	alpha	motif	domain	containing	9	like	[Source:HGNC	Symbol;Acc:HGNC:1349]
HERC6 HECT	and	RLD	domain	containing	E3	ubiquitin	protein	ligase	family	member	6	[Source:HGNC	Symbol;Acc:HGNC:26072]
IFI27 interferon	alpha	inducible	protein	27	[Source:HGNC	Symbol;Acc:HGNC:5397]
IFI44 interferon	induced	protein	44	[Source:HGNC	Symbol;Acc:HGNC:16938]
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Up-regulation of the cholesterol homeostasis pathway in JDM 
The GSEA also highlighted that the cholesterol homeostasis Hallmark pathway was 
up-regulated across cell types and sample group comparisons (Figure V.1). This 
pathway was up-regulated in JDM pre-treatment and on-treatment compared to CHC, 
suggesting that medication within the first year of treatment does not restore 
cholesterol homeostasis to comparative levels seen in CHC. However, the significant 
gene expression changed between cell types and across sample comparison (Figure 
V.3). Phospholipid scramblase 1 (PLSCR1) and F-box O6 (FBXO6) protein coding 
genes were up-regulated in all cell types when JDM pre-treatment was compared to 
both JDM on-treatment and CHC samples. This up-regulation was lost after 
treatment, but in CD4+ T cells the JDM on-treatment compared to CHC samples had 
an up-regulation of fatty acid synthase (FASN) and 7-Dehydrocholesterol reductase 
(DHCR7) protein coding genes. When JDM pre-treatment were compared to CHC a 
high proportion of the cholesterol homeostasis Hallmark pathway genes were 
upregulated in all three cell types (Table V.3). As both the interferon and cholesterol 
pathways were up-regulated, especially in JDM pre-treatment compared to CHC 
samples, I wanted to investigate the relationship between them.  
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Figure V.3  Volcano plots representing the log fold change and adjusted p value 
for the genes present in the GSEA Hallmark cholesterol homeostasis pathway. A) 
CD19+ B cells, B) CD4+ T cells, and C) CD8+ T cells were sorted from JDM pre-
/on-treatment JDM and child healthy controls samples. Gene expression was 
measured by RNA-sequencing and adjusted p value (by Bonferroni) and log fold 
change was calculated comparing pre-treatment JDM to on-treatment JDM, pre-
treatment JDM to child healthy control and on-treatment JDM to child healthy 
control. For Bonferroni multiple comparison the adjusted p value significance level 
was 0.1. The fold change significance was +/-0.5. 
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Table V.3 A list of upregulated cholesterol homeostasis genes in all cell types 
 
I mined the GSEA and gene expression data to select a profile of cholesterol pathway 
genes; UPD-Glucose ceramide glucosyltransferase (UGCG), ELOVL fatty acid 
elongase 5 (ELOV5), stearoyl-CoA desaturase (SCD), F-box 06 (FBX06), syntaxin 5 
(STX5) and malic enzyme 1 (ME1). JDM pre- and on-treatment CD19+ B cells had 
significantly decreased expression of ELOV5 than CHC (Figure V.4A). JDM pre- 
treatment CD4+ T cells had significantly increased expression of UGCG than JDM 
on-treatment and CHC (Figure V.4B). JDM pre- treatment CD4+ and CD8+ T cells 
had significantly increased expression of SCD than JDM on-treatment and CHC 
(Figure V.4B). JDM pre- treatment CD19+ B cells, CD8+ and CD4+ T cells had 
significantly increased expression of FBX06 than JDM on-treatment and CHC 
(Figure V.4A-B). JDM pre- treatment CD8+ T cells had significantly decreased 
expression of ME1 than JDM on-treatment and CHC (Figure V4B). The selected 
genes were used to investigate the effect of IFNa stimulation on B and T cell 
expression of cholesterol related genes.  
Cholesterol homeostasis gene Description
JAG1 jagged 1 [Source:HGNC Symbol;Acc:HGNC:6188]
PLSCR1 phospholipid scramblase 1 [Source:HGNC Symbol;Acc:HGNC:9092]
GNAI1 G protein subunit alpha i1 [Source:HGNC Symbol;Acc:HGNC:4384]
FBXO6 F-box protein 6 [Source:HGNC Symbol;Acc:HGNC:13585]
ATF3 activating transcription factor 3 [Source:HGNC Symbol;Acc:HGNC:785]
SCD stearoyl-CoA desaturase [Source:HGNC Symbol;Acc:HGNC:10571]
LDLR low density lipoprotein receptor [Source:HGNC Symbol;Acc:HGNC:6547]
HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 [Source:HGNC Symbol;Acc:HGNC:5007]
STX5 syntaxin 5 [Source:HGNC Symbol;Acc:HGNC:11440]
FASN fatty acid synthase [Source:HGNC Symbol;Acc:HGNC:3594]
NSDHL NAD(P) dependent steroid dehydrogenase-like [Source:HGNC Symbol;Acc:HGNC:13398]
ACTG1 actin gamma 1 [Source:HGNC Symbol;Acc:HGNC:144]
SREBF2 sterol regulatory element binding transcription factor 2 [Source:HGNC Symbol;Acc:HGNC:11290]
MVK mevalonate kinase [Source:HGNC Symbol;Acc:HGNC:7530]
TRIB3 tribbles pseudokinase 3 [Source:HGNC Symbol;Acc:HGNC:16228]
ECH1 enoyl-CoA hydratase 1 [Source:HGNC Symbol;Acc:HGNC:3149]
CYP51A1 cytochrome P450 family 51 subfamily A member 1 [Source:HGNC Symbol;Acc:HGNC:2649]
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Figure V.4  A comparison of the expression of selected genes from the GSEA 
Hallmark cholesterol homeostasis pathway from B cells and CD4+/8+ T cells sorted 
from JDM pre-/on- treatment and child healthy control samples. Scatter plots 
showing the reads per kilobase per million mapped reads (RPKM) of the genes 
UGCG, ELOVL5, FBXO6, STX5 and ME1 for A) B cells and B) T cells from pre- and 
on-treatment JDM and child healthy control (CHC) samples. Values represent mean 
± SEM. *p<0.05, **p<0.01, ***p<0.001 
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Change in expression of cholesterol related genes from B and T cells after IFNa 
stimulation 
Isolated B and T cells from adult healthy control PBMC samples were stimulated for 
2hours, 6hours and 24hours with IFN-a. After stimulation, we isolated the RNA and 
measured gene expression by qPCR. There was not a significant change in the 
expression of UGCG or SCD from either cell type after stimulation with IFNa for any 
time point. After 24hours of stimulation with IFN-a there was a trend towards a 
decrease in expression of ELOVL5 from the B cells (Figure V.5A) comparative to the 
expression results seen in JDM pre-treatment (Figure V.4A). There was significant 
increase in FBX06 expression from T cells after a 2hr stimulation with IFN-a, there 
was a trend for a maintained increase at 6hours and 24hours (Figure V.5B). There 
was no significant change in the expression of STX5 or ME1 from T cells after 
stimulation with IFN-a for any time point (Figure V.5B). These results suggest that 
ELOVL5 expression from B cells and FBX06 expression from T cells were 
influenced by IFN-a. Due to limitations in the quantity of B cell cDNA the number of 
genes analysed by qPCR was limited, therefore I can only hypothesise that FBX06 
expression from B cells would also be increased. 
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Figure V.5 IFN stimulation over time; gene expression from B and T cells. T cell 
and B cell expression of cholesterol homeostatic genes after 2hour, 6hour and 24hour 
culture, stimulated +/- IFN-a. A) Scatter plots showing the B cell relative gene 
expression of UGCG, SCD and ELOVL5. B) Scatter plots showing the T cell relative 
gene expression of UGCG, ELOVL5, FBX60, STX5 and ME1. Values represent mean 
± SEM. *p<0.05, **p<0.01, ***p<0.001 
 
Lymphocyte membrane glycosphingolipids decreased after IFNa stimulation 
Since plasma membrane lipid composition is known to influence immune cell 
function I also assessed whether IFN-a stimulation influenced plasma membrane lipid 
expression. I analysed the frequency expression of glycosphingolipid (GSL) (using 
CTB binding) and cholesterol (filipin binding) in CD19+ B cells, CD4+ and CD8+ T 
cells after culture with IFNa for 2hours, 6hours and 24hours. CTB is a surrogate 
marker for GSL expression (McDonald et al., 2014) and are markers of plasma 
membrane associated lipids and cholesterol. The gating strategy used is shown in 
Figure V.6. Both B cells and CD8+ T cells had a significant decrease in CTB binding 
after 24 hours of IFNa stimulation (Figure V.7A). There was also a trend towards a 
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decrease in CTB expression from CD4+ T cells but it did not reach significance. No 
change in filipin expression was seen in any of the cell types (Figure V.7B). 
Therefore IFNa stimulation did not alter PM cholesterol levels but did influence GSL 
content. 
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Figure V.6 Flow cytometry gating strategy for surface markers, CTB and filipin 
expression 
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Figure V.7 - CD4/8+ T cell and B cell expression of CTB and filipin after 2hour, 
6hour and 24hour culture, stimulated +/- IFN-a. A) Scatter plots showing the 
frequency of CD4+, CD8+ T cells and B cells expressing CTB. B) Scatter plots 
showing the filipin MFI from CD4+, CD8+ T cells and B cells. Values represent 
mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 
 
ADM patients have a high B cell expression of HMGCR 
A sub-group of adult myositis patients develop an auto-antibody against 3-hydroxy-3-
methylglutaryl-CoA reductase (HMGCR), this is most commonly induced by statin 
use as HMGCR is the pharmacological target for statins. I investigated the B cell 
expression of HMGCR and the related genes FASN, sterol regulatory element-
binding protein 1 (SREBP1) and SREBP2. In JDM compared to CHC there was no 
change in HMGCR expression, but a trend emerged towards an increased expression 
of FASN from JDM on-treatment samples (Figure V.8A). In adult DM (ADM) 
compared to adult HC (AHC) samples there was a significant increase of HMGCR 
expression. No change in expression of FASN or SREBP2 were noted. A significant 
decrease in expression of SREBP1 was seen in ADM compared to AHC, but the n 
CD4+ T cells
Vehicle 2hrs 6hrs 24hrs
0
1
2
3
IFN-  stimulation 
 
C
TB
 F
re
qu
en
y 
CD8+ T cells
Vehicle 2hrs 6hrs 24hrs
0.0
0.5
1.0
1.5
2.0
IFN-  stimulation 
 
C
TB
 F
re
qu
en
y 
*
*
*
B cells
Vehicle 2hrs 6hrs 24hrs
0
5
10
IFN-  stimulation 
 
C
TB
 F
re
qu
en
y *
*
*
*
A
B CD4+ T cells
Vehicle 2hrs 6hrs 24hrs
1200
1300
1400
1500
1600
IFN-  stimulation 
 
Fi
lip
in
  M
FI
CD8+ T cells
Vehicle 2hrs 6hrs 24hrs
1300
1400
1500
1600
1700
IFN-  stimulation 
 
Fi
lip
in
  M
FI
B cells
Vehicle 2hrs 6hrs 24hrs
1200
1400
1600
1800
2000
IFN-  stimulation 
 
Fi
lip
in
  M
FI
 201 
number was two (Figure V.8B). The final experiment repeated the design from figure 
5, taking four AHC PBMC samples and isolated the B cells. We stimulated the B cells 
with IFN-a for 6hours and 24hours, isolated RNA and analysed for gene expression 
by qPCR (Figure V.8C). A significant difference was not identified for any of the 
four genes. There was however a trend towards an increase in HMGCR and FASN 
expression, but a decrease in SREBP2 expression.  
 
Figure V.8 B cell expression of cholesterol associated genes in patients and 
healthy controls. A) Scatter plots showing the reads per kilobase per million mapped 
reads (RPKM) of the genes HMGCR and FASN for B cells from pre- and on-
treatment JDM and child healthy control (CHC) samples. B) Scatter plots showing 
the relative gene expression of HMGCR, FASN, SREPB1 and SREBP2 for B cells 
from adult DM and adult healthy control (AHC) samples. C) Scatter plots showing 
relative gene expression of HMGCR, FASN, SREPB1 and SREBP2 for B cells from 
AHC samples cultured for 6hours and 24hours +/- IFN-a. Values represent mean ± 
SEM. *p<0.05, **p<0.01, ***p<0.001  
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DISCUSSION 
These results confirmed that the type I IFN pathway genes were up-regulated in all 
cell types in samples taken from JDM patients pre-treatment compared to both JDM 
on-treatment and healthy child controls. The cholesterol homeostasis pathway genes 
were also up-regulated in all cell types in samples taken from JDM patients pre-
treatment compared to both JDM on-treatment and CHC. However the genes were 
also up-regulated when JDM on-treatment was compared to CHC. These findings 
suggest that the dysregulation of cholesterol homeostasis was not corrected by a year 
on treatment with prednisolone and methotrexate, unlike the type I IFN pathway. As 
both these pathways were up-regulated in JDM, I explored the relationship between 
IFN-a stimulation and the dysregulation of lipid rafts and cholesterol related genes.  
 
Previous studies have identified a mechanism by which changes in cholesterol 
biosynthesis were linked to an increase in type I IFN expression (York et al., 2015). 
My data showed that although there was a trend towards a decrease in B cell UGCG 
expression in response to stimulation with IFN-a, this was not seen for the T cells. 
UGCG is a gene that encodes an enzyme that catalyses the first glycosylation step in 
the biosynthesis of glycosphingolipids. GSL expression can be detected using the 
specific association of CTB with the ganglioside GM1 (Waddington and Jury, 2015). 
The UGCG gene expression data correlated to the significantly decreased B cell 
expression of CTB after stimulation with IFN-a. A possible mechanism could be that 
type I IFN inhibits UGCG expression, which in turn inhibits the production of 
glycosphingolipids in the lipid rafts and leads to abnormal levels. A reduction of 
glycosphingolipids could lead to aberrant BCR signalling between immune cells. 
When exposed to an antigen the BCR has been shown to associate with the lipid rafts. 
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The lipid rafts aid amplification of BCR signalling after ligand binding. Increasing 
evidence highlights the process of initial endocytosis of antigens and the presentation 
onto a MHC-II receptor are coordinated within membrane domains (Gupta and 
DeFranco, 2007). Therefore, a disruption in lipid rafts would affect the antigen 
presentation between immune cells, especially in B cells.  
 
ELOVL5 was another gene whose expression in B cells was decreased from both the 
RNA-seq JDM pre-treatment data and from the healthy control samples stimulated 
with IFN-a. This gene codes for elongation of very long chain fatty acid protein 5, 
catalysing the formation of very long-chain fatty acids. The fatty acids are 
components of membrane lipids, including the sphingolipids (Kihara, 2012). A study 
has shown that the expression of this gene was up-regulated after treatment with 
atorvastatin (Ishihara et al., 2017). This study suggests that statins increase the plasma 
concentration of arachidonic acid, an w-6 long-chained polyunsaturated fatty acid 
(LCPUFA), but decrease the concentrations of eicosapentaenoic acid and 
docosahexaenoic acid, which are ω-3 LCPUFAs. Schwartz et al. reported that JDM 
patients with active disease, high eotaxin and MCP-1 and cholesterol levels in the 
upper normal range may have an increased risk of cardiac dysfunction (Schwartz et 
al., 2014). Therefore, if JDM patients have decreased expression of ELOVL5 they 
may be more susceptible to higher cholesterol which could be induced by the type I 
IFN pathway. 
 
Myositis is known to be associated with a dysregulation of the cholesterol pathway 
(Tisseverasinghe et al., 2009). There is an identified sub-group of adult patients that 
test positive for the anti-HMGCR antibody. These patients are most commonly 
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associated with statin use (Mohassel and Mammen, 2013). The results showed that 
HMGCR expression was increased in B cells from adult but not JDM patient samples. 
HMGCR is a transmembrane glycoprotein that acts as the rate-limiting enzyme in 
cholesterol biosynthesis and the biosynthesis of non-sterol isoprenoids, both pathways 
are essential for normal cell function. HMGCR function is inhibited by the 
pharmacological agent, statins. This inhibition in the liver stimulates the low-density 
lipoprotein (LDL)-receptors, and in turn there is increased clearance of the LDL from 
the bloodstream and a decrease in blood cholesterol levels (Brown and Goldstein, 
1980). The results from this study suggest that ADM patients have higher expression 
of HMGCR, which could alter cholesterol homeostasis. However, as statins have 
known myopathic side effects it may not be advisable to use them as cholesterol 
lowering preventative treatment in this disease. 
 
Abnormal levels of glycosphingolipids in T cells have been identified to lead to 
abnormal T cell function, specifically in SLE (Kidani and Bensinger, 2014, 
McDonald et al., 2014). It was shown that by culturing healthy control T cells with 
SLE patient serum there was an increase in glycosphingolipids, this was comparative 
to the levels seen in T cells from SLE patients. These results suggest that SLE patients 
over-express a protein pathway within the serum that up-regulates T cell 
glycosphingolipids. A possible pathway would be type I IFN which is known to be 
up-regulated in SLE and other autoimmune diseases (Bilgic et al., 2009). The RNA-
seq data supported this hypothesis in the context of JDM. FBX06, a gene identified 
within the Hallmark cholesterol homeostasis pathway, has been shown to be 
important for the controlled degradation on cellular regulatory proteins (Cenciarelli et 
al., 1999). FBX06 was significantly increased in B cells and T cells from JDM pre-
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treatment samples, but also in HC T cells after stimulation with IFN-a. This gene 
showed an opposite trend to that seen of UGCG, and therefore CTB expression. The 
data showed no change in cholesterol by filipin expression over time after stimulation 
with IFN-a. Previous data collected by my laboratory group suggested that 
cholesterol should increase after 72hour of stimulation with IFN-a. The time points 
used for these experiments appeared too short to observe changes in cholesterol, but 
were correct for detecting changes in gene expression. This highlights the importance 
of ascertaining the correct time point to detect important changes in gene expression 
and phenotypic changes, which are likely to be different between cell types and 
within sub-populations. 
 
The SCD gene codes for an endoplasmic reticulum enzyme that catalyses the 
formation of monounsaturated fatty acids. This enzyme has been identified to play an 
important role in the biogenesis of the plasma membrane, and for cell proliferation 
and survival of certain types of cancer (Belkaid et al., 2015). The RNA-seq data 
showed that the expression of SCD was significantly higher in all T cells, particularly 
CD8+ T cells, from JDM patients on-treatment, and there was a trend for this in B 
cells. There was a possible trend for an increased expression of SCD from HC T cells 
after 24hour of stimulation with IFN-a, but again this induction may be more 
pronounced after longer stimulation. If IFN-a affects the expression of SCD from T 
cells this could lead to an increase of monounsaturated fatty acids and in turn 
disrupting the plasma membrane. Further experimentation would be required. 
 
I have shown that IFN-a stimulation of T and B cells does change the expression of 
some genes that are part of the Hallmark cholesterol homeostasis pathway. This 
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stimulation also altered lipid rafts. These data were only preliminary as most results 
were dependent upon just three or four healthy controls. To confirm the findings, it 
would be important to repeat this set of experiments with an increased number of 
samples. The results showed a change of CTB expression and thus lipid rafts for the 
time points used, but no change in cholesterol was observed. It would be useful to 
repeat the experiments for gene, CTB and filipin expression at longer time points. 
Also, an altered CTB:filipin ration could be important as it may reflect changes in 
membrane fluidity.  
 
 
 
Figure V.9 IFN-a stimulation of T and B cells does change the expression of 
some genes that are part of the Hallmark cholesterol homeostasis pathway. 
Stimulation of B and T cells with IFN-a recapitulated the increase in expression of 
certain cholesterol homeostasis pathway genes that were seen in IIM including; 
UGCG, FBX06 and HMGCR. Equally at a more functional level there were changes 
in glycosphingolipids and cholesterol at the lipid bilayer.  
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Chapter VI 
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Discussion Summary 
My thesis has explored the immunopathogenesis of IIM in both adult and juvenile 
patients. It has addressed three main aims. Firstly, the investigation of the 
mechanisms driving B cell lymphocytosis and to define pathological features of B 
cells in the blood of JDM patients. The identification of specific immune cell 
signatures and cytokine profiles for myositis disease subtypes and correlation of this 
data with measurements of disease activity. Finally, delineation of a correlation 
between the up-regulated type I interferon signature and dysfunction of cholesterol 
homeostasis in immune cells. 
 
The results identified that JDM patients with active disease had a significantly 
expanded immature B cell population which was correlated with the type I IFN 
signature. The expanded population and up-regulated type I IFN signature resolved 
after the patients received treatment with prednisolone and methotrexate. Activation 
through TLR7 and IFN-a may drive the expansion of immature B cells in JDM and 
skew the cells towards a more pro-inflammatory phenotype. To proceed with this 
work, it would be important to untangle the mechanism by which these interpretations 
are linked.  
 
To establish, whether the expanded immature B cell population is skewed towards a 
pro-inflammatory phenotype, it would be important to delineate which IL-10 inducing 
pathway is dominant in the context of JDM. I propose further experimentation 
whereby by B cells taken from JDM pre- and on-treatment patients and CHC samples 
are stimulated with vehicle, IFN-a, R848 and cultured with or without CD40L CHO 
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cells for 72 hours. This experiment could be taken further by which immature B cells 
are isolated from each sample group. This may be required as after 72 hours of culture 
it is difficult to identify B cell subsets by flow cytometry due to down-regulation of 
cell surface markers. However, due to small PBMC numbers it can be difficult to 
isolate enough immature B cells. It would also be useful to repeat this experiment 
using ADM samples both pre- and on-treatment comparing with AHC to establish if 
the same mechanisms are apparent in adult disease. 
 
My hypothesis would be that under dual stimulation the TLR7 would override that of 
the CD40-CD40L pathway, and that the JDM B cells would express less IL-10 than 
that of the CHC B cells. This would suggest that the immature B cell population in 
JDM are skewed away from B regulatory cell differentiation and towards a pro-
inflammatory phenotype due to the over-activation of the type I IFN pathway. With 
further investigation, these data support a growing body of evidence that novel 
therapeutic agents that target the TLR7 and IFN-a response pathways could be useful 
for the treatment of dermatomyositis. 
 
The novel in-depth immunophenotyping of patients with myositis showed that there 
were unique immune signatures in adult disease sub-types and this highlighted the 
heterogeneous nature of the myopathies. There were changes in cell populations 
between DM, PM and JDM, but also with changes in disease activity, treatment and 
auto-antibody presence. One particular signature was of an expanded Th17 T cell 
population in the peripheral blood of ADM patients. To expand on this result, it 
would be important to establish this signature in a larger cohort and confirm that it 
was specific to DM rather than PM. Equally, it is known that Th17 cells are tissue 
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residing in the biopsies from IIM patients (Chevrel et al., 2003, Page et al., 2004, 
Tournadre et al., 2009). Therefore, it would be useful to correlate the proportion of 
Th17 cells in the peripheral blood with that found in the inflamed muscle tissue at 
diagnosis. This ratio could be used establish a biomarker for monitoring disease 
progression. The use of IL-17A inhibitors could be efficacious to treat patients with a 
Th17 signature, but further exploration of the mechanism would be required. 
 
My results demonstrated that the expanded Th17 population correlated with an 
expansion of activated T cells and also increased IL-6 expression from memory B 
cells. The highest immune cell expression of IL-6 and CD69 was noted in the ADM 
group. This would suggest that the Th17 expansion seen in the peripheral blood of 
ADM patients is linked with the activated cellular IL-6 signature. It has been 
identified that CD69 employs a complex immune-regulatory role in humans and 
animal models by the inhibition of Th17 differentiation and function (Martin et al., 
2010, Cruz-Adalia et al., 2010). This would suggest that the increased activated Treg 
population found in the ADM group may be exerting an immune-regulatory role in 
response to the expanded Th17 population. IL-17 is a known inducer of IL-6 as part 
of its central role in the migration and differentiation of mononuclear cells. An 
increase in Th17 cells could lead to an increased expression of IL-6 by B cells. To 
investigate this mechanism PBMC from ADM and AHC could be cultured in the 
presence or absence of an IL-17A inhibitor, then the expression of IL-6 from B cells 
could be measured by flow cytometry and ELISA. If the IL-17A inhibitor did reduce 
the expression of IL-6 from B cells this would form supporting evidence for the use of 
IL-17A inhibitors in the treatment of ADM. 
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Lastly, I showed that IFN-a stimulation of T and B cells does change the expression 
of some genes that are part of the Hallmark cholesterol homeostasis pathway and that 
this pathway was up-regulated in JDM patients compared to CHC. IFN-a stimulation 
also altered lipid rafts. Changes in cholesterol, cholesterol homeostasis gene 
expression and membrane fluidity may affect T cell signalling and antigen 
presentation between immune cells, which are noted changes in autoimmune disease 
(Baechler et al., 2003, Cedeno et al., 2003). If type I IFNs do alter lipid rafts in 
autoimmune disease then, diseases like myositis, may require lipid raft modulating 
therapeutic agents. These would work in conjunction with existing agents such as 
anti-CD20 antibodies (rituximab) and statins that exert their effect in part via the lipid 
raft (Kabouridis and Jury, 2008). Further experimentation would be required to 
establish this mechanism. 
 
In conclusion, the study provides further evidence that anti- IFNa biologics could be 
efficacious in the treatment of JDM. That unique cell signatures could help to choose 
treatments and assess disease outcomes. Also, the need for further investigation for 
the use of IL-17A inhibitors in the treatment of IIM. 
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Future work aims 
1. Further delineate the pathogenic role of immature B cells in IIM 
a. Does type I IFN blockade increase IL-10 expression and restore the 
regulatory nature of immature B cells? 
b. Are these immature B cells infiltrating muscle tissue and exerting a 
pathogenic effect? 
c. Is the expansion of pro-inflammatory immature B cells in pre-
treatment patients a common trait in IIM or is it unique to JDM? 
2. Re-capitulate the immune signatures found in the IIM sub-groups in a defined 
cohort 
3. Investigate the immunopathogenesis of the specific cell types found to be 
associated with disease e.g. B cells , Th17 and C8+CM 
a. Are they found to infiltrate inflamed muscle tissue? 
b. What is driving these changes in immune cell type? 
4. Establish mechanisms by which type I IFN alters cholesterol and lipid 
metabolism in immune cells 
a. Is this pathway a potential therapeutic target? 
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